Methods and compositions for treating staphylococcal infections

By developing engineered antibodies containing 3F6 antibodies and introducing glycosylation modifications in their Fc region, the treatment problem of methicillin-resistant Staphylococcus aureus infection was solved, effective neutralization and decolonization of MRSA were achieved, and the Immune response to MRSA.

CN114929750BActive Publication Date: 2024-11-22UNIVERSITY OF CHICAGO
View PDF 79 Cites 0 Cited by

Patent Information

Application Number
CN202080078967.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-03-20
Filing Date
2020-09-11
Publication Date
2024-11-22
Estimated Expiration
2040-09-11

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat methicillin-resistant Staphylococcus aureus (MRSA) infection, especially in the prevention and treatment of Staphylococcus infection, and the problem of antibiotic resistance is becoming increasingly serious.

Method used

An engineered antibody was developed, including the light chain variable region and heavy chain variable region of the 3F6 antibody, and glycosylation modification was introduced in the Fc region through which these antibodies bind to the virulence factor and superantigen-like protein of MRSA, Block its infection pathway, promotes an immune response against MRSA, and is expressed in host cells to produce antibodies against MRSA.

Benefits of technology

The antibody can effectively neutralize the virulence factor of MRSA, promote its decolonization, improve the host's immune response to MRSA, reduce the risk of infection, and display significant lethality in vivo and in vitro, providing a potential treatment and prevention of MRSA Methods of infection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003641134250000051
    Figure BDA0003641134250000051
  • Figure BDA0003641134250000052
    Figure BDA0003641134250000052
  • Figure BDA0003641134250000061
    Figure BDA0003641134250000061
Patent Text Reader

Abstract

The present disclosure provides novel compositions for treating bacterial infections. Therefore, aspects of the present disclosure relate to engineered antibodies comprising: LCDR1, LCDR2 and LCDR3 of the light chain variable region of the 3F6 antibody and HCDR1, HCDR2 and HCDR3 of the heavy chain variable region of the 3F6 antibody. Compositions comprising antibodies and nucleic acids encoding the heavy chain or light chain (or both) of the antibodies are also provided. Other aspects relate to host cells comprising antibodies and / or nucleic acids of the present disclosure. Other aspects relate to methods for preventing or treating staphylococcal infections, the methods comprising administering antibodies of the present disclosure to subjects in need thereof. Yet another aspect relates to a method for preparing antibodies, comprising expressing nucleic acids of the present disclosure in cells and isolating the expressed proteins.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Patent Application No. 62 / 900,170, filed on September 13, 2019, and U.S. Provisional Patent Application No. 62 / 992,457, filed on March 20, 2020, which are incorporated herein by reference in their entireties.

[0003] Government Support Statement

[0004] This invention was made with government support under Grant No. AI052474 awarded by the National Institutes of Health. The government has certain rights in this invention. background

[0005] I. Technical field

[0006] The present invention relates generally to the fields of immunology, microbiology and pathology. More specifically, it relates to methods and compositions involving modified antibodies that can be used to treat bacterial infections.

[0007] II. Background Technology

[0008] In recent years, the number of both community-acquired and hospital-acquired infections has increased with the increased use of intravascular devices. Hospital-acquired (nosocomial) infections are a major cause of morbidity and mortality, especially in the United States, affecting more than 2 million patients each year. The most common infections are urinary tract infections (33% of infections), followed by pneumonia (15.5%), surgical site infections (14.8%), and primary bloodstream infections (13%) (Emorl and Gaynes, 1993).

[0009] The major nosocomial pathogens included Staphylococcus aureus, coagulase-negative staphylococci (primarily S. epidermidis), Enterococcus species, Escherichia coli, and Pseudomonas aeruginosa. Although these pathogens cause roughly the same number of infections, the severity of illness they can produce combined with the frequency of antibiotic-resistant isolates balances the ranking of S. aureus and S. epidermidis as the most important nosocomial pathogens.

[0010] Staphylococci can cause a variety of illnesses in humans and other animals through the production or invasion of toxins. Staphylococcal toxins are also a common cause of food poisoning because the bacteria can grow in improperly stored food.

[0011] Staphylococcus epidermidis is a normal skin commensal and an important opportunistic pathogen that can cause infections of compromised medical devices and surgical site infections. Medical devices infected by S. epidermidis include pacemakers, cerebrospinal fluid shunts, continuous ambulatory peritoneal dialysis catheters, orthopedic devices, and prosthetic heart valves.

[0012] S. aureus is the most common cause of hospital-acquired infections, with significant morbidity and mortality. It is responsible for some cases of osteomyelitis, endocarditis, septic arthritis, pneumonia, abscesses, and toxic shock syndrome. S. aureus can survive on dry surfaces, which increases the chance of transmission. Any S. aureus infection can lead to staphylococcal scalded skin syndrome, a skin reaction to exotoxins absorbed into the bloodstream. It can also lead to a potentially life-threatening form of sepsis called sepsis. Problematically, methicillin-resistant S. aureus (MRSA) has become a leading cause of hospital-acquired infections.

[0013] S. aureus and S. epidermidis infections are usually treated with antibiotics, with penicillin being the drug of choice and vancomycin used for methicillin-resistant isolates. The percentage of Staphylococcus strains that exhibit broad-spectrum resistance to antibiotics is becoming increasingly common, posing a threat to effective antimicrobial therapy. In addition, the recent emergence of vancomycin-resistant S. aureus strains has raised concerns that MRSA strains are emerging and spreading without available effective treatments.

[0014] Alternative approaches to the treatment of staphylococcal infections using antibodies against staphylococcal antigens instead of antibiotics are being investigated. Such therapies include administration of polyclonal antisera (WO00 / 15238, WO00 / 12132) or treatment with monoclonal antibodies against lipoteichoic acid (WO98 / 57994).

[0015] Another method is to use active vaccination to generate an immune response against staphylococci. The Staphylococcus aureus genome has been sequenced and many coding sequences have been identified (WO02 / 094868, EP0786519), which allows the identification of potential antigens. This also applies to Staphylococcus epidermidis (WO01 / 34809). As an improvement to this method, others have identified proteins recognized by hyperimmune sera from patients with staphylococcal infections (WO01 / 98499, WO02 / 059148).

[0016] Staphylococcus aureus secretes a large number of virulence factors into the extracellular environment (Archer, 1998; Dinges et al., 2000; Foster, 2005; Shaw et al., 2004; Sibbald et al., 2006). Like most secreted proteins, these virulence factors are translocated across the plasma membrane by the Sec machinery. Proteins secreted by the Sec machinery carry an N-terminal leader peptide that is removed by the leader peptidase once the preprotein engages the Sec translocon (Dalbey and Wickner, 1985; van Wely et al., 2001). Recent genomic analyses have shown that members of the Actinobacteria and Firmicutes phyla encode additional secretion systems that recognize a subset of proteins in a Sec-independent manner (Pallen, 2002). ESAT-6 (early secretory antigenic target 6 kDa) and CFP-10 (culture filtrate antigen 10 kDa) of Mycobacterium tuberculosis are the first substrates of this novel secretion system called ESX-1 or Snm in Mycobacterium tuberculosis (Andersen et al., 1995; Hsu et al., 2003; Pym et al., 2003; Stanley et al., 2003). In Staphylococcus aureus, the Ess pathway (ESAT-6 secretion system) secretes two ESAT-6-like factors called EsxA and EsxB (Burts et al., 2005).

[0017] First generation vaccines against Staphylococcus aureus or the exoproteins it produces have had limited success (Lee, 1996). There remains a need to develop effective vaccines against Staphylococcus infections. There is also a need for other compositions for treating Staphylococcus infections. Summary of the invention

[0018] The present disclosure satisfies the needs of the art by providing a novel composition for treating bacterial infection. Therefore, aspects of the present disclosure relate to engineered antibodies comprising: LCDR1, LCDR2 and LCDR3 of the light chain variable region of the 3F6 antibody and HCDR1, HCDR2 and HCDR3 of the heavy chain variable region of the 3F6 antibody. Other aspects relate to engineered antibodies comprising light chain variable regions and heavy chain variable regions, comprising: LCDR1, LCDR2 and LCDR3 of the light chain variable region of the 3F6 antibody and HCDR1, HCDR2 and HCDR3 of the heavy chain variable region of the 3F6 antibody, and wherein the antibody comprises an Fc region containing at least one glycosylated amino acid. Compositions comprising an antibody and a nucleic acid encoding the heavy chain or light chain (or both) of the antibody are also provided. Other aspects relate to vectors comprising nucleic acids of the present disclosure. Other aspects relate to host cells comprising antibodies and / or nucleic acids of the present disclosure. Other aspects relate to methods for preventing or treating staphylococcal infection and / or colonization, comprising the step of administering an antibody of the present disclosure to an object in need thereof. Yet another aspect relates to a method of preparing an antibody, comprising expressing a nucleic acid of the disclosure in a cell and isolating the expressed protein. Other embodiments relate to the use of an antibody of the disclosure in the preparation of a medicament for treating or preventing a staphylococcal infection.

[0019] Other embodiments relate to an antibody heavy chain comprising a heavy chain variable region comprising HCDR1, HCDR2, and HCDR3 of the heavy chain variable region of the 3F6 antibody and an Fc region comprising at least one glycosylation-modified amino acid.

[0020] The term "engineered antibody" refers to an antibody comprising at least one substitution starting from the naturally occurring sequence of the antibody or an antibody comprising a secondary modification different from that found in nature, such as N-acetylglucosamine, mannose, galactose, fucose or N-acetylneuraminic acid (sialic acid). In embodiments of the present disclosure, the antibodies described herein comprise an Fc region. In certain embodiments, the Fc region is modified with substitutions of non-conservative amino acids. In some embodiments, the antibody is a humanized antibody or a chimeric antibody. In some embodiments, the engineered antibody is a humanized 3F6 antibody. Therefore, the humanized 3F6 antibody comprises 6 CDRs of the 3F6 antibody grafted onto the human framework region.

[0021] In certain aspects, the CDRs of 3F6 are as follows:

[0022] sequence SEQ ID NO: HCDR1 GFTFNTNA 2 HCDR2 IRSKSNNYAT 3 HCDR3 VTEHYDYDYYVMDY 4 LCDR1 ESVEYSGASL 5 LCDR2 AAS 6 LCDR3 QQSRKVPST 7

[0023] In some embodiments, HCDR1, HCDR2, and HCDR3 comprise an amino acid sequence having at least 70% sequence identity to SEQ ID NOs: 2, 3, and 4, respectively, and wherein LCDR1, LCDR2, and LCDR3 comprise an amino acid sequence having at least 70% sequence identity to SEQ ID NOs: 5, 6, and 7, respectively. In some embodiments, HCDR1, HCDR2, and HCDR3 comprise an amino acid sequence of SEQ ID NOs: 2, 3, and 4, respectively, and wherein LCDR1, LCDR2, and LCDR3 comprise an amino acid sequence of SEQ ID NOs: 5, 6, and 7, respectively. In some embodiments, the antibody may comprise a CDR having at least 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range derivable therein) sequence identity to SEQ ID NOs: 2 to 7.

[0024] In certain aspects, the polypeptide may comprise 1, 2 and / or 3 CDRs from the variable heavy chain of MAb 3F6, e.g., SEQ ID NO: 2, SEQ ID NO: 3 and / or SEQ ID NO: 4. In other embodiments, the polypeptide may have CDRs with 1, 2 and / or 3 amino acid changes (1 or 2 amino acid additions, 1 or 2 amino acid deletions or substitutions) relative to these 1, 2 and / or 3 CDRs. In other embodiments, the antibody may be alternatively or additionally humanized in regions other than the CDR and / or variable regions. In some aspects, the polypeptide additionally or alternatively comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity or homology with the amino acid sequence of the variable region, i.e., the framework region of the variable region, of the non-CDR sequence.

[0025] From the amino terminus to the carboxyl terminus, the CDRs are CDR1, CDR2, and CDR3. In certain aspects, the polypeptide may comprise 1, 2, and / or 3 CDRs from the variable light chain of MAb 3F6, e.g., SEQ ID NO: 5, SEQ ID NO: 6, and / or SEQ ID NO: 7. In other embodiments, the polypeptide may have CDRs with 1, 2, and / or 3 amino acid changes (1 or 2 amino acid additions, 1 or 2 amino acid deletions or substitutions) relative to these 1, 2, and / or 3 CDRs. In some embodiments, the CDRs of SEQ ID NOs: 2 to 7 may also comprise 1, 2, 3, 4, 5, or 6 additional amino acids at the amino or carboxyl termini of the CDRs. The additional amino acids may be from the heavy and / or light chain framework regions of SEQ ID NOs: 9 and 10, respectively, which are shown as being adjacent to the CDRs. Thus, embodiments relate to antibodies comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and / or LCDR3 having at least or at most or exactly 1, 2, 3, 4, 5, 6 or 7 amino acids at the amino terminus of the CDR or at the carboxyl terminus of the CDR, wherein the additional amino acids are 1, 2, 3, 4, 5, 6 or 7 amino acids of SEQ ID NOs: 9 and 10 shown as being immediately adjacent to the CDR. Other embodiments relate to antibodies comprising one or more than one CDR, wherein the CDR is a fragment of SEQ ID NOs: 2 to 7, and wherein the fragment lacks 1, 2, 3, 4 or 5 amino acids at the amino terminus or carboxyl terminus of the CDR. In some embodiments, the CDR may lack one, 2, 3, 4, 5, 6 or 7 amino acids at the carboxyl terminus and may also comprise 1, 2, 3, 4, 5, 6, 7 or 8 amino acids from the framework region at the amino terminus of the CDR. In some embodiments, CDR can lack one, 2, 3, 4, 5, 6 or 7 amino acids of amino terminal and can also comprise 1, 2, 3, 4, 5, 6, 7 or 8 amino acids from the framework region of CDR carboxyl terminal.In other embodiments, antibody can be alternatively or additionally humanized in the region outside CDR and / or variable region.In some aspects, polypeptide additionally or alternatively comprises the amino acid sequence of variable region, i.e., variable region framework region, of non-CDR sequence with at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity or homology.

[0026] In other embodiments, the polypeptide or protein comprises 1, 2, 3, 4, 5 or 6 CDRs from one or both of the light chain variable region and the heavy chain variable region of mAb 3F6 and 1, 2, 3, 4, 5 or 6 CDRs may have 1, 2 and / or 3 amino acid changes relative to these CDRs. In some embodiments, part or all of the antibody sequence outside the variable region has been humanized. The protein may comprise one or more than one polypeptide. In some aspects, the protein may contain one or two polypeptides similar to the heavy chain polypeptide and / or one or two polypeptides similar to the light chain polypeptide. In other embodiments, the polypeptide may be a single chain antibody or other antibody discussed herein as long as the polypeptide has at least 70% sequence identity or homology with 1, 2, 3, 4, 5 or 6 CDRs of mAb 3F6.

[0027] In some embodiments, the heavy chain of the humanized 3F6 antibody comprises the following sequence:

[0028] In some embodiments, the light chain of the humanized 3F6 antibody comprises the following sequence:

[0029] In some embodiments, the antibody is humanized. In some embodiments, the antibody is chimeric. In some embodiments, the antibody comprises at least one or at least two glycosylated amino acids. In some embodiments, the antibody comprises a crystallizable fragment region γ (Fcγ). In some embodiments, the Fc region of the antibody comprises one or more than one substitution, and one or more than one substitution includes S254A, Q311E, L432S, N434P and / or H435R. In some embodiments, the Fc region of the antibody comprises S254A, Q311E, L432S and N434P substitutions. In some embodiments, the Fc region of the antibody comprises H435R substitutions. In some embodiments, the antibody comprises at least one, at least two or at least 3 substitutions at one or more than one amino acid at positions 226 to 447 of the Fc region of the antibody. In some embodiments, the antibody comprises at least one, at least two, or at least 3 substitutions at one or more amino acids at positions 109 to 330 of SEQ ID NO:1 or at one or more amino acids at positions 6 to 227 of SEQ ID NO:8.

[0030] An exemplary human immunoglobulin heavy chain gamma 1 constant region comprises the following amino acid sequence:

[0031]

[0032] The positions of the antibody corresponding to positions 297, 254, 311, 432, 434 and 435 are highlighted in SEQ ID NO: 1 and correspond to positions 180, 137, 194, 315, 317 and 318 of SEQ ID NO: 1, respectively.

[0033] In some embodiments, the constant region comprises the following sequence: The positions of the antibody corresponding to positions 297, 254, 311, 432, 434 and 435 are highlighted in SEQ ID NO:8 and correspond to positions 77, 34, 91, 212, 214 and 215 of SEQ ID NO:8, respectively.

[0034] In some embodiments, the Fc region of the antibody comprises four substitutions (S254A, Q311E, L432S, N434P) in combination with one or more substitutions, and one or more substitutions include T307R, T307Q, A378V, alone or in combination. In some embodiments, the Fc region of the antibody comprises an H435R substitution in combination with one or more substitutions, and one or more substitutions include T256D, N286D, T307R, T307Q, Q311V, A378V, alone or in combination. In some embodiments, the antibody comprises at least 1, 2, 3, 4, 5 or 6 substitutions selected from T256D, N286D, T307R, T307Q, Q311V, A378V, or any derivable range thereof. The positions of the antibodies corresponding to positions 256, 286, 307, 311 and 378 are highlighted in SEQ ID NO:8 and correspond to positions 36, 66, 87, 91 and 158 of SEQ ID NO:8, respectively.

[0035] In some embodiments, the antibody comprises the Fc region of the antibody of SEQ ID NO: 1 or 8, in the CDR region of SEQ ID NO: 2 to 7, or in the CDR region of SEQ ID NO: 8, respectively. NO: 9 or 10 in the heavy or light chain at amino acid 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277 77, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335 5.336,337,338,339,340,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393 , 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451,In some embodiments, the antibody of SEQ ID NO: 1 or 8 comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 or any range derivable therein. In some embodiments, the antibody of SEQ ID NO: 1 or 8 comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 or any range derivable therein. 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270 0, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371 1, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, ​​383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421,The amino acid at position 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459 or 460 is replaced by alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine.

[0036] In some embodiments, the Fc region of an antibody of SEQ ID NO: 1 or 8, the CDR region of SEQ ID NO: 2 to 7, or the224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311 1, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342 42, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, ​​383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, or 460.

[0037] In some embodiments, the Fc region of an antibody of SEQ ID NO: 1 or 8, the CDR region of SEQ ID NO: 2 to 7, or the224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311 1, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342 42, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372 , 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, ​​383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403 3. The amino acid at position 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459 or 460 is substituted with a non-conservative amino acid.

[0038] In some embodiments, the antibody is capable of increasing OPK activity in a subject compared to tifizumab. In some embodiments, the glycosylated amino acid comprises a galactosylated amino acid. In some embodiments, the amino acid is monogalactosylated. In some embodiments, the amino acid is digalactosylated. In some embodiments, the antibody has Asn at the Fc region of the antibody. 297 In some embodiments, Asn 297 Corresponding to amino acid position 180 of SEQ ID NO: 1. In some embodiments, Asn 297 Corresponding to amino acid position 77 of SEQ ID NO: 8. In some embodiments, the antibody is afucosylated. The term "afucosylated" refers to the absence of fucosyl modification. Afucosylation can be due to removal of existing fucosyl groups or production of the antibody under conditions that do not support fucosylation. In some embodiments, the antibody is afucosylated at Asn 297 In some embodiments, the antibody is desialylated. The term desialylated refers to the absence of sialic acid modification. Desialylation can be due to removal of existing sialic acid groups or production of the antibody under conditions that do not support sialylation. In some embodiments, the antibody is desialylated at Asn 297 or at amino acid position 180 of SEQ ID NO: 1. In some embodiments, the antibody is desialylated at Asn 297 In some embodiments, the antibody is further defined as having a modified structure of G2S2F, G2F, G1F, G2 or G1. Fig.16 Examples are given in the following sections.

[0039] In some embodiments, the cells of the present disclosure include the expression of heterologous glycosyltransferases. The term "heterologous" refers to proteins expressed from nucleic acids transferred into cells by gene transfer. Nucleic acids can be expressed from transfer nucleic acids that are integrated or edited into the genome or separated from the host genome. In some embodiments, glycosyltransferases are modified. In some embodiments, cells are modified to reduce or eliminate the expression of one or more than one fucosylation and / or sialylase. In some embodiments, cells are modified to reduce or eliminate the expression of Fut8 and / or 23STGal4 / 6. In some embodiments, cells include mammalian cells. In some embodiments, cells include human cells. In some embodiments, cells include endogenous glycosyltransferase activity. In some embodiments, cells include CHO cells.

[0040] In some embodiments, the method includes culturing cells in a medium supplemented with galactose alone or in a medium supplemented with galactose in combination with manganese chloride and / or uridine. In some embodiments, the method includes culturing cells in a medium supplemented with N-acetylmannosamine (ManNAc) and / or butyrylated ManNAc.

[0041] In some embodiments, the method comprises culturing cells in an afucosylation enrichment medium. The term afucosylation enrichment medium refers to a medium that inhibits fucosylation of polypeptides to enrich for afucosylated polypeptides. In some embodiments, the afucosylation enrichment medium comprises kifnosine. In some embodiments, the method comprises culturing cells in a desialylation enrichment medium. The term desialylation enrichment medium refers to a medium that inhibits sialylation of polypeptides to enrich for desialylated polypeptides. In some embodiments, the desialylation enrichment medium comprises neuraminidase.

[0042] In some embodiments, treatment or prevention includes promoting Staphylococcus aureus to colonize, preventing invasive MRSA disease and improving one or more than one of the results of MRSA bloodstream infection in the subject. In some embodiments, staphylococcal infection and / or colonization include infection and / or colonization of Staphylococcus bacteria, and wherein the bacteria include Staphylococcus aureus bacteria. In some embodiments, Staphylococcus is resistant to one or more than one treatment. In some embodiments, the bacteria is methicillin-resistant. In some embodiments, the subject does not show any signs of toxicity from the separated polypeptide or composition. In some embodiments, the subject does not show any signs of anaphylactic shock from the separated polypeptide or composition. In some embodiments, the subject is human. In some embodiments, the antibody is administered intravenously.

[0043] One or more than one sequence or composition can be used based on any method described herein. Other embodiments are discussed throughout this application. Any embodiment discussed about one aspect of the disclosure is also applicable to other aspects of the disclosure, and vice versa. For example, any step in the method described herein can be applied to any other method. In addition, any method described herein can exclude any step or step combination. The embodiments in the example section should be understood as embodiments applicable to all aspects of the technology described herein.

[0044] In this application, the term "about" is used according to its plain and ordinary meaning in the art of cell biology to indicate a value that includes the standard deviation of error for the device or method being employed to determine the value.

[0045] When used in conjunction with the term "comprising", the indefinite quantifier preceding the element can mean "a", and can also mean "one or more", "at least one", and "one or more than one".

[0046] As used herein, the terms "or" and "and / or" are used to describe multiple components that are mutually combined or mutually exclusive. For example, "x, y, and / or z" can refer to "x" alone, "y" alone, "z" alone, "x, y, and z", "(x and y) or z", "x or (y and z)", or "x or y or z". It is specifically contemplated that x, y, or z can be specifically excluded from an embodiment.

[0047] The words "comprising", "having", "including", "characterized by", or "containing" are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.

[0048] Compositions and methods of use thereof may "include," "consist essentially of," or "consist of" any ingredient or step disclosed throughout the specification. The phrase "consisting of" excludes any element, step, or ingredient not specified. The phrase "consisting essentially of" limits the scope of the subject matter to the specified materials or steps, as well as materials or steps that do not materially affect the basic and novel features thereof. It is contemplated that embodiments described in the context of the term "comprising" may also be implemented in the context of the term "consisting of" or "consisting essentially of."

[0049] It is particularly contemplated that any limitation discussed with respect to one embodiment of the invention may be applicable to any other embodiment of the invention. In addition, any composition of the invention may be used in any method of the invention, and any method of the invention may be used to produce or utilize any composition of the invention. Aspects of the embodiments described in the examples are also embodiments that may be implemented in the context of embodiments discussed in other parts of the different examples or other parts of the application, such as the summary of the invention, the detailed description, the claims, and the accompanying drawings.

[0050] Other purposes, features and advantages of the present invention will become apparent due to the following specific embodiments. However, it should be understood that the specific embodiments and specific examples, although indicating specific embodiments of the present invention, are given as illustrations only, because those skilled in the art will be aware of various changes and modifications within the spirit and scope of the present invention based on the specific embodiments. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] In order to obtain and understand in detail the above-mentioned features, advantages and purposes of the present invention and other contents that will become clear, the more specific description of the present invention briefly summarized above and certain embodiments are shown in the accompanying drawings. These drawings constitute a part of the specification. However, it should be noted that the accompanying drawings illustrate certain embodiments of the present invention and therefore should not be considered as limiting the scope of the present invention.

[0052] Figures 1A-1B. Staphylococcal immunoglobulin binding proteins (IBPs) block opsonophagocytic killing (OPK) of MRSA. MRSA secretes three IBPs, Staphylococcal protein A (SpA), Staphylococcal immunoglobulin binder (Sbi), and Staphylococcal superantigen-like protein 10 (SSL10). IBPs bind to the hinge region of IgG (composed of CH2 and CH3), thereby blocking the effector function of Fcγ in activating C1q. (A) IBP binding to IgG blocks opsonization of MRSA in phagocytes and OPK of MRSA. (B) Structure of human IgG with heavy chain (VH-CH1-CH2-CH3) and light chain (VL-CL) and antigen binding paratope (CDR1-2-3).

[0053] Figure 2A-2B. B cell superantigen activity (BCSA) of Staphylococcal protein A (SpA) blocks adaptive immune responses during MRSA infection. (A) MRSA secretes SpA, which crosslinks the VH3 B cell receptor (BCR), thereby activating B cell proliferation and secretion of VH3 IgG that cannot bind MRSA antigens. Together with the Fcγ binding activity of IBP, the BCSA of SpA ensures that MRSA cannot be opsonized and killed in phagocytes. (B) Structure of the BCR before and after SpA crosslinking.

[0054] Figure 3A to Figure 3G. Staphylococcal protein A (SpA) is a key virulence factor and target for therapeutic antibodies. (A) SpA and its KK (does not bind to Fcγ), SpA AA (does not bind to VH3 Fab) and SpA KKAA (Does not bind to human IgG) primary structure. (B) Has anti-SpA KKAA Fluorescence microscopy of Staphylococcus aureus and flow cytometry of Staphylococci incubated with labeled human IgG F(ab)2 or Fcγ. (C) Patients with MRSA bacteremia and no previous infection (blank) or with previous infection with wild-type or spa KKAA (D) Serum IgG responses of mice in (C) before MRSA challenge. (E) Disease phenotypes associated with S. aureus bacteremia after challenge with wild-type and spa mutant strains. (F) SpA KKAA(G) MAb 3F6-IgG2a mediates protection against MRSA bacteremia. (H) MAb 3F6-IgG2a induced MRSA OPK in mouse blood compared to isotype control (IgG2a). Giemsa-stained blood showed that 3F6-IgG2a induced MRSA uptake into granulocytes.

[0055] Figures 4A to 4F. SpA-IgG1 glycoforms are determinants of MRSA therapeutic efficacy. (A) N-linked glycan types of IgG therapeutics. (B) Structure of 3F6-hIgG1 that binds and neutralizes SpA; Asn297 is highlighted in red. When purified from CHO cells or HEK293 F cells, SpA-IgG1 differed only in the relative abundance of specific glycoforms. 3F6-hIgG1 injected into mice 24 hours before MRSA bacteremia challenge CHO and 3F6-hIgG1 HEK Quantification of MRSA load in renal tissue (C) and MRSA abscess lesions (D). (E) 3F6-hIgG1 HEK Higher binding affinity to human C1q than 3F6-hIgG1 CHO 3F6-hIgG1 HEK and 3F6-hIgG1 CHO Used to synthesize antibodies with uniform glycoforms (G0F, G1F and G2F) and analyze their efficacy in preventing MRSA replication (F) and renal abscess lesions in mice (G). The G2F glycoform of 3F6-hIgG1 provided the best protection against MRSA.

[0056] Figures 5A to 5M. IgG1 Fcγ variants are unresponsive to interference with Staphylococcal IBP. (A) Diagram illustrating the binding sites of 3F6 MAb on SpA and Sbi and 2A12 MAb on ClfA. (B) SpA and Sbi expression protects MRSA USA300 LAC from killing by opsonized phagocytes in human blood for 60 minutes. Cytochalasin-D blocks phagocytosis and ensures survival of the ΔspaΔsbi mutant in human blood. The first data bar in each group represents USA300 and the second data bar in each group represents ΔspaΔsbi. (C) Four amino acid substitutions (S in Fcγ) were observed in the IgG1 Fcγ mutants. 254 A.Q 311 E.L 432 S and N 434 P) 3F6-1gG1 ASEP (D) 3F6-hIgG1 and 2A12-hIgG1 induce MRSA OPK in human blood. Compared with 3F6-hIgG1, 3F6-IgG1ASEP OPK enhancement of MRSA USA300 LAC was measured for 3F6-hIgG1 and 3F6-hIgG1 ASEP For (E)SpA AA (binds to Fcγ but not V H (J) The figure illustrates the deposition of pIII at the tip of M13KO7 phage carrying an empty pIII-Fcγ phagemid, which results in the deposition of pIII-Fcγ at the tip of the filamentous phage. Immunoblotting with anti-hIgG HRP conjugate was used to identify pIII-Fcγ and pIII-Fcγ dimers. (K) M13KO7 pIII and M13KO7 pIII-Fcγ particles were isolated and measured for binding to SpA. The Fcγ coding sequence in pIII-Fcγ was mutagenized using error-prone PCR, and M13KO7 pIII-Fcγ particles that could not bind SpA but retained the ability to bind FcRn were isolated and sequenced. The binding of the best six pIII-Fcγ variants to (L) SpA and (M) FcRn was analyzed.

[0057] Figure 6A-6B. 3F6 MAb promotes clearance of S. aureus from the nasopharynx and gastrointestinal tract of colonized mice. (A) C57BL / 6 mice (n=10) were inoculated with S. aureus WU1 and nasopharyngeal colonization was measured by swabbing; each symbol represents the log from one animal. 10 CFU / swab (n=10). Median values ​​are represented by horizontal bars. Animals were treated with IgG2a control antibody or 3F6-mIgG2a and analyzed for colonization at weekly intervals. (B) Serum IgG against purified S. aureus antigens was measured by ELISA and analyzed by paired comparison with naive, colonized or cleared animals. For binding to S. aureus antigens, analysis was performed by paired comparison with colonized or cleared animals.

[0058] Figure 7A to Figure 7H. 3F6-hIgG1 produced by HEK 293F cells protects mice from MRSA bloodstream infection. a, Human V H Schematic diagram of the recombinant antibodies produced by exchanging the complementary determining regions (CDRs) of 1-idiotypic IgG1 with the CDRs of the mouse hybridoma 3F6-mhIgG2a. Production in CHO-DG44 and HEK 293F cells produced 3F6-hIgG1, respectively. CHO and 3F6-hIgG1 HEKb, Coomassie-stained antibody gel. Non-reducing, reducing: non-reducing and reducing conditions. c, Binding of antibodies to SpAKKAA determined by enzyme-linked immunosorbent assay (ELISA) and reported as binding constant (Ka) (n=3); A 450 , absorbance at 450 nm. d, antibody 3F6-hIgG1 CHO and 3F6-hIgG1 HEK It blocks the binding of SpA to human IgG better than human IgG1 (hIgG1). The values ​​are normalized to the interaction of SpA with human IgG in PBS (n=3). For each set of three bars, the bars in d represent hIgG1, 3F6-hIgG1 from left to right. CHO and 3F6-hIgG1 HEK e to f, Animals (Balb / c) received PBS, human IgG1 (hIgG1), mouse hybridoma monoclonal antibodies 3F6-mhIgG2a, 3F6-hIgG1 before challenge with S. aureus MW2. CHO or 3F6-hIgG1 HEK 15 days after infection, kidneys (n=16 to 20, from two independent experiments) were removed and either ground for CFU / g tissue counts (e) or fixed and stained for internal abscess counts (f). g, 3F6-hIgG1 was administered before infection HEK Promotes enhanced anti-staphylococcal serum immunoglobulin G response. Sera from the animals shown in e (n=3) were tested for antibodies against the indicated Staphylococcus aureus antigens. Each group of data bars represents hIgG1, 3F6-hIgG1, CHO and 3F6-hIgG1 HIK ; h, Plasma concentration-time curves after intraperitoneal administration of antibodies to Balb / c mice (n=5). Data are expressed as mean±sem. (c to h). Significant differences were determined by one-way ANOVA using two-tailed t-test (d, g) and Kruskal-Wallis test (e, f): **, P<0.01; *, P<0.05. ns=not significant.

[0059] Figure 8A to Figure 8J. 3F6-hIgG1 glycoforms are a determinant of the therapeutic effect against MRSA. a, 3F6-hIgG1 with glycan structure CHO (Left) and 3F6-hIgG1 HEK(right) MALDI-TOF mass spectra of: fucose (brown), N-acetylglucosamine, mannose and galactose. b, Quantification of glycoforms from the mass spectra shown in a. c to j, Animals (Balb / c) received the indicated test antibodies prior to challenge with S. aureus MW2. Body weights were recorded daily (n=10) and reported as % of initial body weight; each group of data bars represents, from left to right, 3F6-hIgG1, 3F6-hIgG2, 3F6-hIgG3 and 3F6-hIgG4, respectively. CHO and 3F6-hIgG1 HIK ; (c, f). 15 days after infection, kidneys and serum were obtained during necropsy as described in Figure 1; kidneys (n = 16 to 20; from two independent experiments) were examined for CFU (d, g), and internal abscesses (e, h) and animal sera (n = 6 to 10) were tested for antibodies against the indicated S. aureus antigens (i, j). Data are expressed as mean ± sem. (c to j). Significant differences were determined using one-way ANOVA with Kruskal-Wallis test (d, e, g, f) and two-tailed t-test (i to j), and: **, P < 0.01; *, P < 0.05. ns = not significant. In i, the bars in each group of six data bars represent, from left to right, hIgG1, 3F6-hIgG1, CHO 、3F6-IgG1 CHO -Gal 、3F6-hIgG1 HEK 、3F6-hIgG1 HEK -deGal and 3F6-hIgG1 HEK -deSia In j, the bars in each group of seven data bars represent hIgG1, 3F6-hIgG1, CHO 、3F6-IgG1 CHO -G2F 、3F6-hIgG1 HEK 、3F6-hIgG1 HEK -G0F 、3F6-hIgG1 HEK -G1F and 3F6-hIgG1 HEK -G2F .

[0060] Figures 9A to 9H. Complement and FcγR responses to 3F6-hIgG1 HEK Contribution of mediated protection against MRSA bloodstream infection. a to c, Animals (Balb / c, n=10, two independent experiments) received control hIgG1, 3F6-hIgG1H before challenge with S. aureus MW2 EK 、3F6-hIgG1 HEK -KA or 3F6-hIgG1HEK -LALA. Disease was assessed as in Figure 1. d to e, before challenge with S. aureus MW2, with or without CVF and control hIgG1 or 3F6-hIgG1 HEK Treated animals (Balb / c, n=16 to 20 from two independent experiments). Disease was assessed by measuring bacterial load and abscess lesions in the kidneys 15 days after challenge. f to h, Before challenge with S. aureus MW2, control hIgG1, 3F6-hIgG1 HEK or 3F6-hIgG1 HEK -afu antibody treated animals (Balb / c, n=10, two independent experiments). Disease was assessed as described in Figure 1. Data are presented as mean±sem. Significant differences were determined by one-way ANOVA using the Kruskal-Wallis test: **, P<0.01; *, P<0.05. One of two replicates is shown.

[0061] Figures 10A to 10C. 3F6-hIgG1 HEK Use of complement and FcγR to promote opsonophagocytic killing in human blood. a to b, Opsonophagocytosis of S. aureus MW2 in human blood in the absence of cytochalasin D (CD) and in the absence of CVF (n=4). c, Opsonophagocytosis of S. aureus MW2 in human blood with hIgG1 and 3F6-hIgG1 HEK Compared to the opsonophagocytic killing activity of antibody variants against Staphylococcus aureus MW2 in human blood (n=10). Data are plotted as mean±sem. CFU after 60 minutes of incubation in blood (set to 100%) compared to CFU of the inoculum. Significant differences were determined using a two-tailed t-test: *P<0.05; **P<0.01.

[0062] Figures 11A-11C. 3F6-hIgG1 produced by HEK 293F cells protects mice from MRSA bloodstream infection. a, Whole kidney from the animal of Figure 1e. Examples of discoloration and abscesses are indicated by gray and white arrows, respectively. b, Sera from animals passively immunized with PBS or 3F6-mhIgG2a (n=3) were tested for antibodies against the indicated S. aureus antigens. c, ELISA detection of 3F6-hIgG1 CHO Affinity of 3F6-hIgG1 HEK and 3F6-hIgG1 HEK for human neonatal Fc receptor FcRn (n=3). Data are presented as mean±sem. (b to c). Significant differences were determined using a two-tailed t-test (b): **, P<0.01; *, P<0.05.

[0063] Figures 12A to 12J. Biochemical characterization of 3F6-hIgG1 glycoforms. Antibodies were serially diluted on ELISA plates coated with ECL (a, e) and SNA (b, h) to compare galactosylation and sialylation content, respectively. c, f, i, Coomassie-stained SDS-PAGE of purified antibodies. Numbers on the left side of the gel indicate molecular weights in kDa. d, g, j, Antibodies were serially diluted on ELISA plates coated with SpA KKAA Serial dilutions were applied to ELISA plates to calculate the binding constants shown in bold. Data are presented as mean ± sem. (a, b, d, e, g, h, j). Experiments were performed in triplicate and affinity measurements are reported in the Figures and Table 1.

[0064] Figures 13A to 13G. Effect of antibody glycosylation on C1q and FcγR binding. Antibodies were serially diluted on ELISA plates coated with ligands as follows: C1q (a, b, e to g), mouse FcγR (c), and human FcγR (d). Data are presented as mean ± sem. Experiments were performed in triplicate and affinity measurements are reported in the figures and Table 2.

[0065] Figure 14A to Figure 14I. Compared with wild-type 3F6-hIgG1 HEK In comparison, 3F6-hIgG1 HEK -KA or 3F6-hIgG1 HEK Characterization of -LALA variants. a, Coomassie-stained SDS-PAGE of purified antibodies. Numbers on the left side of the gel indicate molecular weight markers in kDa. b to f, SpA-coated KKAA (b), antibodies serially diluted on ELISA plates for lectins SNA, AAL and ECL (c), human and mouse C1q (d), human FcγR (e) and mouse FcγR (f). g, i, Sera from animals of Figure 3a (g) and Figure 3b (i) (n = 8 to 10) were tested for antibodies against the indicated S. aureus antigens. Significant differences were determined using a two-tailed t-test: **, P < 0.01; *, P < 0.05. h, whole kidney from an animal of Figure 3b. Examples of discoloration and abscesses are indicated by gray and white arrows, respectively. Data are expressed as mean ± sem. Experiments were performed in triplicate (b to f) and duplicate (g, i), and affinity measurements are reported in the Figures and Table 2.

[0066] Figures 15A to 15G. 3F6-hIgG1 HEK and 3F6-hIgG1 HEK -afu Characterization of antibodies. a, Coomassie-stained SDS-PAGE of purified antibodies. Numbers on the left side of the gel indicate molecular weight markers in kDa. b to f, SpA-coated KKAA(b), antibodies were serially diluted on ELISA plates for lectins SNA, AAL and ECL (c), human and mouse C1q (d), mouse FcγR (e) and human FcγR (f). g, Sera from animals in Figure 3c (n = 8 to 10) were tested for antibodies against the indicated S. aureus antigens. Significant differences were determined using a two-tailed t-test (g): **, P < 0.01; *, P < 0.05. Data are expressed as mean ± sem. Experiments were performed in triplicate (b to f) and duplicate (g), and affinity measurements are reported in the figures and Table 2.

[0067] Fig.16 Schematic G2S2F, G1F, G2F, G2 and G1 structures of antibodies are shown.

[0068] Figures 17A to 17G. Amino acid substitutions were made in the Fc domain of 3F6-hIgG1 to block the interaction between SpA and Fc. (a, f) ELISA was used to measure the affinity of candidate antibodies to purified SpA and SpA KKAA Affinity. The control antibody hIgG1 has high affinity only for SpA. (b, g) The affinity of the candidate antibodies to S. aureus Newman wild-type (WT) and spakkaa variant isogenic strains was measured using ELISA. The control antibody hIgG1 only bound to the WT strain; as expected, none of the antibodies interacted with bacteria from the Δspa strain lacking the spa gene. (c) Addition of SpA instead of SpA KKAA , reducing the binding between Tefi and its ligand ClfA-A. (d) Tefi has stronger binding to S. aureus Newman spakkaa than WT strain. The bars in each group of two data bars represent hIgG1 and Tefi from left to right, respectively. (e) By increasing SpA AA (SpA protein mutant that can only bind to the Fc region of the antibody instead of the Fab) concentration to replace the candidate antibody variant and SpA KKAA Immune complexes (IC) between them.

[0069] Figures 18A to 18C. (a) Mouse antibody 3F6-mIGg2a has an inhibitory effect on SpA compared to SpA KKAA (b) All antibody variants have a higher affinity for SpA. KKAA (c) The NewmanΔspa strain cannot be recognized by 3F6-hIgG1 and its variants.

[0070] Figure 19A to Fig.19E SpA no longer blocks human c1q (hc1q) and 3F6-hIgG1AESP or 3F6-hIgG1 R (a) The interaction between 3F6-hIgG1 and hc1q is greatly reduced in the presence of SpA and to a lesser extent in the presence of SpAKKAA. AESP and 3F6-hIgG1 R This is not the case, regardless of the presence or absence of SpA or SpA KKAA , both of which showed similar binding to hc1q. (b) SpA blocked the association of the IC formed between Tefi and ClfA-A with hc1q. (c) Compared with 3F6-hIgG1, 3F6-hIgG1 AESP or 3F6-hIgG1 R Higher hc1q binding in the Newman WT strain and similar hc1q binding in the Newman spakkaa strain. (d) Increasing Tefi gradually enhanced hc1q binding to S. aureus Neman spakkaa, but not to the WT strain. (e) SpA did not block antibody binding to human FcγR, and amino acid substitutions in the antibody variants had no effect on human FcγR interaction. The bars in each group of bars in c represent, from left to right, PBS, no hc1q or HS; PBS; hIgG1; 3F6-hIgG1; 3F6-hIgG1 R ; and 3F6-hIgG1 AESP The bars in each group of bars in e from left to right represent PBS, no ligand; PBS; hIgG1; 3F6-hIgG1; 3F6-hIgG1 R ; and 3F6-hIgG1 AESP .

[0071] Figure 20A-20B. (a) SpA disrupts the interaction between 3F6-mIgG2a and mouse c1q (mc1q). (b) hIgG1 retains the ability to bind to mutant bacterial SpA. aa The combination of AA Variant strains that no longer bind V H 3 antibodies, indicating that the hIgG1 used in this assay is a non-V H 3 Antibodies.

[0072] Figures 21A to 21K. (a) SpA interacts with mIgG2a, mIgG2b, and mIgG3, but not with mIgG1. (b) SpA interacts with hIgG1, hIgG2, and hIgG4, but not with hIgG3. (c, d) Injection of SpA in mice (n=5) does not alter the levels of mIgG1 (c) and mIgG2b (d) in serum. (e, f) Newman WT and spakkaa-infected mice (n=5) show comparable levels of mIgG1 (e) and mIgG2b (f) in serum. (g to j) Newman WT strain infection results in V H Amplification of 3 clones mIgG1 (g), mIgG2a (h), mIgG2b (i), and mIgG3 (j). (k) SpA injection but not SpA injection KKAA Enhanced immunogenicity of tefi in mice (n=5). The bars in each group of bars in k represent Tefi, Tefi+SpA and Tefi+SpA from left to right, respectively. KKAA .

[0073] Figures 22A to 22I. SpA interferes with the interaction of FcRn with antibodies and affects the stability of antibodies in animals unless the antibodies carry Fc substitutions, such as 3F6-hIgG1 AESP and 3F6-hIgG1 R (a) The interaction of mIgG2a, mIgG2b, and mIgG3 with mouse FcRn (mFcRn) at pH 6.0 is controlled by SpA but not SpA KKAA (b) The interaction of hIgG1, hIgG2, and hIgG4 with human FcRn (hFcRn) at pH 6.0 is regulated by SpA but not SpA KKAA (c, d) Injection of SpA instead of injection of SpA KKAA Resulted in decreased levels of mIgG2a (c) and mIgG3 (d) in mouse serum at 6 hours (h) and 6 hours, 24 hours, and 3 days (d) after SpA injection, respectively. (e, f) Mice infected with the WT Newman strain showed lower levels of mIgG2a (e) and mIgG3 (f) in serum early after infection compared to mice infected with Newman spakkaa (n=5 mice per group). (g) hIgG1 or hIgG3 were injected intraperitoneally into μMT mice (100 μg antibody / mouse) before staphylococcal infection. Infection with S. aureus Newman WT, but not mutant spakkaa strains, resulted in lower levels of hIgG1 but not hIgG3 in μMT mice (n=5). (h) SpA reduced the stability of Tefi in WT mice. SpA (4 μg) or SpAKKAA (4 μg) was mixed with Tefi (100 μg), and the mixture was then injected intraperitoneally into WT mice. (i) Antibody half-life in animals. AESP and 3F6-hIgG1 R In contrast, the half-life of 3F6-hIgG1 was greatly shortened when animals were injected with SpA. KKAA The half-lives of the 247 cells / mL and 104 μg / mL mice were comparable, although their stability was higher after PBS inoculation.

[0074] Figure 23A-23B. 3F6-hIgG1 AESP and 3F6-hIgG1 R Enhanced anti-staphylococcal activity in vitro and in vivo. (a) 3F6-hIgG1 AESP (fourth bar) and 3F6-hIgG1 R (third bar) Better MW2 killing than original 3F6-hIgG1 (second bar). First bar is hIgG1 control. (b) Tefi uniquely increases killing of S. aureus Newmanspakkaa strain.

[0075] Figure 24A to Figure 24E. (a) 3F6-hIgG1 AESP (The third bar in each data set) enhanced the killing ability of USA300 in human blood. The first bar in each data set is hIgG1, and the second bar in each data set is 3F6-hIgG1. (b and c) Compared with 3F6-hIgG1, 3F6-hIgG1 R The affinity of 3F6-hIgG1 for mFcRn at pH 6.0 (b) and pH 7.0 (c) was comparable to that of 3F6-hIgG1 for mFcRn, and was higher than that of 3F6-hIgG1. AESP The affinity of 3F6-hIgG1 to mFcRn was lower at pH 6.0 and pH 7.0. (d) Compared with 3F6-hIgG1, 3F6-hIgG1 AESP and 3F6-hIgG1 R The affinity for hFcRn is lower at pH 6.0. (e) All antibodies have no affinity for hFcRn at pH 7.0.

[0076] Figures 25A to 25D. (a) New variants of 3F6-hIgG1 are shown in SDS-PAGE under non-reducing and reducing conditions. Non-redu is non-reducing; Redu is reducing. (b) All new variants show similar affinity for the Newman spakkaa strain. (c) All variants show no affinity for the NewmanΔspa strain. (d) 3F6-hIgG1R-QVV (the third bar in each group) and 3F6-hIgG1 R-DDRVV (The fourth bar in each group) was highly immunogenic in WT mice. 3F6-hIgG1 was detected in WT mice on days 11 and 31 after antibody injection. R-QVV and 3F6-hIgG1 R-DDRVV The first, second, and fifth bars in each group represent 3F6-hIgG1, 3F6-hIgG1 R and 3F6-hIgG1 AESP .

[0077] Figure 26A to Figure 26D. New 3F6-hIgG1 variants have improved affinity for human FcRn at pH 6. (a) The new antibody variants have comparable affinity to the Newman WT strain. (b) Compared to 3F6-hIgG1 AESP and 3F6-hIgG1 R (c) The binding affinity of the new variants to human and mouse FcRn (hFcRn, mFcRn) was tested at pH 6 and pH 7. Antibodies with higher stability in vivo are expected to show high affinity to FcRn at pH 6 and low affinity at pH 7. (d) Comparison with 3F6-hIgG1, 3F6-hIgG1 AESP and 3F6-hIgG1 R Compared with the half-life of 3F6-hIgG1 in mice R-QVV and 3F6-hIgG1 R-DDRVV The half-life of these human antibody variants was significantly reduced. This is not unexpected considering the high affinity of these antibodies for mFcRn at pH 7. Therefore, the stability of these human antibody variants cannot be accurately assessed in wild-type mice and should be evaluated in transgenic mouse models of human FcRn.

[0078] Fig. 27 Compared with 3F6-hIgG1, 3F6-hIgG1 R-QVV and 3F6-hIgG1 R-DDRVV Promoted the increase of MW2's killing ability. Including antibody 3F6-hIgG1 R and 3F6-hIgG1 AESP As a control. DETAILED DESCRIPTION

[0079] Methicillin-resistant Staphylococcus aureus (MRSA) colonizes the nasopharynx and gastrointestinal tract of healthy individuals and hospitalized patients. Colonization is a key risk factor for both community-acquired and hospital-acquired MRSA invasive disease. MRSA infection is associated with treatment failure, increased morbidity, and increased mortality. Previous attempts to develop vaccines or immunotherapies that could prevent MRSA colonization or invasive disease or improve the outcome of MRSA infection have failed. Infected individuals fail to mount a protective antibody response (immunity), which allows MRSA to persist within host tissues and lead to disease recurrence. MRSA immune escape is based on immunoglobulin binding proteins, specifically staphylococcal protein A (SpA) and staphylococcal binders of immunoglobulins (Sbi). SpA and Sbi block the effector function of human IgG by binding to the Fcγ domain of antibodies. SpA also binds to V H The variant heavy chains of idiotypic immunoglobulins bind and cross-link IgM B cell receptors, thereby activating B cell proliferation and V-cells that cannot recognize MRSA. H 3 cloned antibodies. This B cell superantigen activity (BCSA) of SpA is essential for shifting antibody responses during MRSA colonization and invasive disease. The present disclosure relates to antibodies that bind and neutralize SpA and Sbi. The inventors show that galactosylation of MAb 3F6 on Fcγ promotes C1q binding, MAb 3F6-dependent opsonophagocytic killing (OPK) of MRSA, and protection of mice from MRSA bloodstream infection. In addition, the inventors isolated a variant MAb 3F6 with amino acid substitutions in Fcγ that eliminates SpA and Sbi binding and enhances OPK activity. The inventors also report that SpA is essential for suppressing antibody responses (BCSA) against bacterial colonization factors, thereby enabling Staphylococcus aureus to persist in the nasopharynx and gastrointestinal tract. Intravenous injection of MAb3F6 into mice neutralized circulating SpA and blocked its BCSA, thereby promoting antibody responses against bacterial surface antigens and removing Staphylococcus aureus from the nasopharynx and gastrointestinal tract. Here, the inventors will test the hypothesis that intravenous administration of saccharide and Fcγ engineered human 3F6-IgG1 in preclinical models a) elicits a broad-spectrum antibody response against S. aureus, b) promotes decolonization of MSSA and MRSA, c) induces immunity to prevent recolonization and invasive MSSA and MRSA disease, and d) improves the outcome of MRSA bloodstream infections. Saccharide and Fcγ engineered 3F6 antibodies that achieve this product profile can be further developed for clinical testing to prevent and treat MRSA infections in U.S. hospitals.

[0080] I. Antibodies

[0081] Aspects of the present disclosure relate to antibodies comprising the heavy chain or light chain of monoclonal antibody clone 3F6, respectively, or fragments thereof. The term "antibody" refers to a complete immunoglobulin of any isotype or a fragment thereof that can compete with a complete antibody for specific binding to a target antigen, including chimeric, humanized, fully humanized and bispecific antibodies. As used herein, the terms "antibody" or "immunoglobulin" are used interchangeably and refer to any of several classes of structurally related proteins that function as part of an animal's immune response, including IgG, IgD, IgE, IgA, IgM, and related proteins, as well as polypeptides comprising antibody CDR domains that retain antigen binding activity.

[0082] The term "antigen" refers to a molecule or a portion of a molecule that is capable of being bound by a selective binding agent such as an antibody. An antigen may have one or more than one epitope that is capable of interacting with different antibodies.

[0083] The term "epitope" includes any region or portion of a molecule that can elicit an immune response by binding to an immunoglobulin or T cell receptor. Epitope determinants may include chemically active surface groups such as amino acids, sugar side chains, phosphoryl or sulfonyl groups, and may have specific three-dimensional structural characteristics and / or specific charge characteristics. Typically, antibodies specific for a particular target antigen will preferentially recognize an epitope on the target antigen in a complex mixture.

[0084] Many different epitope mapping techniques well known in the art can be used to identify the epitope region of a given polypeptide, including: X-ray crystallography, nuclear magnetic resonance spectroscopy, site-directed mutagenesis mapping, protein display arrays, see, for example, Epitope Mapping Protocols, (Johan Rockberg and Johan Nilvebrant, Ed., 2018) Humana Press, New York, New York. Such techniques are known in the art and described in, for example, U.S. Patent No. 4,708,871; Geysen et al. Proc. Natl. Acad. Sci. USA 81: 3998-4002 (1984); Geysen et al. Proc. Natl. Acad. Sci. USA 82: 178-182 (1985); Geysen et al. Molec. Immunol. 23: 709-715 (1986). In addition, standard antigenicity and hydrophilicity maps can also be used to predict and identify the antigenic region of a protein.

[0085] The term "immunogenic sequence" refers to a molecule that includes an amino acid sequence of at least one epitope, such that the molecule is capable of stimulating the production of antibodies in an appropriate host. The term "immunogenic composition" refers to a composition comprising at least one immunogenic molecule (eg, antigen or carbohydrate).

[0086] A complete antibody is usually composed of two full-length heavy chains and two full-length light chains, but may include fewer chains in some cases, such as antibodies naturally occurring in camelid mammals may only contain heavy chains. Antibodies as disclosed herein may be derived from only a single source or may be "chimeric", i.e., different parts of the antibody may be derived from two different antibodies. For example, the variable region or CDR region may be derived from rat or mouse sources, while the constant region is derived from different animal sources, such as humans. Antibodies or binding fragments can be produced in hybridomas by recombinant DNA technology or by enzymatic or chemical cleavage of intact antibodies. Unless otherwise indicated, the term "antibody" includes derivatives, variants, fragments and mutant proteins thereof, examples of which are described below (Sela-Culang et al., Front Immunol. 2013; 4: 302; 2013).

[0087] The term "light chain" includes full-length light chains and fragments thereof having sufficient variable region sequences to confer binding specificity. A full-length light chain has a molecular weight of about 25,000 daltons and includes a variable region domain (abbreviated herein as VL) and a constant region domain (abbreviated herein as CL). There are two classifications of light chains, kappa (κ) and lambda (λ). The term "VL fragment" refers to a light chain fragment of a monoclonal antibody that includes all or part of the light chain variable region, including CDRs. The VL fragment may also include a light chain constant region sequence. The variable region domain of the light chain is located at the amino terminus of the polypeptide.

[0088] The term "heavy chain" includes full-length heavy chains and fragments thereof having sufficient variable region sequences to confer binding specificity. A full-length heavy chain has a molecular weight of about 50,000 daltons and includes a variable region domain (abbreviated herein as VH) and three constant region domains (abbreviated herein as CH1, CH2, and CH3). The term "VH fragment" refers to a heavy chain fragment of a monoclonal antibody including all or part of the heavy chain variable region, including CDRs. The VH fragment may also include a heavy chain constant region sequence. The number of heavy chain constant region domains depends on the isotype. The VH domain is located at the amino terminus of the polypeptide, and the CH domain is located at the carboxyl terminus, with CH3 being closest to the -COOH terminus. The isotype of an antibody may be IgM, IgD, IgG, IgA, or IgE, defined by the presence of a heavy chain, respectively, and there are five classifications: mu (μ), delta (d), gamma (γ), alpha (α), or epsilon (e) chain. IgG has several subtypes, including but not limited to IgG1, IgG2, IgG3, and IgG4. IgM subtypes include IgM1 and IgM2. IgA subtypes include IgA1 and IgA2.

[0089] Antibodies can be complete immunoglobulins of any isotype or classification, chimeric antibodies, or hybrid antibodies specific for two or more antigens. They can also be fragments (e.g., F(ab')2, Fab', Fab, Fv, etc.), including hybrid fragments. Immunoglobulins also include natural, synthetic or genetically engineered proteins that act as antibodies by binding to specific antigens to form complexes. The term antibody includes genetically engineered or otherwise modified forms of immunoglobulins, such as:

[0090] The term "monomer" refers to a unit containing only one Ig unit. Monomer is the basic functional unit of an antibody. The term "dimer" refers to an antibody comprising two Ig units connected to each other by the constant domain (Fc or crystallizable fragment region) of the antibody heavy chain. The complex can be stabilized by connecting (J) chain proteins. The term "multimer" refers to an antibody containing more than two Ig units connected to each other by the constant domain (Fc region) of the antibody heavy chain. The complex can be stabilized by connecting (J) chain proteins.

[0091] The term "bivalent antibody" refers to an antibody that contains two antigen binding sites. The two binding sites can have the same antigen specificity or they can be bispecific, meaning that the two antigen binding sites have different antigen specificities.

[0092] Bispecific antibodies are a class of antibodies with two paratopes, and the two paratopes have different binding sites for two or more than two different epitopes. In some embodiments, bispecific antibodies can be biparatopic, wherein bispecific antibodies can specifically recognize different epitopes from the same antigen. In some embodiments, bispecific antibodies can be constructed by a pair of different single-domain antibodies called "nanoantibodies". Single-domain antibodies are derived from cartilaginous fish and camelid mammals and modified. Nanoantibodies can be connected together by joints using typical techniques for those skilled in the art; such methods for selecting and connecting nanoantibodies are described in PCT Publication No. WO2015044386A1, No. WO2010037838A2 and Anal Chem.86 of Bever et al.: 7875–7882 (2014), each of which is incorporated herein by reference in its entirety.

[0093] Bispecific antibodies can be constructed as: complete IgG, Fab'2, Fab'PEG, diabodies, or as scFv. Diabodies and scFv can be constructed without the Fc region, using only the variable domains, which may reduce the impact of anti-idiotypic reactions. Bispecific antibodies can be produced by a variety of methods, including but not limited to fusion of hybridomas or connection of Fab' fragments. See, for example, Songsivilai and Lachmann, Clin. Exp. Immunol. 79: 315-321 (1990); Kostelny et al., J. Immunol. 148: 1547-1553 (1992), each of which is incorporated herein by reference in its entirety.

[0094] In certain aspects, the antigen-binding domains can be multispecific or heterospecific by multimerizing with VH and VL regions that bind different antigens. For example, the antibody can bind or interact with (a) a cell surface antigen, (b) an Fc receptor on the surface of an effector cell, or (c) at least one other component. Thus, aspects can include, but are not limited to, bispecific, trispecific, tetraspecific, and other multispecific antibodies or antigen-binding fragments thereof directed against epitopes and other targets, such as Fc receptors on effector cells.

[0095] In some embodiments, multispecific antibodies can be used and directly connected by short flexible polypeptide chains using conventional methods known in the art. Such an example is a bivalent bispecific antibody, in which the VH and VL domains are expressed on a single polypeptide chain and a linker that is too short to pair between domains on the same chain is used, thereby forcing the domain to pair with the complementary domain of another chain, resulting in two antigen binding sites. The linker function is applicable to embodiments of tribodies, tetrabodies, and higher-order antibody multimers. (For example, see Hollinger et al., Proc Natl. Acad. Sci. USA 90: 6444-6448 (1993); Polijak et al., Structure 2: 1121-1123 (1994); Todorovska et al., J. Immunol. Methods 248: 47-66 (2001)).

[0096] In contrast to bispecific complete antibodies, bispecific diabodies can also be advantageous because they can be easily constructed and expressed in E. coli. Phage display (WO94 / 13804) can be used to easily select diabodies (and other polypeptides, such as antibody fragments) with appropriate binding specificity from a library. If one arm of a diabody remains constant, for example, with specificity for a protein, a library can be established in which the other arm changes and selects antibodies with appropriate specificity. Bispecific complete antibodies can be prepared by alternative engineering methods described in Ridgeway et al. (Protein Eng., 9: 616-621, 1996) and Krah et al. (N Biotechnol. 39: 167-173, 2017), each of which is incorporated herein by reference in its entirety.

[0097] Heteroconjugate antibodies consist of two covalently linked monoclonal antibodies with different specificities. See, e.g., U.S. Pat. No. 6,010,902, which is incorporated herein by reference in its entirety.

[0098] The portion of the Fv fragment of an antibody molecule that binds to an antigen epitope with high specificity is referred to herein as the "paratope". The paratope consists of amino acid residues that contact the antigen epitope to promote antigen recognition. Each of the two Fv fragments of an antibody consists of two variable domains V H and V L The primary structure of each variable domain includes three hypervariable loops, which are separated by and located on both sides of the framework region (FR). The hypervariable loop is the region with the highest primary sequence variability in antibody molecules from any mammal. The term hypervariable loop is sometimes used interchangeably with the term "complementarity determining region (CDR)". The length of the hypervariable loop (or CDR) varies from antibody molecule to antibody molecule. The framework regions of all antibody molecules from a given mammal have a high degree of primary sequence similarity / consistency. Those skilled in the art can use the consensus sequence of the framework region to identify the framework region and the hypervariable loops (or CDRs) interspersed between the framework regions. The hypervariable loops are given identification names to distinguish their location in the polypeptide and on which domain they appear. L The CDRs in the domain are identified as L1, L2, and L3, with L1 occurring in the C L The most distal end of the domain, L3 appears closest to C L The location of the domain. CDRs may also be designated as CDR-1, CDR-2, and CDR-3. L3 (CDR-3) is usually the region with the highest variability among all antibody molecules produced by a given organism. CDRs are regions of the polypeptide chain that are arranged linearly in the primary structure and are separated from each other by framework regions. LThe amino terminus (N-terminus) of the chain is referred to as FR1. The region labeled FR2 occurs between the L1 and L2 hypervariable loops. FR3 occurs between the L2 and L3 hypervariable loops, and the FR4 region is closest to the C L Domain. H This structure and nomenclature are repeated in the 1 chain, which includes three CDRs designated H1, H2, and H3. H and V L ) are part of the framework region (about 85%). The three-dimensional or tertiary structure of the antibody molecule is such that the framework region is located more internally in the molecule and provides the majority of the structure, while the CDRs are on the exterior surface of the molecule.

[0099] Several methods have been developed that can be used by those skilled in the art to identify the exact amino acids that make up each of these regions. This can be accomplished using any of a variety of multiple sequence alignment methods and algorithms that identify conserved amino acid residues that make up the framework regions, and thus identify CDRs that may vary in length but are located between framework regions. Three commonly used methods have been developed to identify the CDRs of antibodies: Kabat (described in TT Wu and EA Kabat, “AN ANALYSIS OF THE SEQUENCES OF THE VARIABLE REGIONS OF BENCEJONES PROTEINS AND MYELOMA LIGHT CHAINS AND THEIR IMPLICATIONS FOR ANTIBODY COMPLEMENTARITY,” J Exp Med, vol. 132, no. 2, pp. 211–250, Aug. 1970); Chothia (described in C. Chothia et al., “Conformations of immunoglobulin hypervariable regions,” Nature, vol. 342, no. 6252, pp. 877–883, Dec. 1989); and IMGT (described in M.-P. Lefranc et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Developmental & Comparative Biology, 2003; 15(5): 117–118. Immunology, vol. 27, no. 1, pp. 55–77, Jan. 2003). Each of these methods includes a unique numbering system for identifying the amino acid residues that make up the variable region. In most antibody molecules, the amino acid residues that actually contact the antigen epitope appear in the CDRs, although in some cases, residues within the framework region contribute to antigen binding.

[0100] A person skilled in the art can use any of a variety of methods to determine the paratope of an antibody. These methods include: 1) computational prediction of the tertiary structure of the antibody / epitope binding interaction based on the chemical properties of the variable region amino acid sequence of the antibody and the composition of the epitope; 2) hydrogen deuterium exchange and mass spectrometry; 3) polypeptide fragmentation and peptide mapping analysis methods, in which multiple overlapping peptide fragments are generated from the full length of the polypeptide and the binding affinity of these peptides to the epitope is evaluated; 4) antibody phage display library analysis, in which mammalian antibody Fab fragment encoding genes are expressed by phage to bind to the phage coat. The Fab-expressing phage population is then allowed to interact with an antigen that has been fixed or can be expressed by different exogenous expression systems. The non-bound Fab fragments are washed away, leaving only the specifically bound Fab fragments that bind to the antigen. The bound Fab fragments can be easily separated and the genes encoding them can be determined. This method can also be used for smaller regions of Fab fragments, which include Fv fragments or appropriate specific V H and V L Structural domain.

[0101] In certain aspects, affinity matured antibodies are enhanced by one or more modifications in one or more of their CDRs, resulting in an increase in the affinity of the antibody for the target antigen compared to a parent antibody that does not have these changes. Certain affinity matured antibodies will have nanomolar or picomolar affinities for the target antigen. Affinity matured antibodies are produced by processes known in the art, for example, Marks et al., Bio / Technology 10:779 (1992) describes the use of V H and V L Affinity maturation by domain shuffling, random mutagenesis of CDR and / or framework residues for phage display is described in Rajpal et al. PNAS. 24:8466-8471 (2005) and Thie et al. Methods Mol Biol. 525:309-22 (2009) in combination with computational methods demonstrated in Tiller et al. Front. Immunol. 8:986 (2017).

[0102] Chimeric immunoglobulins are the product of fused genes from different species; a "humanized" chimera typically has framework regions (FRs) from a human immunoglobulin and one or more CDRs from a non-human source.

[0103] In certain aspects, portions of the heavy and / or light chains are identical or homologous to corresponding sequences from another specific species or belonging to a specific antibody class or subclass, while the remainder of the chain is identical or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, as long as they exhibit the desired biological activity. U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851 (1984). For methods related to chimeric antibodies, see, e.g., U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. 81:6851-6855 (1985), each of which is incorporated herein by reference in its entirety. Examples of CDR grafting are described in, e.g., U.S. Patent Nos. 6,180,370, 5,693,762, 5,693,761, 5,585,089, and 5,530,101, which are incorporated herein by reference in their entirety for all purposes.

[0104] In some embodiments, minimizing the antibody polypeptide sequence from non-human species optimizes chimeric antibody function and reduces immunogenicity. Specific amino acid residues from the non-antigen recognition region of non-human antibodies are modified to be homologous to the corresponding residues in human antibodies or isotypes. An example is a "CDR transplant" antibody, in which the antibody comprises one or more CDRs from a specific species or belonging to a specific antibody class or subclass, and the rest of the antibody chain is identical or homologous to the corresponding sequence in an antibody derived from another species or belonging to another antibody class or subclass. In order to be used for humans, the V region composed of CDR1, CDR2 and part of CDR3 from the light chain and heavy chain variable region of non-human immunoglobulins has transplanted human antibody framework regions, replacing the naturally occurring antigen receptors of human antibodies with non-human CDRs. In some cases, the corresponding non-human residues replace the framework region residues of human immunoglobulins. In addition, humanized antibodies may include residues not found in receptor antibodies or donor antibodies to further improve performance. Humanized antibodies may also include at least a portion of an immunoglobulin constant region (Fc), typically a constant region of a human immunoglobulin. See, e.g., Jones et al., Nature 321:522 (1986); Riechmann et al., Nature 332:323 (1988); Presta, Curr. Op. Struct. Biol. 2:593 (1992); Vaswani and Hamilton, Ann. Allergy, Asthma and Immunol. 1:105 (1998); Harris, Biochem. Soc. Transactions 23;1035 (1995); Hurle and Gross, Curr. Op. Biotech. 5:428 (1994); Verhoeyen et al., Science 239:1534-36 (1988).

[0105] Intracellular antibodies are intracellularly localized immunoglobulins that bind to intracellular antigens, as opposed to secreted antibodies that bind to antigens in the extracellular space.

[0106] Polyclonal antibody preparations usually include different antibodies against different determinants (epitopes). In order to produce polyclonal antibodies, a host, such as a rabbit or goat, is immunized with an antigen or antigen fragment, usually with an adjuvant, and if necessary, in combination with a carrier. Antibodies against the antigen are then collected from the host's serum. Polyclonal antibodies can be affinity purified against the antigen to make them monospecific.

[0107] A monoclonal antibody or "mAb" refers to an antibody obtained from a homogeneous population of antibodies from a dedicated parent cell, i.e., the population is identical except for naturally occurring mutations that may be present in minor amounts. Each monoclonal antibody is directed against a single antigenic determinant.

[0108] A. Functional Antibody Fragments and Antigen-Binding Fragments

[0109] 1. Antigen Binding Fragment

[0110] Certain aspects relate to antibody fragments, such as antibody fragments that bind and / or neutralize inflammatory mediators. The term functional antibody fragment includes an antigen-binding fragment of an antibody that retains the ability to specifically bind to an antigen. These fragments consist of various arrangements of variable region heavy chains (VH) and / or light chains (VL); and in some embodiments, they include constant region heavy chains 1 (CH1) and light chains (CL). In some embodiments, they lack the Fc region consisting of heavy chain 2 (CH2) and 3 (CH3) domains. Embodiments of antigen-binding fragments and modifications thereof may include: (i) Fab fragment types consisting of VL, VH, CL and CH1 domains; (ii) Fd fragment types consisting of VH and CH1 domains; (iii) Fv fragment types consisting of VH and VL domains; (iv) single domain fragment type dAb consisting of a single VH or VL domain (Ward, 1989; McCafferty et al., 1990; Holt et al., 2003); (v) isolated complementarity determining region (CDR) regions. For example, these terms are described in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, NY (1989); Molec. Biology and Biotechnology: A Comprehensive Desk Reference (Myers, RA (ed.), New York: VCH Publisher, Inc.); Huston et al., Cell Biophysics, 22: 189-224 (1993); Pluckthun and Skerra, Meth. Enzymol., 178: 497-515 (1989) and Day, ED, Advanced Immunochemistry, 2d ed., Wiley-Liss, Inc. New York, NY (1990); Antibodies, 4: 259-277 (2015). The citations in this paragraph are all incorporated by reference.

[0111] Antigen binding fragments also include antibody fragments that retain just, at least or at most 1, 2 or 3 complementary determining regions (CDRs) from the light chain variable region. Fusion of sequences comprising CDRs to Fc regions (or their CH2 or CH3 regions) is included within the scope of this definition, including, for example, scFvs fused directly or indirectly to Fc regions are included herein.

[0112] The term Fab fragment refers to a monovalent antigen-binding fragment of an antibody comprising VL, VH, CL and CH1 domains. The term Fab' fragment refers to a monovalent antigen-binding fragment of a monoclonal antibody that is larger than a Fab fragment. For example, a Fab' fragment includes VL, VH, CL and CH1 domains and all or part of the hinge region. The term F(ab')2 fragment refers to a divalent antigen-binding fragment of a monoclonal antibody that includes two Fab' fragments connected by a disulfide bond at the hinge region. A F(ab')2 fragment includes, for example, all or part of two VH and VL domains, and may also include all or part of two CL and CH1 domains.

[0113] The term Fd fragment means a heavy chain fragment of a monoclonal antibody including CDRs, which includes all or part of VH. The Fd fragment may also include a CH1 region sequence.

[0114] The term Fv fragment refers to a monovalent antigen-binding fragment of a monoclonal antibody, which includes all or part of VL and VH, and does not have CL and CH1 domains. VL and VH include, for example, CDRs. Single-chain antibodies (sFv or scFv) are Fv molecules in which the VL and VH regions have been connected by a flexible linker to form a single polypeptide chain, thereby forming an antigen-binding fragment. Single-chain antibodies are discussed in International Patent Application Publication No. WO 88 / 01649 and U.S. Patent Nos. 4,946,778 and 5,260,203, the disclosures of which are incorporated herein by reference. The term (scFv) 2 refers to a bivalent or bispecific sFv polypeptide chain, the C-terminus of which includes an oligomerization domain separated from the sFv by a hinge region (Pack et al., 1992). The oligomerization domain includes a self-associating α-helix, such as a leucine zipper, which can be further stabilized by additional disulfide bonds. (scFv) 2 fragments are also referred to as "mini antibodies" or "mini antibodies".

[0115] Single domain antibodies are antigen binding fragments that contain only a VH or VL domain. In some cases, two or more VH regions are covalently linked with a peptide linker to produce a bivalent domain antibody. The two VH regions of a bivalent domain antibody can target the same or different antigens.

[0116] 2. Crystallizable fragment region, Fc

[0117] The Fc region comprises two heavy chain fragments, which comprise the CH2 and CH3 domains of the antibody. The two heavy chain fragments are held together by two or more disulfide bonds and the hydrophobic interactions of the CH3 domains. As used herein, the term "Fc polypeptide" includes polypeptides derived from the natural form and mutant protein form of the Fc region of the antibody. Truncated forms of such polypeptides are included that contain hinge regions that promote dimerization.

[0118] B. Polypeptides Having Antibody CDRs and Scaffold Domains Displaying CDRs

[0119] According to an embodiment, an antigen-binding peptide scaffold, such as a complementary determining region (CDR), is used to generate a molecule that binds to a protein. Generally, one skilled in the art can determine the type of protein scaffold on which to graft at least one CDR. It is well known that the scaffold preferably meets a number of criteria, such as: good phylogenetic conservation; known three-dimensional structure; small size; little or no post-transcriptional modification; and / or ease of production, expression, and purification. Skerra, J Mol Recognit, 13: 167-87 (2000).

[0120] Protein scaffolds may be derived from, but are not limited to, fibronectin type III FN3 domain (referred to as "monoantibody"), fibronectin type III domain 10, lipocalin, anticalin, the Z domain of protein A of Staphylococcus aureus, thioredoxin A, or proteins with repeating motifs such as "ankyrin repeats," "armadillo repeats," "leucine-rich repeats," and "triangular tetratricopeptide repeats." Such proteins are described in U.S. Patent Publication Nos. 2010 / 0285564, 2006 / 0058510, 2006 / 0088908, 2005 / 0106660, and PCT Publication No. WO2006 / 056464, each of which is incorporated herein by reference in its entirety. Scaffolds from toxins of scorpions, insects, plants, mollusks, etc., as well as protein inhibitors of neuronal nitric oxide synthase (PIN) may also be used.

[0121] C. Antibody Type

[0122] Antibodies can be complete immunoglobulins of any isotype or classification, chimeric antibodies, or hybrid antibodies specific for two or more antigens. They can also be fragments (e.g., F(ab')2, Fab', Fab, Fv, etc.), including hybrid fragments. Immunoglobulins also include natural, synthetic or genetically engineered proteins that act as antibodies by binding to specific antigens to form complexes. The term antibody includes genetically engineered or otherwise modified forms of immunoglobulins.

[0123] The term "monomer" refers to an antibody containing only one Ig unit. A monomer is the basic functional unit of an antibody. The term "dimer" refers to an antibody comprising two Ig units connected to each other by the constant domain (Fc or crystallizable fragment region) of the antibody heavy chain. The complex can be stabilized by connecting (J) chain proteins. The term "multimer" refers to an antibody containing more than two Ig units connected to each other by the constant domain (Fc region) of the antibody heavy chain. The complex can be stabilized by connecting (J) chain proteins.

[0124] The term "bivalent antibody" refers to an antibody that contains two antigen binding sites. The two binding sites can have the same antigen specificity or they can be bispecific, meaning that the two antigen binding sites have different antigen specificities.

[0125] Bispecific antibodies are a class of antibodies with two paratopes and two or more different binding sites for different epitopes. In some embodiments, bispecific antibodies can be biparatopic, wherein bispecific antibodies can specifically recognize different epitopes from the same antigen. In some embodiments, bispecific antibodies can be constructed by a pair of different single-domain antibodies called "nanoantibodies". Single-domain antibodies are derived from cartilaginous fish and camelid mammals and modified. Nanoantibodies can be connected together by joints using typical techniques of those skilled in the art; such methods for selecting and connecting nanoantibodies are described in PCT Publication No. WO2015044386A1, No. WO2010037838A2 and Anal Chem.86 of Bever et al.: 7875–7882 (2014), each of which is incorporated herein by reference in its entirety.

[0126] Bispecific antibodies can be constructed as: complete IgG, Fab'2, Fab'PEG, diabodies, or as scFv. Diabodies and scFv can be constructed without the Fc region, using only the variable domains, which may reduce the impact of anti-idiotypic reactions. Bispecific antibodies can be produced by a variety of methods, including but not limited to fusion of hybridomas or connection of Fab' fragments. See, for example, Songsivilai and Lachmann, Clin. Exp. Immunol. 79: 315-321 (1990); Kostelny et al., J. Immunol. 148: 1547-1553 (1992), each of which is incorporated herein by reference in its entirety.

[0127] In certain aspects, the antigen-binding domains can be multispecific or heterospecific by multimerizing with VH and VL regions that bind different antigens. For example, the antibody can bind or interact with (a) a cell surface antigen, (b) an Fc receptor on the surface of an effector cell, or (c) at least one other component. Thus, aspects can include, but are not limited to, bispecific, trispecific, tetraspecific, and other multispecific antibodies or antigen-binding fragments thereof directed against epitopes and other targets, such as Fc receptors on effector cells.

[0128] In some embodiments, multispecific antibodies can be used and directly connected by short flexible polypeptide chains using conventional methods known in the art. Such an example is a bivalent bispecific antibody, in which the VH and VL domains are expressed on a single polypeptide chain, and a linker that is too short to pair between domains on the same chain is used, thereby forcing the domain to pair with the complementary domain of another chain, producing two antigen binding sites. The linker function is applicable to embodiments of tri-antibodies, tetra-antibodies, and higher-order antibody multimers. (For example, see Hollinger et al., Proc Natl. Acad. Sci. USA 90: 6444-6448 (1993); Polijak et al., Structure 2: 1121-1123 (1994); Todorovska et al., J. Immunol. Methods 248: 47-66 (2001)).

[0129] In contrast to bispecific complete antibodies, bispecific diabodies can also be advantageous because they can be easily constructed and expressed in E. coli. Phage display (WO94 / 13804) can be used to easily select diabodies (and other polypeptides, such as antibody fragments) with appropriate binding specificity from a library. If one arm of a diabody remains constant, for example, with specificity for a protein, a library can be established in which the other arm changes and selects antibodies with appropriate specificity. Bispecific complete antibodies can be prepared by alternative engineering methods described in Ridgeway et al. (Protein Eng., 9: 616-621, 1996) and Krah et al. (N Biotechnol. 39: 167-173, 2017), each of which is incorporated herein by reference in its entirety.

[0130] Heteroconjugate antibodies consist of two covalently linked monoclonal antibodies of different specificities. See, e.g., U.S. Pat. No. 6,010,902, incorporated herein by reference in its entirety.

[0131] The Fv fragment portion of an antibody molecule that binds to an antigenic epitope with high specificity is referred to herein as a "paratope". The paratope is composed of amino acid residues that contact the antigenic epitope to promote antigen recognition. Each of the two Fv fragments of an antibody is composed of two variable domains, VH and VL, in a dimerization configuration. The primary structure of each variable domain includes three hypervariable loops, separated by a framework region (FR) and located on both sides thereof. The hypervariable loop is the region with the highest primary sequence variability in an antibody molecule from any mammal. The term hypervariable loop is sometimes used interchangeably with the term "complementarity determining region (CDR)". The length of the hypervariable loop (or CDR) varies from antibody molecule to antibody molecule. The framework region of all antibody molecules from a given mammal has a high degree of primary sequence similarity / consistency. Those skilled in the art can use the consensus sequence of the framework region to identify the framework region and the hypervariable loops (or CDRs) interspersed between the framework regions. The hypervariable loops are given identification names to distinguish their positions in the polypeptide and on which domain they appear. The CDRs in the VL domain are identified as L1, L2, and L3, with L1 occurring at the farthest end of the CL domain and L3 occurring closest to the CL domain. CDRs may also be designated as CDR-1, CDR-2, and CDR-3. L3 (CDR-3) is generally the region with the highest variability among all antibody molecules produced by a given organism. CDRs are regions of the polypeptide chain that are arranged linearly in the primary structure and are separated from each other by framework regions. The amino terminus (N-terminus) of the VL chain is called FR1. The region designated FR2 occurs between the L1 and L2 hypervariable loops. FR3 occurs between the L2 and L3 hypervariable loops, with the FR4 region being closest to the CL domain. The VH chain repeats this structure and nomenclature, which includes three CDRs designated H1, H2, and H3. Most of the amino acid residues in the variable domains or Fv fragments (VH and VL) are part of the framework region (about 85%). The three-dimensional or tertiary structure of the antibody molecule causes the framework region to be more internal to the molecule and provide most of the structure, with the CDRs being on the outer surface of the molecule.

[0132] Several methods have been developed that can be used by those skilled in the art to identify the exact amino acids that make up each of these regions. This can be accomplished using any of a variety of multiple sequence alignment methods and algorithms that identify the conserved amino acid residues that make up the framework regions, and thus identify CDRs that may vary in length but are located between framework regions. Three commonly used methods have been developed to identify the CDRs of antibodies: Kabat (described in TT Wu and EA Kabat, “AN ANALYSIS OF THE SEQUENCES OF THE VARIABLE REGIONS OF BENCEJONES PROTEINS AND MYELOMA LIGHT CHAINS AND THEIR IMPLICATIONS FOR ANTIBODY COMPLEMENTARITY,” J Exp Med, vol. 132, no. 2, pp. 211–250, Aug. 1970); Chothia (described in C. Chothia et al., “Conformations of immunoglobulin hypervariable regions,” Nature, vol. 342, no. 6252, pp. 877–883, Dec. 1989); and IMGT (described in M.-P. Lefranc et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Developmental & Comparative Biology, 2003; 15(5): 117–118. Immunology, vol. 27, no. 1, pp. 55–77, Jan. 2003). Each of these methods includes a unique numbering system for identifying the amino acid residues that make up the variable region. In most antibody molecules, the amino acid residues that actually contact the antigen epitope appear in the CDRs, although in some cases, residues within the framework region contribute to antigen binding.

[0133] Those skilled in the art can use any of a variety of methods to determine the paratope of an antibody. These methods include: 1) computational prediction of the tertiary structure of the antibody / epitope binding interaction based on the chemical properties of the antibody variable region amino acid sequence and the epitope composition. 2) Hydrogen-deuterium exchange and mass spectrometry 3) polypeptide fragmentation and peptide mapping methods, in which multiple overlapping peptide fragments are generated from the full length of the polypeptide and the binding affinity of these peptides to the epitope is evaluated. 4) antibody phage display library analysis, in which mammalian antibody Fab fragment encoding genes are expressed by phage to bind to the phage coat. The Fab-expressing phage population is then allowed to interact with an antigen that has been fixed or can be expressed by different exogenous expression systems. The non-bound Fab fragments are washed away, leaving only the specific binding Fab fragments that bind to the antigen. The bound Fab fragments can be easily separated and the genes encoding them can be determined. This method can also be used for smaller regions of Fab fragments, which include Fv fragments or appropriate specific VH and VL domains.

[0134] In certain aspects, affinity matured antibodies are enhanced by one or more modifications in one or more of their CDRs, resulting in an increase in the affinity of the antibody for the target antigen compared to a parent antibody that does not have these changes. Certain affinity matured antibodies will have nanomolar or picomolar affinities for the target antigen. Affinity matured antibodies are produced by processes known in the art, for example, Marks et al., Bio / Technology 10:779 (1992) describes the use of V H and V L Affinity maturation by domain shuffling, random mutagenesis of CDR and / or framework residues for phage display is described in Rajpal et al. PNAS. 24:8466-8471 (2005) and Thie et al. Methods Mol Biol. 525:309-22 (2009) in combination with computational methods demonstrated in Tiller et al. Front. Immunol. 8:986 (2017).

[0135] Chimeric immunoglobulins are the product of fused genes from different species; a "humanized" chimera typically has framework regions (FRs) from a human immunoglobulin and one or more CDRs from a non-human source.

[0136] In certain aspects, portions of the heavy and / or light chains are identical or homologous to corresponding sequences from another specific species or belonging to a specific antibody class or subclass, while the remainder of the chain is identical or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, as long as they exhibit the desired biological activity. U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851 (1984). For methods related to chimeric antibodies, see, e.g., U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. 81:6851-6855 (1985), each of which is incorporated herein by reference in its entirety. Examples of CDR grafting are described in, e.g., U.S. Pat. Nos. 6,180,370, 5,693,762, 5,693,761, 5,585,089, and 5,530,101, which are incorporated herein by reference in their entirety for all purposes.

[0137] In some embodiments, minimizing the antibody polypeptide sequence from non-human species optimizes chimeric antibody function and reduces immunogenicity. Specific amino acid residues from the non-antigen recognition region of non-human antibodies are modified to be homologous to the corresponding residues in human antibodies or isotypes. An example is a "CDR transplant" antibody, in which the antibody comprises one or more CDRs from a specific species or belonging to a specific antibody class or subclass, and the rest of the antibody chain is identical or homologous to the corresponding sequence in an antibody derived from another species or belonging to another antibody class or subclass. In order to be used for humans, the V region composed of CDR1, CDR2 and part of CDR3 from the light chain and heavy chain variable region of non-human immunoglobulins has transplanted human antibody framework regions, replacing the natural antigen receptors of human antibodies with non-human CDRs. In some cases, the corresponding non-human residues replace the framework region residues of human immunoglobulins. In addition, humanized antibodies may include residues not found in receptor antibodies or donor antibodies to further improve performance. Humanized antibodies may also include at least a portion of an immunoglobulin constant region (Fc), typically a constant region of a human immunoglobulin. See, e.g., Jones et al., Nature 321:522 (1986); Riechmann et al., Nature 332:323 (1988); Presta, Curr. Op. Struct. Biol. 2:593 (1992); Vaswani and Hamilton, Ann. Allergy, Asthma and Immunol. 1:105 (1998); Harris, Biochem. Soc. Transactions 23;1035 (1995); Hurle and Gross, Curr. Op. Biotech. 5:428 (1994); Verhoeyen et al., Science 239:1534-36 (1988).

[0138] Intracellular antibodies are intracellularly localized immunoglobulins that bind to intracellular antigens, as opposed to secreted antibodies that bind to antigens in the extracellular space.

[0139] Polyclonal antibody preparations typically include different antibodies against different determinants (epitopes). In order to produce polyclonal antibodies, a host, such as a rabbit or goat, is immunized with an antigen or antigen fragment, usually with an adjuvant, and if necessary, in combination with a carrier. Antibodies against the antigen are then collected from the host's serum. Polyclonal antibodies can be affinity purified against the antigen to make them monospecific.

[0140] A monoclonal antibody or "mAb" refers to an antibody obtained from a homogeneous population of antibodies from a dedicated parent cell, i.e., the population is identical except for naturally occurring mutations that may be present in minor amounts. Each monoclonal antibody is directed against a single antigenic determinant.

[0141] D. Antibody Binding

[0142] The term "selective binding agent" refers to a molecule that binds to an antigen. Non-limiting examples include antibodies, antigen-binding fragments, scFv, Fab, Fab', F(ab')2, single-chain antibodies, peptides, peptide fragments, and proteins.

[0143] The term "binding" refers to direct binding between two molecules, for example due to covalent, electrostatic, hydrophobic and ionic and / or hydrogen bonding interactions, which include interactions such as salt bridges and water bridges. "Immunoreactivity" means that a selective binding agent or antibody of interest will bind to an antigen present in a biological sample. The term "immune complex" refers to the combination formed when an antibody or selective binding agent binds to an epitope on an antigen.

[0144] 1. Affinity / Avidity

[0145] The term "affinity" refers to the strength of an antibody or selective binding agent binding epitope. In an antibody binding reaction, this is expressed as the affinity constant (Ka or ka is sometimes referred to as the association constant) of any given antibody or selective binding agent. Affinity is measured as a comparison of the binding strength of an antibody to its antigen relative to the binding strength of the antibody to an unrelated amino acid sequence. Affinity can be expressed as, for example, a 20-fold higher binding capacity of an antibody to its antigen than to an unrelated amino acid sequence. As used herein, the term "affinity" refers to the resistance of a complex of two or more reagents to dissociation after dilution. With respect to antibodies and / or selective binding agents, the terms "immunoreactivity" and "preferential binding" are used interchangeably herein.

[0146] Several experimental methods are available to those skilled in the art to assess the binding affinity of any given antibody or selective binding agent for its antigen. This is usually accomplished by measuring the equilibrium dissociation constant (KD or Kd), using the equation KD=koff / kon=[A][B] / [AB]. The term koff is the dissociation rate between the antibody and the antigen per unit time, and is related to the concentration of the antibody and antigen present in the solution in unbound form at equilibrium. The term kon is the rate of antibody and antigen binding per unit time, and is related to the concentration of the bound antigen-antibody complex at equilibrium. The unit used to measure KD is mol / L (molar concentration or M) or concentration. The Ka of an antibody is the opposite of the KD and is determined by the equation Ka=1 / KD. Examples of some experimental methods that can be used to determine KD values ​​are: enzyme-linked immunosorbent assay (ELISA), isothermal titration calorimetry (ITC), fluorescence anisotropy, surface plasmon resonance (SPR), and affinity capillary electrophoresis (ACE). The affinity constant (Ka) of an antibody is the opposite of the KD and is determined by the equation Ka=1 / KD.

[0147] Antibodies that are considered useful in certain embodiments may have a 6 M, 10 7 M, 10 8 M, 10 9 M or 10 10 M, or any range derivable therein. Similarly, in some embodiments, an antibody may have an affinity constant (Ka) of about, at least about, or at most about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 The dissociation constant (KD) of about 10 M or any derivable range therein is reported for the antibodies discussed herein, and the same assay can be used to assess the binding properties of such antibodies. -8 M, an antibody of the invention is said to "specifically bind" to its target antigen. -9 M, the antibody specifically binds to the antigen with “high affinity” and has a KD of about 5×10 -10 The antibody has a "very high affinity" at M.

[0148] 2. Epitope specificity

[0149] The epitope of an antigen is a specific region of an antigen to which an antibody has binding affinity. In the case of a protein or polypeptide antigen, an epitope is a specific residue (or specific amino acid or protein fragment) to which an antibody binds with high affinity. An antibody does not necessarily contact every residue in a protein. Every amino acid substitution or deletion in a protein does not necessarily affect binding affinity. For the purposes of this specification and the appended claims, the terms "epitope" and "antigenic determinant" are used interchangeably to refer to sites on an antigen to which B cells and / or T cells react or recognize an antigen. A polypeptide epitope can be formed by contiguous and non-contiguous amino acids juxtaposed by the tertiary folding of a polypeptide. An epitope typically includes at least 3, typically 5 to 10 amino acids with a unique spatial conformation.

[0150] The epitope specificity of an antibody can be determined in a variety of ways. For example, one method involves testing a set of overlapping peptides having approximately 15 amino acids across the complete sequence of a protein and differing in increments of a small number of amino acids (e.g., 3 to 30 amino acids). The peptides are fixed in different wells of a microtiter plate. For example, immobilization can be achieved by biotinylating one end of the peptide. This process can affect the affinity of the antibody to the epitope, so different samples of the same peptide can be biotinylated at the N-terminus and the C-terminus and fixed in different wells for comparison. This is useful for identifying end-specific antibodies. Optionally, it can include additional peptides that terminate in a specific target amino acid. This method can be used to identify end-specific antibodies of internal fragments. Screening antibodies or antigen-binding fragments to bind to each of the various peptides. Epitope definition is an amino acid fragment common to all peptides that show high affinity when an antibody binds.

[0151] 3. Modification of the Antibody-Binding Domain

[0152] It should be understood that the antibodies of the present invention can be modified so that they are substantially identical to the antibody polypeptide sequences or fragments thereof and still bind to the epitopes of the present invention. When optimally aligned using programs such as Clustal Omega, IGBLAST, GAP or BESTFIT using default gap weights, polypeptide sequences are "substantially identical" if they share at least 80% sequence identity, at least 90% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity or at least 99% sequence identity or any range therein.

[0153] As discussed herein, minor changes in the amino acid sequence of an antibody or antigen binding region thereof are considered to be included in the present invention, provided that the change in the amino acid sequence maintains at least 75%, more preferably at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% and most preferably at least 99% sequence identity. In particular, conservative amino acid substitutions are contemplated.

[0154] Conservative substitutions are substitutions that occur within a family of amino acids that are related in their side chains. Genetically encoded amino acids are generally divided into several classes based on the chemical properties of their side chains; for example, acidic (aspartic acid, glutamic acid), basic (lysine, arginine, histidine), nonpolar (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), and uncharged polar (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine). For example, it is reasonable to expect that a single replacement of a leucine moiety with an isoleucine or valine moiety, or a similar amino acid replacement with a structurally related amino acid in the same class, will not have a significant effect on the binding or properties of the resulting molecule, particularly if the replacement does not involve an amino acid within a framework site. Whether an amino acid change produces a functional peptide can be easily determined by measuring the specific activity of the polypeptide derivative. One skilled in the art can perform standard ELISA, surface plasmon resonance (SPR), or other antibody binding assays to quantitatively compare the antigen binding affinity between an unmodified antibody and any polypeptide derivative with a conservative substitution produced by any of several methods available to one skilled in the art.

[0155] Those skilled in the art can easily prepare fragments or analogs of antibodies or immunoglobulin molecules. The amino-terminal and carboxyl-terminal of the preferred fragments or analogs appear near the boundaries of the functional domains. The structure and functional domains can be identified by comparing the nucleotide and / or amino acid sequence data with public or proprietary sequence databases. Preferably, computerized comparison methods are used to identify sequence motifs or predicted protein conformation domains that appear in other proteins with known structures and / or functions. Standard methods for identifying protein sequences that fold into known three-dimensional structures are available to those skilled in the art; Dill and McCallum., Science 338: 1042-1046 (2012). Several algorithms for predicting protein structures and gene sequences encoding them have been developed, many of which can be found at the National Center for Biotechnology Information (ncbi.nlm.nih.gov / guide / proteins / on the World Wide Web) and the Bioinformatics Resource Portal (expasy.org / proteomics on the World Wide Web). Therefore, the foregoing examples show that those skilled in the art can identify sequence motifs and structural conformations that can be used to define the structure and functional domains according to the present invention.

[0156] Framework modifications may be made to an antibody to reduce immunogenicity, for example, by "backmutating" one or more framework residues to the corresponding germline sequence.

[0157] It is also contemplated that the antigen-binding domains can be multispecific or multivalent by multimerizing the antigen-binding domains with pairs of VH and VL regions that bind the same antigen (multivalent) or different antigens (multispecific).

[0158] E. Chemical modification of antibodies

[0159] In some aspects, glycosylation variants of antibodies are also contemplated, in which the number and / or type of glycosylation sites have been changed compared to the amino acid sequence of the parent polypeptide. The glycosylation of a polypeptide can be altered, for example, by modifying one or more glycosylation sites within the polypeptide sequence to increase the affinity of the polypeptide for an antigen (U.S. Pat. Nos. 5,714,350 and 6,350,861). In certain embodiments, the antibody protein variant comprises a greater or lesser number of N-linked glycosylation sites than a native antibody. The N-linked glycosylation site is characterized by the following sequence: Asn-X-Ser or Asn-X-Thr, where the amino acid residue designated as X can be any amino acid residue except proline. The substitution of amino acid residues produces this sequence, providing a potential new site for the addition of N-linked sugar chains. Alternatively, the substitution that eliminates or alters the sequence will prevent the addition of N-linked sugar chains present in the native polypeptide. For example, glycosylation can be reduced by deleting Asn or by replacing Asn with a different amino acid. In other embodiments, one or more new N-linked glycosylation sites are created. Antibodies typically have an N-linked glycosylation site in the Fc region.

[0160] Additional antibody variants include cysteine ​​variants in which one or more than one cysteine ​​residue in the parent or native amino acid sequence is deleted or replaced with another amino acid (e.g., serine). Cysteine ​​variants are useful, especially when the antibody must be refolded into a biologically active conformation. Cysteine ​​variants can have fewer cysteine ​​residues than native antibodies, and typically have an even number to minimize interactions caused by unpaired cysteines.

[0161] In some aspects, the polypeptide can be pegylated to increase the biological half-life by reacting the polypeptide with polyethylene glycol (PEG) or a reactive ester or aldehyde derivative of PEG under conditions where one or more than one PEG group is attached to the polypeptide. Polypeptide pegylation can be carried out by acylation or alkylation with a reactive PEG molecule (or a similar reactive water-soluble polymer). Methods for pegylated proteins are known in the art and can be applied to the polypeptides of the present invention to obtain pegylated derivatives of antibodies. See, for example, EP 0154316 and EP 0401384. In some aspects, the antibody is conjugated or otherwise attached to transthyretin (TTR) or a TTR variant. TTR or a TTR variant can be chemically modified with a chemical selected from, for example, dextran, poly (n-vinyl pyrrolidone), polyethylene glycol, propylene glycol homopolymer, polypropylene oxide / ethylene oxide copolymer, polyoxyethylated polyol, and polyvinyl alcohol. As used herein, the term "polyethylene glycol" is intended to encompass any of the forms of PEG that have been used to derivatize other proteins.

[0162] 1. Conjugation

[0163] Derivatives of the antibodies and antigen-binding fragments described herein are also provided. Derivatized antibodies or fragments thereof may include any molecule or substance that imparts the desired properties to the antibody or fragment. Derivatized antibodies may include, for example, a detectable (or labeling) portion (e.g., radioactive, colorimetric, antigenic or enzyme molecule, or detectable beads), a molecule that binds to another molecule (e.g., biotin or streptavidin), a therapeutic or diagnostic portion (e.g., a radioactive, cytotoxic or pharmaceutically active portion), or a molecule that increases the suitability of the antibody for a particular use (e.g., administration to a subject, such as a human subject, or other in vivo or in vitro uses).

[0164] Optionally, the immunology part of the antibody or antibody can be chemically conjugated to other proteins or expressed as fusion proteins with other proteins. In some aspects, the polypeptide can be chemically modified by conjugating or merging the polypeptide with serum proteins such as human serum albumin to increase the half-life of the resulting molecule. See, for example, EP 0322094 and EP 0486525. In some aspects, the polypeptide can be conjugated with a diagnostic agent and used for diagnosis, for example, to monitor the development or progress of the disease and determine the efficacy of a given treatment regimen. In some aspects, the polypeptide can also be conjugated with a therapeutic agent to provide a treatment combined with the therapeutic effect of the polypeptide. Other suitable conjugated molecules include ribonucleases (RNA enzymes), DNA enzymes I, antisense nucleic acids, inhibitory RNA molecules such as siRNA molecules, immunostimulatory nucleic acids, aptamers, ribozymes, triplex formation molecules and external guide sequences. Functional nucleic acid molecules can serve as effectors, inhibitors, regulators and stimulants of the specific activity possessed by the target molecule, or functional nucleic acid molecules can have an activity independent of any other molecules from the beginning.

[0165] In some aspects, antibodies and antibody-like molecules connected to at least one reagent to form an antibody conjugate or a useful load are disclosed. In order to improve the efficacy of the antibody molecule as a diagnostic or therapeutic agent, it is usually connected or covalently bound or compounded with at least one desired molecule or part. This molecule or part can be but is not limited to at least one effector molecule or reporter molecule. Effector molecules include molecules with desired activity such as cytotoxic activity. Non-limiting examples of effector molecules include toxins, therapeutic enzymes, antibiotics, radiolabeled nucleotides, etc. In contrast, reporter molecules are defined as any part that can be detected using an assay. Non-limiting examples of reporter molecules conjugated to antibodies include enzymes, radiolabels, haptens, fluorescent markers, phosphorescent molecules, chemiluminescent molecules, chromophores, luminescent molecules, photoaffinity molecules, colored particles or ligands.

[0166] 2. Conjugation type

[0167] Some examples of antibody conjugates are those in which the antibody is connected to a detectable label. "Detectable label" is a compound and / or element that allows detection of the antibody and / or further quantification of the antibody if necessary, due to its specific functional properties and / or chemical characteristics. Examples of detectable labels include, but are not limited to, radioisotopes, fluorescent agents, semiconductor nanocrystals, chemiluminescent agents, chromophores, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, dyes, metal ions, metal sols, ligands (e.g., biotin, streptavidin or haptens), etc. Specific examples of labels are, but are not limited to, horseradish peroxidase (HRP), fluorescein, FITC, rhodamine, dansyl, umbelliferone, dimethyl acridinium ester (DMAE), Texas Red, luminol, NADPH and α-galactosidase or β-galactosidase. Antibody conjugates include those that are primarily used in vitro, in which the antibody is connected to a second binding ligand and / or enzyme to produce a colored product when in contact with a chromogenic substrate. Examples of suitable enzymes include, but are not limited to, urease, alkaline phosphatase, (horseradish) catalase, or glucose oxidase. Preferred second binding ligands are biotin and / or avidin and streptavidin compounds. The use of such labels is well known to those skilled in the art and is described in, for example, U.S. Patents 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149 and 4,366,241; each of which is incorporated herein by reference. Molecules containing an azide group can also be used to form a covalent bond with a protein via a reactive nitrene intermediate generated by low intensity ultraviolet light (Potter and Haley, 1983).

[0168] In some aspects, it is contemplated to include antibodies or antigen binding fragments thereof conjugated to cytotoxic agents such as chemotherapeutics, drugs, growth inhibitors, toxins (e.g., enzymatically active toxins of bacterial, fungal, plant or animal origin, or fragments thereof), or radioactive isotopes (i.e., radioactive conjugates). In this way, the reagent of interest can directly target cells with cell surface antigens. The antibody and the reagent can be bound by non-covalent interactions, such as by electrostatic forces or by covalent bonds. Various joints known in the art can be used to form immunoconjugates. In addition, immunoconjugates can be provided in the form of fusion proteins. On the one hand, antibodies can be conjugated to target cell surface antigens with a variety of therapeutic substrates. Examples of conjugates include, but are not limited to, metal chelates, drugs, toxins and other effector molecules, such as cytokines, lymphokines, chemokines, immunomodulators, radiosensitizers, asparaginases, carboranes and radioactive halogens.

[0169] In an antibody drug conjugate (ADC), an antibody (Ab) is conjugated to one or more drug moieties (D) via a linker (L). ADCs can be prepared by several routes using organic chemistry reactions, conditions, and reagents known to those skilled in the art, including: (1) reacting a nucleophilic group of the antibody with a divalent linker reagent to form Ab-L via a covalent bond, which is then reacted with the drug moiety D; and (2) reacting a nucleophilic group of the drug moiety with a divalent linker reagent to form DL via a covalent bond, which is then reacted with a nucleophilic group of the antibody. Antibody drug conjugates can also be produced by modifying an antibody to introduce an electrophilic moiety that can react with a nucleophilic substituent on a linker reagent or drug. Alternatively, a fusion protein comprising an antibody and a cytotoxic agent can be prepared, for example, by recombinant techniques or peptide synthesis. The length of DNA can include regions encoding the two portions of the conjugate, adjacent to each other or separated by a region encoding a linker peptide that does not destroy the desired properties of the conjugate. In yet another aspect, the antibody can be conjugated to a "receptor" (e.g., streptavidin) for pretargeting of tumor or cancer cells, wherein the antibody-receptor conjugate is administered to the patient, unbound conjugate is then removed from the circulation using a clearing agent, and then a "ligand" (e.g., avidin) conjugated to a cytotoxic agent (e.g., radionucleotide) is administered.

[0170] Examples of antibody-drug conjugates known to those skilled in the art are for local delivery of cytotoxic agents or cytostatic agents, i.e., prodrugs of drugs that kill or inhibit tumor cells in cancer treatment (Syrigos and Epenetos, Anticancer Res. 19:605-614 (1999); Niculescu-Duvaz and Springer, Adv. Drg. Del. Rev. 26:151-172 (1997); U.S. Pat. No. 4,975,278). In contrast, systemic administration of these unconjugated drug agents can produce unacceptable levels of toxicity to normal cells as well as target tumor cells (Baldwin et al., Lancet 1:603-5 (1986); Thorpe, (1985) "Antibody Carriers of Cytotoxic Agents in Cancer Therapy: A Review," In: Monoclonal Antibodies '84: Biological and Clinical Applications, A. Pincera et al., (eds.) pp.475-506). It has been reported that both polyclonal and monoclonal antibodies can be used in these strategies (Rowland et al., Cancer Immunol. Immunother. 21:183-87 (1986)).

[0171] In certain aspects, ADCs include covalent or aggregated conjugates of antibodies or antigen-binding fragments thereof with other proteins or polypeptides, for example, by expressing a recombinant fusion protein comprising a heterologous polypeptide fused to the N-terminus or C-terminus of an antibody polypeptide. For example, the conjugated peptide can be a heterologous signal (or leader) polypeptide, such as a yeast alpha factor leader sequence, or a peptide such as an epitope tag (e.g., V5-His). Fusion proteins containing antibodies may include added peptides to facilitate purification or identification of the antibody (e.g., polyhistidine). Antibody polypeptides may also be linked to, as described in Hopp et al., Bio / Technology 6:1204 (1988) and U.S. Pat. No. 5,011,912. (Sigma-Aldrich, St. Louis, MO) peptides. Oligomers containing one or more than one antibody polypeptide can be used as antagonists. The oligomers can be in the form of dimers, trimers, or oligomers higher than trimers that are covalently or non-covalently linked. It is contemplated that oligomers containing two or more than two antibody polypeptides can be used. Other oligomers include heterodimers, homotrimers, heterotrimers, homotetramers, heterotetramers, etc. In some aspects, the oligomer comprises a plurality of antibody polypeptides connected by covalent or non-covalent interactions between peptide moieties fused to the antibody polypeptide. Such peptides can be peptide linkers (spacers), or peptides having properties that promote oligomerization. Leucine zippers and certain polypeptides derived from antibodies are peptides that can promote oligomerization of antibody polypeptides linked thereto, as described in more detail below.

[0172] 3. Conjugation Method

[0173] Several methods for attaching or conjugating antibodies to their conjugate moieties are known in the art. Some methods of attachment include the use of metal chelate complexes, e.g., organic chelators such as diethylenetriaminepentaacetic anhydride (DTPA); ethylenediaminetetraacetic acid; N-chloro-p-toluenesulfonamide; and / or tetrachloro-3-6-diphenylglycoluril-3 (U.S. Pat. Nos. 4,472,509 and 4,938,948, each incorporated herein by reference) attached to antibodies. Monoclonal antibodies can also be reacted with enzymes in the presence of coupling agents such as glutaraldehyde or periodate. A variety of bifunctional protein coupling agents can also be used to prepare conjugates, such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (e.g., dimethyl HCl adipate), active esters (e.g., disuccinimidyl suberate), aldehydes (e.g., glutaraldehyde), bis-azido compounds (e.g., bis(p-azidobenzoyl)hexanediamine), bis-diazo derivatives (e.g., bis(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (e.g., toluene 2,6-diisocyanate), and bis-active fluorine compounds (e.g., 1,5-difluoro-2,4-dinitrobenzene). In some aspects, it is contemplated to derivatize immunoglobulins by selectively introducing sulfhydryl groups in the Fc region of immunoglobulins using reaction conditions that do not alter the antibody combining site. Antibody conjugates produced according to this method are disclosed to show improved lifespan, specificity, and sensitivity (U.S. Pat. No. 5,196,066, incorporated herein by reference). Site-specific attachment of effector or reporter molecules, wherein the reporter or effector molecule is conjugated to a carbohydrate residue in the Fc region, has also been disclosed in the literature (O'Shannessy et al., 1987).

[0174] II. Protein

[0175] As used herein, "protein" or "polypeptide" refers to a molecule comprising at least five amino acid residues. As used herein, the term "wild type" refers to the endogenous form of a molecule naturally occurring in an organism. In some embodiments, the wild type form of a protein or polypeptide is used, however, in many embodiments of the present disclosure, a modified protein or polypeptide is used to produce an immune response. The above terms can be used interchangeably. "Modified protein" or "modified polypeptide" or "variant" refers to a protein or polypeptide whose chemical structure, particularly the amino acid sequence of a protein or polypeptide, has been changed relative to a wild-type protein or polypeptide. In some embodiments, the modified / variant protein or polypeptide has at least one modified activity or function (recognizing that a protein or polypeptide can have multiple activities or functions). It is particularly contemplated that a modified / variant protein or polypeptide may be altered in one activity or function, but retains the activity or function of the wild type in other aspects such as immunogenicity.

[0176] Where a protein is specifically mentioned herein, it generally refers to a natural (wild type) or recombinant (modified) protein, or optionally, a protein in which any signal sequence has been removed. The protein can be isolated directly from its natural organism, produced by recombinant DNA / exogenous expression methods, or produced by solid phase peptide synthesis (SPPS) or other in vitro methods. In a specific embodiment, there are isolated nucleic acid fragments and recombinant vectors comprising nucleic acid sequences encoding polypeptides (e.g., antibodies or fragments thereof). The term "recombinant" can be used in conjunction with the name of a polypeptide or a specific polypeptide, which generally refers to a polypeptide produced by a nucleic acid molecule that has been manipulated in vitro or a replication product of the molecule.

[0177] In certain embodiments, the size of a protein or polypeptide (wild type or modified) can include, but is not limited to, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65 44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90 0, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 6 00, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1100, 1200, 1300, 1400, 1500, 1750, 2000, 2250, 2500 or more than 2500 amino acid residues and any range derivable therein, or derivatives of the corresponding amino acid sequences described or referenced herein. It is contemplated that the polypeptides may be mutated by truncation to make them shorter than their corresponding wild-type forms, and they may be altered by fusion or conjugation to heterologous protein or polypeptide sequences having specific functions (e.g., for targeting or localization, for enhancing immunogenicity, for purification purposes, etc.). As used herein, the term "domain" refers to any distinct functional or structural unit of a protein or polypeptide, and generally refers to an amino acid sequence having a structure or function recognizable to those skilled in the art.

[0178] In some embodiments, the protein, polypeptide or nucleic acid may comprise Fcγ or monoclonal antibody 3F6 or SEQ ID 43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211,212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237、238、239、240、241、242、243、244、245、246、247、248、249、250、251、252、253、254、255、256、257、258、259、260、261、 262、263、264、265、266、267、268、269、270、271、272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、 287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、 312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、 337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、 362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、 387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、 437、438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、456、457、458、459、460、461、 462、463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、481、482、483、484、485、486、 487、488、489、490、491、492、493、494、495、496、497、498、499、500、501、502、503、504、505、506、507、508、509、510、511、 512、513、514、515、516、517、518、519、520、521、522、523、524、525、526、527、528、529、530、531、532、533、534、535、536、 537、538、539、540、541、542、543、544、545、546、547、548、549、550、551、552、553、554、555、556、557、558、559、560、561、 562、563、564、565、566、567、568、569、570、571、572、573、574、575、576、577、578、579、580、581、582、583、584、585、586、 587、588、589、590、591、592、593、594、595、596、597、598、599、600、601、602、603、604、605、606、607、608、609、610、611、612、613、614、615、616、617、618、619、620、621、622、623、624、625、626、627、628、629、630、631、632、633、634、635、636、 637、638、639、640、641、642、643、644、645、646、647、648、649、650、651、652、653、654、655、656、657、658、659、660、661、 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687、688、689、690、691、692、693、694、695、696、697、698、699、700、701、702、703、704、705、706、707、708、709、710、711、 712、713、714、715、716、717、718、719、720、721、722、723、724、725、726、727、728、729、730、731、732、733、734、735、736、 737、738、739、740、741、742、743、744、745、746、747、748、749、750、751、752、753、754、755、756、757、758、759、760、761、 762、763、764、765、766、767、768、769、770、771、772、773、774、775、776、777、778、779、780、781、782、783、784、785、786、 787、788、789、790、791、792、793、794、795、796、797、798、799、800、801、802、803、804、805、806、807、808、809、810、811、812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860 60, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908 8, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956 , 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999 or 1000 (or any range derivable therein) of consecutive amino acids.

[0179] In some embodiments, the polypeptide, protein or nucleic acid can comprise an Fcγ, monoclonal antibody 3F6 or one of SEQ ID NOs: 1 to 10 that is at least, at most, or about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% (or any range derivable therein) similar, identical or homologous to Fcγ, monoclonal antibody 3F6 or one of SEQ ID NOs: 1 to 10. NO: at least, at most, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65 , 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90 ,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,1 29, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165,166、167、168、169、170、171、172、173、174、175、176、177、178、179、180、181、182、183、184、185、186、187、188、189、190、 191、192、193、194、195、196、197、198、199、200、201、202、203、204、205、206、207、208、209、210、211、212、213、214、215、 216、217、218、219、220、221、222、223、224、225、226、227、228、229、230、231、232、233、234、235、236、237、238、239、240、 241、242、243、244、245、246、247、248、249、250、251、252、253、254、255、256、257、258、259、260、261、262、263、264、265、 266、267、268、269、270、271、272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、287、288、289、290、 291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、 316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、 341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、387、388、389、390、 391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、 416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、437、438、439、440、 441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、456、457、458、459、460、461、462、463、464、465、 466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、481、482、483、484、485、486、487、488、489、490、 491、492、493、494、495、496、497、498、499、500、501、502、503、504、505、506、507、508、509、510、511、512、513、514、515、 516、517、518、519、520、521、522、523、524、525、526、527、528、529、530、531、532、533、534、535、536、537、538、539、540、 541、542、543、544、545、546、547、548、549、550、551、552、553、554、555、556、557、558、559、560、561、562、563、564、565、566、567、568、569、570、571、572、573、574、575、576、577、578、579、580、581、582、583、584、585、586、587、588、589、590、 591、592、593、594、595、596、597、598、599、600、601、602、603、604、605、606、607、608、609、610、611、612、613、614、615、 616、617、618、619、620、621、622、623、624、625、626、627、628、629、630、631、632、633、634、635、636、637、638、639、640、 641、642、643、644、645、646、647、648、649、650、651、652、653、654、655、656、657、658、659、660、661、662、663、664、665、 666、667、668、669、670、671、672、673、674、675、676、677、678、679、680、681、682、683、684、685、686、687、688、689、690、 691、692、693、694、695、696、697、698、699、700、701、702、703、704、705、706、707、708、709、710、711、712、713、714、715、 716、717、718、719、720、721、722、723、724、725、726、727、728、729、730、731、732、733、734、735、736、737、738、739、740、 741、742、743、744、745、746、747、748、749、750、751、752、753、754、755、756、757、758、759、760、761、762、763、764、765、766、767、768、769、770、771、772、773、774、775、776、777、778、779、780、781、782、783、784、785、786、787、788、789、790、 791、792、793、794、795、796、797、798、799、800、801、802、803、804、805、806、807、808、809、810、811、812、813、814、815、 816、817、818、819、820、821、822、823、824、825、826、827、828、829、830、831、832、833、834、835、836、837、838、839、840、 841、842、843、844、845、846、847、848、849、850、851、852、853、854、855、856、857、858、859、860、861、862、863、864、865、 866、867、868、869、870、871、872、873、874、875、876、877、878、879、880、881、882、883、884、885、886、887、888、889、890、 891、892、893、894、895、896、897、898、899、900、901、902、903、904、905、906、907、908、909、910、911、912、913、914、915、 916、917、918、919、920、921、922、923、924、925、926、927、928、929、930、931、932、933、934、935、936、937、938、939、940、 941、942、943、944、945、946、947、948、949、950、951、952、953、954、955、956、957、958、959、960、961、962、963、964、965、966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999 or 1000 (or any derivable range therein) consecutive amino acids.

[0180] In some aspects, there is a NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 ,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147 , 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178 8, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 2 09, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240、241、242、243、244、245、246、247、248、249、250、251、252、253、254、255、256、257、258、259、260、261、262、263、264、265、266、267、268、269、270、271、272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、437、438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、456、457、458、459、460、461、462、463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、481、482、483、484、485、486、487、488、489、490、491、492、493、494、495、496、497、498、499、500、501、502、503、504、505、506、507、508、509、510、511、512、513、514、515、516、517、518、519、520、521、522、523、524、525、526、527、528、529、530、531、532、533、534、535、536、537、538、539、540、541、542、543、544、545、546、547、548、549、550、551、552、553、554、555、556、557、558、559、560、561、562、563、564、565、566、567、568、569、570、571、572、573、574、575、576、577、578、579、580、581、582、583、584、585、586、587、588、589、590、591、592、593、594、595、596、597、598、599、600、601、602、603、604、605、606、607、608、609、610、611、612、613、614、615、616、617、618、619、620、621、622、623、624、625、626、627、628、629、630、631、632、633、634、635、636、637、638、639、640、641、642、643、644、645、646、647、648、649、650、651、652、653、654、655、656、657、658、659、660、661、662、663、664、665、666、667、668、669、670、671、672、673、674、675、676、677、678、679、680、681、682、683、684、685、686、687、688、689、690、691、692、693、694、695、696、697、698、699、700、701、702、703、704、705、706、707、708、709、710、711、712、713、714、715、716、717、718、719、720、721、722、723、724、725、726、727、728、729、730、731、732、733、734、735、736、737、738、739、740、741、742、743、744、745、746、747、748、749、750、751、752、753、754、755、756、757、758、759、760、761、762、763、764、765、766、767、768、769、770、771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829 ,830,831,832,833,834,835,836,837,838,839,840,841,842,843,844,845,846,847,848,849,850,851,852,853,854,855,856,857,858,859,860,861,862,863,864,865,866,867,868,869,870,871,872,873,874,875,876,877,878,879,880,881,882,883,884,885,886,887,888 , 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947 , 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, or 1000 and comprises Fcγ, monoclonal antibody 3F6 or SEQ ID NO: ID NO: at least, at most, or about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 4, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 1 04, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 1 29, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154、155、156、157、158、159、160、161、162、163、164、165、166、167、168、169、170、171、172、173、174、175、176、177、178、 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228,229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254、255、256、257、258、259、260、261、262、263、264、265、266、267、268、269、270、271、272、273、274、275、276、277、278、 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、 329、330、331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、 354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、 379、380、381、382、383、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、 404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、437、438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、 454、455、456、457、458、459、460、461、462、463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、 479、480、481、482、483、484、485、486、487、488、489、490、491、492、493、494、495、496、497、498、499、500、501、502、503、 504、505、506、507、508、509、510、511、512、513、514、515、516、517、518、519、520、521、522、523、524、525、526、527、528、 529、530、531、532、533、534、535、536、537、538、539、540、541、542、543、544、545、546、547、548、549、550、551、552、553、 554、555、556、557、558、559、560、561、562、563、564、565、566、567、568、569、570、571、572、573、574、575、576、577、578、 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604、605、606、607、608、609、610、611、612、613、614、615、616、617、618、619、620、621、622、623、624、625、626、627、628、629、630、631、632、633、634、635、636、637、638、639、640、641、642、643、644、645、646、647、648、649、650、651、652、653、 654、655、656、657、658、659、660、661、662、663、664、665、666、667、668、669、670、671、672、673、674、675、676、677、678、 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704、705、706、707、708、709、710、711、712、713、714、715、716、717、718、719、720、721、722、723、724、725、726、727、728、 729、730、731、732、733、734、735、736、737、738、739、740、741、742、743、744、745、746、747、748、749、750、751、752、753、 754、755、756、757、758、759、760、761、762、763、764、765、766、767、768、769、770、771、772、773、774、775、776、777、778、 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828,829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873 73, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917 7, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, or 1000 (or any range derivable therein) consecutive amino acids or nucleotides.

[0181] Nucleotide and protein, polypeptide and peptide sequences of various genes have been previously disclosed and can be found in recognized computerized databases. Two commonly used databases are the Genbank and GenPept databases of the National Center for Biotechnology Information (ncbi.nlm.nih.gov / on the World Wide Web) and the Universal Protein Resource (UniProt; on uniprot.org on the World Wide Web). The coding regions of these genes can be amplified and / or expressed using the techniques disclosed herein or techniques known to those of ordinary skill in the art.

[0182] It is contemplated that in the compositions of the present disclosure, about 0.001 mg to about 10 mg of total polypeptide, peptide and / or protein will be present per milliliter. The concentration of protein in the composition may be about, at least about, or at most about 0.001 mg / ml, 0.010 mg / ml, 0.050 mg / ml, 0.1 mg / ml, 0.2 mg / ml, 0.3 mg / ml, 0.4 mg / ml, 0.5 mg / ml, 0.6 mg / ml, 0.7 mg / ml, 0.8 mg / ml, 0.9 mg / ml, 1.0 mg / ml, 1.5 mg / ml, 2.0 mg / ml, 2.5 mg / ml, 3.0 mg / ml, 4.5 mg / ml, 5.0 mg / ml, 6.0 mg / ml, 7.0 mg / ml, 8.0 mg / ml, 9.0 mg / ml, 10.0 mg / ml, 11.0 mg / ml, 12.0 mg / ml, 13.0 mg / ml, 14.0 mg / ml, 15.0 mg / ml, 16.0 mg / ml, 17.0 mg / ml, 18.0 mg / ml, 19.0 mg / ml, 20.0 mg / ml, 21.0 mg / ml, 22.0 mg / ml, 23.0 mg / ml, 24.0 mg / ml, 25.0 mg / ml, 26.0 mg / ml, 27.0 mg / ml, 28.0 mg / ml, 29.0 mg / ml, 30.0 mg / ml, 31.0 mg / ml, 32.0 mg / ml, 33.0 mg / ml, 34.0 mg / ml, 35.0 mg / ml 0 mg / ml, 10.0 mg / ml or more (or any range derivable therein).

[0183] 1. Variant Peptide

[0184] The following is a discussion about changing the amino acid subunits of a protein to produce an equivalent or even improved second generation variant polypeptide or peptide. For example, certain amino acids can replace other amino acids in a protein or polypeptide sequence to cause or not significantly lose the ability to interact with a structure such as an antigen binding region of an antibody or a binding site on a substrate molecule. Since the interaction ability and properties of a protein determine the functional activity of the protein, certain amino acid substitutions can be made in a protein sequence and its corresponding DNA encoding sequence, but still produce a protein with similar or desired properties. Therefore, the inventors expect that various changes can be made in the DNA sequence of the gene encoding the protein without significantly losing its biological utility or activity.

[0185] The term "functionally equivalent codons" as used herein refers to codons encoding the same amino acid, such as six different codons for arginine. Also contemplated are "neutral substitutions" or "neutral mutations," which refer to changes in one or more than one codon encoding a biologically equivalent amino acid.

[0186] The amino acid sequence variants of the present invention can be substitution, insertion or deletion variants. Compared with the wild type, the variation of the polypeptide of the present invention can affect 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more than 50 non-continuous or continuous amino acids of proteins or polypeptides. Variants can comprise an amino acid sequence that is at least 50%, 60%, 70%, 80% or 90% identical to any sequence provided or cited herein, and including all values ​​and ranges therebetween. Variants can include 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more than 20 replacement amino acids.

[0187] It is also understood that amino acid and nucleic acid sequences may include additional residues, such as additional N-terminal amino acids or C-terminal amino acids, or 5' sequences or 3' sequences, respectively, but still be substantially identical to one of the sequences disclosed herein, such as the following, as long as the sequence meets the above criteria, including the maintenance of biological protein activity involved in protein expression. The addition of terminal sequences is particularly applicable to nucleic acid sequences, which may, for example, include various non-coding sequences located on both sides of the 5' or 3' ends of the coding region.

[0188] Deletion variants typically lack one or more than one residue of a native or wild-type protein. Single residues may be deleted or a number of consecutive amino acids may be deleted. Stop codons may be introduced (by substitution or insertion) into the sequence of the encoding nucleic acid to produce truncated proteins.

[0189] Insertion mutants generally involve the addition of an amino acid residue at a non-terminal position of a polypeptide. This may include the insertion of one or more than one amino acid residue. Terminal additions may also be produced and may include fusion proteins, which are multimers or concatemers of one or more than one peptide or polypeptide described or referenced herein.

[0190] Substitution variants typically comprise the exchange of one amino acid for another at one or more than one site within a protein or polypeptide, and can be designed to modulate one or more than one property of a polypeptide, with or without retention or loss of other functions or properties. Substitutions can be conservative, i.e., one amino acid is replaced by an amino acid with similar chemical properties. "Conservative amino acid substitutions" can involve the exchange of a member of one amino acid class with another member of the same class. Conservative substitutions are well known in the art and include, for example, the following changes: alanine to serine; arginine to lysine; asparagine glutamine or histidine; aspartic acid to glutamic acid; cysteine ​​to serine; glutamine to asparagine; glutamic acid to aspartic acid; glycine to proline; histidine to asparagine or glutamine; isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine; methionine to leucine or isoleucine; phenylalanine to tyrosine, leucine or methionine; serine to threonine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; and valine to isoleucine or leucine. Conservative amino acid substitutions may include non-naturally occurring amino acid residues that are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. These include peptide mimetics or other inverted or reversed forms of amino acid moieties.

[0191] Alternatively, a substitution may be "non-conservative," thereby affecting the function or activity of a polypeptide. Non-conservative changes generally involve replacing an amino acid residue with a chemically different amino acid residue, such as replacing a non-polar or uncharged amino acid with a polar or charged amino acid, or vice versa. Non-conservative substitutions may involve replacing a member of one amino acid class with a member from another class.

[0192] 2. Notes on replacement

[0193] Those skilled in the art can use well-known techniques to determine suitable variants of polypeptides described herein. Those skilled in the art can identify suitable regions of molecules that can be changed without destroying activity by targeting regions that are considered unimportant to activity. Those skilled in the art will also be able to identify amino acid residues and molecular parts that are conserved in similar proteins or polypeptides. In other embodiments, regions that may be important for biological activity or structure can be subjected to conservative amino acid substitutions without significantly changing biological activity or having adverse effects on protein or polypeptide structure.

[0194] When making such changes, the hydropathicity index of the amino acids can be considered. The hydropathicity distribution of a protein is calculated by assigning a numerical value (the "hydropathy index") to each amino acid and then averaging these values ​​repeatedly along the peptide chain. Each amino acid has been assigned a value based on its hydrophobicity and charge characteristics. They are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine / cysteine ​​(+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5). It is generally understood in the art that the hydropathic amino acid index is important in conferring interactive biological function on a protein (Kyte et al., J. Mol. Biol. 157:105-131 (1982)). It is recognized that the relative hydrophilicity of amino acids contributes to the generation of the secondary structure of a protein or polypeptide, which in turn defines the interaction of the protein or polypeptide with other molecules, such as enzymes, substrates, receptors, DNA, antibodies, antigens, etc. It is also known that certain amino acids can be replaced with other amino acids with similar hydropathic indexes or scores and still retain similar biological activity. When making changes based on the hydropathic index, in certain embodiments, replacement of amino acids whose hydropathic index is within ±2 is included. In some aspects of the invention, those within ±1 are included, and in other aspects of the invention, those within ±0.5 are included.

[0195] It is also understood in the art that substitution of similar amino acids can be effectively performed based on hydrophilicity. U.S. Patent 4,554,101 (incorporated herein by reference) indicates that the maximum local average hydrophilicity of a protein is controlled by the hydrophilicity of its adjacent amino acids, which is related to the biological properties of the protein. In certain embodiments, the maximum local average hydrophilicity of a protein is controlled by the hydrophilicity of its adjacent amino acids, which is related to the immunogenicity and antigen binding of the protein, i.e., as a biological property of the protein. The following hydrophilicity values ​​have been assigned to these amino acid residues: arginine (+3.0); lysine (+3.0); aspartic acid (+3.0 ± 1); glutamic acid (+3.0 ± 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 ± 1); alanine (-0.5); histidine (-0.5); cysteine ​​(-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); and tryptophan (-3.4). When making changes based on similar hydrophilicity values, in certain embodiments, substitution of amino acids with hydrophilicity values ​​within ±2 is included, in other embodiments, those within ±1, and in other embodiments, those within ±0.5. In some cases, epitopes can also be identified from the primary amino acid sequence based on hydrophilicity. These regions are also referred to as "epitope core regions." It should be understood that an amino acid can be substituted with another amino acid having a similar hydrophilicity value and still produce a biologically equivalent and immunologically equivalent protein.

[0196] In addition, one skilled in the art can review structure-function studies to identify residues in similar polypeptides or proteins that are important for activity or structure. In view of this comparison, one can predict the importance of amino acid residues in a protein that correspond to amino acid residues in similar proteins that are important for activity or structure. One skilled in the art can select chemically similar amino acid substitutions for these predicted important amino acid residues.

[0197] Those skilled in the art can also analyze the three-dimensional structure and amino acid sequence related to the structure in similar proteins or polypeptides. In view of this information, those skilled in the art can predict the comparison of the amino acid residues of the antibody relative to its three-dimensional structure. Those skilled in the art can choose not to change the amino acid residues expected on the protein surface, because these residues may involve important interactions with other molecules. In addition, those skilled in the art can prepare test variants comprising a single amino acid replacement at each desired amino acid residue. The combination and / or activity of these variants can then be screened using standard assays, thereby generating information collected from such routine experiments, which can enable those skilled in the art to determine the amino acid position that should be avoided from further replacement alone or in combination with other mutations. Various tools that can be used to determine secondary structure can be found on the World Wide Web at expasy.org / proteomics / protein_structure.

[0198] In some embodiments of the invention, amino acid substitutions are made that: (1) reduce susceptibility to proteolysis, (2) reduce oxidative sensitivity, (3) alter binding affinity for forming a protein complex, (4) alter binding affinity for a ligand or antigen, and / or (5) confer or modify other physicochemical or functional properties of such polypeptides. For example, single or multiple amino acid substitutions (in certain embodiments, conservative amino acid substitutions) may be made in a naturally occurring sequence. Substitutions may be made in portions of an antibody that are located outside of the domains that form intermolecular contacts. In such embodiments, conservative amino acid substitutions that do not significantly alter the structural characteristics of a protein or polypeptide (e.g., one or more replacement amino acids that do not destroy the secondary structural characteristics of a native antibody) may be used.

[0199] III. Nucleic Acids

[0200] In certain embodiments, the nucleic acid sequence can be present in a variety of situations, such as: an integrated sequence encoding one or two chains of an antibody or its fragment, derivative, mutant protein or variant or an isolated fragment and a recombinant vector, a polynucleotide sufficient to be used as a hybridization probe, PCR primer or sequencing primer to identify, analyze, mutate or amplify a polynucleotide encoding a polypeptide, an antisense nucleic acid for inhibiting polynucleotide expression, and a complementary sequence of the aforementioned sequence described herein. Also provided are nucleic acids encoding epitopes of certain antibodies provided herein. Also provided are nucleic acids encoding fusion proteins comprising these peptides. Nucleic acids can be single-stranded or double-stranded and can comprise RNA and / or DNA nucleotides and artificial variants thereof (e.g., peptide nucleic acids).

[0201] The term "polynucleotide" refers to a nucleic acid molecule that is recombinant or has been separated from a total genomic nucleic acid. The term "polynucleotide" includes oligonucleotides (nucleic acids with a length of 100 or less than 100 residues), recombinant vectors, including, for example, plasmids, cosmids, phages, viruses, etc. In some aspects, a polynucleotide includes a regulatory sequence that is substantially separated from its naturally occurring gene or protein coding sequence. A polynucleotide can be single-stranded (coding or antisense) or double-stranded, and can be RNA, DNA (genomic, cDNA or synthetic), its analogs or combinations thereof. Additional coding or non-coding sequences can, but need not be, present in a polynucleotide.

[0202] In this regard, the term "gene", "polynucleotide" or "nucleic acid" is used to refer to a coded protein, polypeptide or peptide (including any sequence required for correct transcription, post-translational modification, or localization). As will be appreciated by those skilled in the art, the term includes genomic sequences, expression cassettes, cDNA sequences and smaller engineered nucleic acid fragments that express or may be suitable for expressing proteins, polypeptides, domains, peptides, fusion proteins and mutants. A nucleic acid encoding all or part of a polypeptide may comprise a continuous nucleic acid sequence encoding all or part of such a polypeptide. It is also contemplated that a particular polypeptide may be encoded by a nucleic acid comprising a variation having a slightly different nucleic acid sequence but still encoding the same or substantially similar protein.

[0203] In certain embodiments, there are polynucleotide variants with substantial identity to the sequences disclosed herein; compared to the polynucleotide sequences provided herein using methods described herein (e.g., BLAST analysis using standard parameters), comprising at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% or higher than 99% sequence identity, including all values ​​and ranges therebetween. In certain aspects, the isolated polynucleotide will comprise a nucleotide sequence encoding a polypeptide having at least 90%, preferably 95% and greater than 95% identity to the amino acid sequence described herein over the entire length of the sequence; or a nucleotide sequence complementary to the isolated polynucleotide.

[0204] Regardless of the length of the coding sequence itself, the nucleic acid fragments can be combined with other nucleic acid sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding fragments, etc., so that their overall length may vary greatly. The nucleic acids can be of any length. For example, they can be 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 175, 200, 250, 300, 350, 400, 450, 500, 750, 1000, 1500, 3000, 5000 or more than 5000 nucleotides in length, and / or can contain one or more than one additional sequence, such as a regulatory sequence, and / or be part of a larger nucleic acid, such as a vector. It is therefore contemplated that nucleic acid fragments of nearly any length may be used, with the overall length preferably being limited by the ease of preparation and use in the intended recombinant nucleic acid protocol. In some cases, a nucleic acid sequence may encode a polypeptide sequence with an additional heterologous coding sequence, e.g., to allow purification, transport, secretion, post-translational modification of the polypeptide, or for therapeutic benefit such as targeting or efficacy. As described above, a tag or other heterologous polypeptide may be added to the modified polypeptide coding sequence, wherein "heterologous" refers to a polypeptide that is different from the modified polypeptide.

[0205] 1. Hybridization

[0206] Nucleic acids that hybridize with other nucleic acids under specific hybridization conditions. Methods for hybridizing nucleic acids are well known in the art. See, for example, Current Protocols in Molecular Biology, John Wiley and Sons, NY (1989), 6.3.1-6.3.6. As defined herein, moderately stringent hybridization conditions use a pre-cleaning solution containing 5x sodium chloride / sodium citrate (SSC), 0.5% SDS, 1.0 mM EDTA (pH 8.0), a hybridization solution containing about 50% formamide, 6xSSC, and a hybridization temperature of 55°C (or other similar hybridization solutions, such as a hybridization solution containing about 50% formamide, and a hybridization temperature of 42°C), and a washing condition of 60°C in 0.5×SSC, 0.1% SDS. Stringent hybridization conditions are hybridized at 45°C in 6xSSC, followed by one or more washes at 68°C in 0.1xSSC, 0.2% SDS. In addition, one skilled in the art can manipulate the hybridization and / or wash conditions to increase or decrease the stringency of hybridization so that nucleic acids comprising at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to each other typically remain hybridized to each other.

[0207] Parameters that influence the choice of hybridization conditions and guidance for designing appropriate conditions are determined by, for example, Sambrook, Fritsch, and Maniatis (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11 (1989); Current Protocols in Molecular Biology, Ausubel et al., eds., John Wiley and Sons, Inc., sections 2.10 and 6.3-6.4 (1995), which are incorporated herein by reference in their entireties for all purposes) and can be readily determined by one of ordinary skill in the art based on, for example, the length and / or base composition of the DNA.

[0208] 2. Mutation

[0209] The change can be introduced into nucleic acid by mutation, so that the amino acid sequence of its encoded polypeptide (such as antibody or antibody derivative) changes. Any technology known in the art can be used to introduce mutation. In one embodiment, one or more than one specific amino acid residues are changed using, for example, a site-directed mutagenesis scheme. In another embodiment, one or more than one randomly selected residues are changed using, for example, a random mutagenesis scheme. No matter how it is prepared, the mutant polypeptide can be expressed and screened for desired properties.

[0210] Mutations can be introduced into nucleic acids without significantly changing the biological activity of the polypeptides encoded therein. For example, nucleotide substitutions that produce amino acid substitutions can be performed at non-essential amino acid residues. Alternatively, one or more than one mutation can be introduced into a nucleic acid to selectively change the biological activity of the polypeptides encoded therein. See, for example, Romain Studer et al., Biochem. J. 449: 581-594 (2013). For example, mutations can quantitatively or qualitatively change biological activity. Examples of quantitative changes include increasing, decreasing, or eliminating activity. Examples of qualitative changes include changing the antigenic specificity of an antibody.

[0211] 3. Probe

[0212] On the other hand, nucleic acid molecules are suitable for use as primers or hybridization probes for detecting nucleic acid sequences. Nucleic acid molecules may comprise only a portion of a nucleic acid sequence encoding a full-length polypeptide, for example, a fragment that can be used as a probe or primer or a fragment encoding an active portion of a given polypeptide.

[0213] In another embodiment, nucleic acid molecules can be used as probes or PCR primers for specific antibody sequences. For example, nucleic acid molecule probes can be used for diagnostic methods or nucleic acid molecule PCR primers can be used for amplifying DNA regions, which are particularly useful for separating nucleic acid sequences for producing variable domains of antibodies. See, for example, Gaily Kivi et al., BMC Biotechnol.16:2 (2016). In a preferred embodiment, nucleic acid molecules are oligonucleotides. In a more preferred embodiment, oligonucleotides are from the highly variable regions of the heavy and light chains of the target antibody. In an even more preferred embodiment, oligonucleotides encode all or part of one or more than one CDR.

[0214] Probes based on the desired nucleic acid sequence can be used to detect nucleic acids or similar nucleic acids, such as transcripts encoding polypeptides of interest. The probes can include labeling groups, such as radioisotopes, fluorescent compounds, enzymes, or enzyme cofactors. Such probes can be used to identify cells expressing the polypeptide.

[0215] IV. Preparation of Antibodies

[0216] A. Embodiments of antibody preparation.

[0217] Methods for preparing and characterizing antibodies for use in diagnostic and detection assays, for purification and as therapeutic agents are well known in the art, for example, as disclosed in U.S. Pat. Nos. 4,011,308; 4,722,890; 4,016,043; 3,876,504; 3,770,380; and 4,372,745 (see, e.g., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988; incorporated herein by reference). These antibodies may be polyclonal or monoclonal antibody preparations, monospecific antisera, human antibodies, hybrid or chimeric antibodies, such as humanized antibodies, altered antibodies, F(ab')2 fragments, Fab fragments, Fv fragments, single domain antibodies, dimer or trimer antibody fragment constructs, miniantibodies or functional fragments thereof that bind to the antigen in question. In certain aspects, polypeptides, peptides and proteins and immunogenic fragments thereof for use in various embodiments may also be synthesized in solution or on a solid support according to conventional techniques. See, for example, Stewart and Young, (1984); Tarn et al., (1983); Merrifield, (1986); and Barany and Merrifield (1979), each of which is incorporated herein by reference.

[0218] In short, polyclonal antibodies are prepared by immunizing an animal with an antigen or part thereof and collecting antiserum from the immunized animal. The antigen may be altered compared to the antigen sequence found in nature. In some embodiments, antibodies are produced using a variant or altered antigenic peptide or polypeptide. Inoculum is usually prepared by dispersing the antigenic composition in a physiologically tolerable diluent to form an aqueous composition. Antiserum is subsequently collected by methods known in the art, and the serum can be used as is for various applications, or the desired antibody portion can be purified by well-known methods, such as affinity chromatography (Harlow and Lane, Antibodies: A Laboratory Manual 1988).

[0219] Methods for preparing monoclonal antibodies are also well known in the art (Kohler and Milstein, 1975; Harlow and Lane, 1988, U.S. Pat. No. 4,196,265, which is incorporated herein by reference in its entirety for all purposes). Typically, the technique involves immunizing a suitable animal with a selected immunogenic composition, such as a purified or partially purified protein, polypeptide, peptide or domain. The antibody-producing B cells or all separated spleen cells from the immunized animal are then induced to fuse with cells from an immortalized cell line to form a hybridoma. The myeloma cell line suitable for the fusion process of producing hybridomas is preferably antibody-free and has a high fusion efficiency and enzyme deficiency, resulting in an inability to grow in certain selective culture media that only support the growth of the desired fused cells (hybridomas). Typically, the fusion partner includes properties that allow the use of a specific culture medium to select the resulting hybridoma. For example, the fusion partner may be sensitive to hypoxanthine / aminopterin / thymidine (HAT). Methods for producing hybrids of spleen or lymph node cells and myeloma cells that produce antibodies generally include mixing somatic cells with myeloma cells in the presence of one or more reagents (chemical or electrical) that promote cell membrane fusion. Next, hybridomas can be selected by culturing cells by monoclonal dilution in microtiter plates, and then testing the desired reactivity of individual clone supernatants (after about two to three weeks). Fusion processes, immunization protocols, and separation of immune spleen cells for fusion techniques for preparing hybridomas are known in the art.

[0220] Other techniques for making monoclonal antibodies include viral or oncogenic transformation of B lymphocytes, molecular cloning methods that can be used to prepare nucleic acids or polypeptides, the selected lymphocyte antibody method (SLAM) (see, e.g., Babcook et al., Proc. Natl. Acad. Sci. USA 93:7843-7848 (1996)), preparing combinatorial immunoglobulin phagemid libraries from RNA isolated from the spleen of an immunized animal and selecting phagemids expressing the appropriate antibodies, or using Cre-mediated site-specific recombination to generate antibody-expressing cells from cellular genomic sequences containing modified immunoglobulin loci (see, e.g., U.S. Pat. No. 6,091,001).

[0221] The monoclonal antibodies can be further purified using filtration, centrifugation, and various chromatographic methods such as HPLC or affinity chromatography. The monoclonal antibodies can be further screened or optimized for properties related to specificity, affinity, half-life, immunogenicity, binding association, binding dissociation, or overall functional properties related to treatment of infection. Thus, the monoclonal antibodies can be altered in the amino acid sequence of the CDRs, including insertions, deletions, or substitutions with conservative or non-conservative amino acids.

[0222] The immunogenicity of a particular immunogenic composition can be enhanced by using a non-specific stimulator of the immune response called an adjuvant. Adjuvants that can be used according to the embodiment include, but are not limited to, IL-1, IL-2, IL-4, IL-7, IL-12, -interferon, GMCSP, BCG, aluminum hydroxide, MDP compounds, such as thur-MDP and nor-MDP, CGP (MTP-PE), lipid A and monophosphoryl lipid A (MPL). Exemplary adjuvants may include complete Freund's adjuvant (a non-specific immune response stimulator containing killed mycobacterium tuberculosis), incomplete Freund's adjuvant and / or aluminum hydroxide adjuvant. In addition to adjuvants, it may be necessary to co-administer biological response modifiers (BRMs), such as, but not limited to, cimetidine (CIM; 1200 mg / d) (Smith / Kline, PA); low-dose cyclophosphamide (CYP; 300 mg / m2) (Johnson / Mead, NJ), cytokines such as beta-interferon, IL-2 or IL-12, or genes encoding proteins involved in immune auxiliary functions, such as B-7. Phage display systems can be used to amplify antibody molecule populations in vitro. Saiki et al., Nature 324:163 (1986); Scharf et al., Science 233:1076 (1986); U.S. Pat. Nos. 4,683,195 and 4,683,202; Yang et al., J Mol Biol. 254:392 (1995); Barbas, III et al., Methods: Comp. Meth Enzymol. (1995) 8:94; Barbas, III et al., Proc Natl Acad Sci USA 88:7978 (1991).

[0223] B. Preparation of fully human antibodies

[0224] The method for preparing fully human antibodies can be used.Using fully human antibodies can minimize the immunogenicity and allergic reactions that may be caused by administering non-human monoclonal antibodies to humans as therapeutic agents.In one embodiment, human antibodies can be produced in non-human transgenic animals, such as transgenic mice that can produce multiple isotypes (e.g., IgG, IgA and / or IgE) of human protein antibodies by VDJ recombination and isotype conversion.Therefore, this aspect is applicable to antibodies, antibody fragments and pharmaceutical compositions thereof, but is also applicable to non-human transgenic animals, B cells, host cells and hybridomas that produce monoclonal antibodies.The application of humanized antibodies includes but is not limited to detecting cells expressing expected proteins in vivo or in vitro, pharmaceutical preparations containing antibodies of the present invention and methods for treating diseases by administering antibodies.

[0225] Fully human antibodies can be prepared by immunizing transgenic animals (usually mice), which are able to produce human antibody repertoires without producing endogenous immunoglobulins. Antigens for this purpose generally have six or more than six consecutive amino acids and are optionally conjugated to a carrier such as a hapten. For example, see Jakobovits et al., Proc. Natl. Acad. Sci. USA 90: 2551-2555 (1993); Jakobovits et al., Nature 362: 255-258 (1993); Bruggermann et al., Yearin Immunol. 7: 33 (1993). In one example, transgenic animals are produced by disabling the endogenous mouse immunoglobulin loci encoding mouse immunoglobulin heavy and light chains, and inserting a large fragment of human genomic DNA containing the loci encoding human heavy and light chain proteins into the mouse genome. Animals with less than partially modified human immunoglobulin loci are then hybridized to obtain animals with all desired immune system modifications. When an immunogen is administered, these transgenic animals produce antibodies that are immunospecific for the immunogen but have human rather than mouse amino acid sequences, including variable regions. For further details of these methods, see, for example, International Patent Application Publication Nos. WO 96 / 33735 and WO 94 / 02602, which are incorporated herein by reference in their entirety. Other methods for making human antibodies related to transgenic mice are described in U.S. Pat. Nos. 5,545,807; 6,713,610; 6,673,986; 6,162,963; 6,300,129; 6,255,458; 5,877,397; 5,874,299 and 5,545,806; in International Patent Application Publication Nos. WO 91 / 10741 and WO 90 / 04036; and in European Patent Nos. EP 546,073 B1 and EP 546,073 A1, all of which are incorporated herein by reference in their entirety for all purposes.

[0226] The transgenic mice, referred to herein as "HuMAb" mice, contain human immunoglobulin gene minilocus encoding unrearranged human heavy and light chain immunoglobulin sequences, and targeted mutations that inactivate endogenous loci (Lonberg et al., Nature 368: 856-859 (1994)). Therefore, the mice exhibit reduced expression of mouse IgM or? chains and in response to immunization, the introduced human heavy and light chain transgenes undergo class switching and somatic mutation to produce high-affinity human IgG? monoclonal antibodies (Lonberg et al., supra; Lonberg and Huszar, Intern. Ref. Immunol. 13: 65-93 (1995); Harding and Lonberg, Ann. NY Acad. Sci. 764: 536-546 (1995)). In Taylor et al., Nucl. Acids Res. 20:6287-6295 (1992); Chen et al., Int. Immunol. 5:647-656 (1993); Tuaillon et al., J. Immunol. 152:2912-2920 (1994); Lonberg et al., supra; Lonberg, Handbook The preparation of HuMAb mice is described in detail in of Exp. Pharmacol. 113:49-101 (1994); Taylor et al., Int. Immunol. 6:579-591 (1994); Lonberg and Huszar, Intern. Ref. Immunol. 13:65-93 (1995); Harding and Lonberg, Ann. NY Acad. Sci. 764:536-546 (1995); Fishwild et al., Nat. Biotechnol. 14:845-851 (1996), all of which are incorporated herein by reference in their entirety for all purposes. See also U.S. Patent Nos. 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,789,650; 5,877,397; 5,661,016; 5,814,318; 5,874,299; 5,770,429; and 5,545,807; and International Patent Application Publication Nos. WO 93 / 1227; WO 92 / 22646; and WO 92 / 03918, all of which are incorporated herein by reference in their entirety for all purposes. Techniques for producing human antibodies in these transgenic mice are also disclosed in WO 98 / 24893 and Mendez et al., Nat. Genetics 15:146-156 (1997), which are incorporated herein by reference.For example, HCo7 and HCo12 transgenic mouse strains can be used to generate human antibodies.

[0227] Using hybridoma technology, antigen-specific humanized monoclonal antibodies with desired specificity can be produced and selected from transgenic mice, such as those described above. Such antibodies can be cloned and expressed using appropriate vectors and host cells, or antibodies can be harvested from cultured hybridoma cells. Fully human antibodies can also be derived from phage display libraries (such as Hoogenboom et al., J. Mol. Biol. 227: 381 (1991); and Marks et al., J. Mol. Biol. 222: 581 (1991) disclosed). Such a technique is described in International Patent Application Publication No. WO 99 / 10494 (incorporated herein by reference), which describes the use of this method to separate high affinity and functional agonist antibodies for MPL- and msk-receptors.

[0228] C. Preparation of Antibody Fragments

[0229] Antibody fragments that retain the ability to recognize the target antigen will also be used herein. Many antibody fragments are known in the art, and they contain antigen binding sites that can exhibit the immunological binding properties of intact antibody molecules, and can be subsequently modified by methods known in the art. Functional fragments, which include only the variable regions of heavy and light chains, can also be prepared using standard techniques, such as recombinant preparation or preferential proteolytic cleavage of immunoglobulin molecules. These fragments are referred to as Fv. See, for example, Inbar et al., Proc. Nat. Acad. Sci. USA 69: 2659-2662 (1972); Hochman et al., Biochem. 15: 2706-2710 (1976); and Ehrlich et al., Biochem. 19: 4091-4096 (1980).

[0230] Single-chain variable fragments (scFv) can be prepared by fusing a DNA encoding a peptide linker between DNA encoding two variable domain polypeptides (VL and VH). scFvs can form antigen-binding monomers, or they can form multimers (e.g., dimers, trimers, or tetramers), depending on the length of the flexible linker between the two variable domains (Kortt et al., Prot. Eng. 10: 423 (1997); Kort et al., Biomol. Eng. 18: 95-108 (2001)). By combining different polypeptides comprising VL and VH, multimeric scFvs that bind to different epitopes can be formed (Kriangkum et al., Biomol. Eng. 18: 31-40 (2001)). Antigen-binding fragments are typically prepared by recombinant DNA methods known to those skilled in the art. Although the two domains of the Fv fragment, VL and VH, are encoded by different genes, they can be linked together by a synthetic linker using recombinant methods, enabling them to be made into a single-chain polypeptide (referred to as single-chain Fv (sFv or scFv); see, e.g., Bird et al., Science 242: 423-426 (1988); and Huston et al., Proc. Natl. Acad. Sci. USA 85: 5879-5883 (1988). Design criteria include determining an appropriate length to span the distance between the C-terminus of one chain and the N-terminus of the other chain, wherein the linker is generally formed by small hydrophilic amino acid residues that are not prone to curling or forming secondary structures. Suitable linkers generally comprise a polypeptide chain of alternating sets of glycine and serine residues, and may include inserted glutamic acid and lysine residues to enhance solubility. Antigen-binding fragments are screened for application in the same manner as intact antibodies. Such fragments include those obtained by amino-terminal and / or carboxyl-terminal deletions, wherein the remaining amino acid sequence is substantially identical to the corresponding positions in the naturally occurring sequence, e.g., deduced from the full-length cDNA sequence.

[0231] Antibodies can also be produced using peptide analogs of epitope determinants disclosed herein, which can be composed of non-peptide compounds having similar properties to the template peptide. These types of non-peptide compounds are referred to as "peptide mimetics" or "peptide mimics". Fauchere, J. Adv. Drug Res. 15: 29 (1986); Veber and Freidinger TINS ​​p. 392 (1985); and Evans et al., J. Med. Chem. 30: 1229 (1987). Liu et al. (2003) also described "antibody-like binding peptide mimics" (ABiPs), which are peptides that act as streamlined antibodies, with longer serum half-lives and less cumbersome synthetic methods. These analogs can be a combination of peptides, non-peptides, or peptide and non-peptide regions. Fauchere, Adv. Drug Res. 15: 29 (1986); Veber and Freidiner, TINS ​​p. 392 (1985); and Evans et al., J. Med. Chem. 30: 1229 (1987), which are incorporated herein by reference in their entirety for any purpose. Peptide mimetics structurally similar to peptides used for treatment can be used to produce similar therapeutic or preventive effects. Such compounds are usually developed with the help of computerized molecular modeling. Generally, the peptide mimetics of the present invention are proteins structurally similar to antibodies, showing the desired biological activity, such as the ability to bind to proteins, but having one or more peptide bonds that are optionally replaced by a bond selected from the following by methods well known in the art: -CH2NH-, -CH2S-, -CH2-CH2-, -CH-CH- (cis and trans), -COCH2-, -CH(OH)CH2- and -CH2SO-. In certain embodiments of the invention, one or more than one amino acid of a consensus sequence can be systematically replaced with a D-amino acid of the same type (e.g., D-lysine instead of L-lysine) to produce a more stable protein. In addition, constrained peptides comprising a consensus sequence or substantially identical consensus sequence variations can be produced by methods known in the art (Rizo and Gierasch, Ann. Rev. Biochem. 61:387 (1992), incorporated herein by reference), for example, by adding internal cysteine ​​residues that can form intramolecular disulfide bonds that cyclize the peptide.

[0232] After the phage display library is generated, it can be used to improve the immunological binding affinity of the Fab molecule using known techniques. For example, see Figini et al., J. Mol. Biol. 239: 68 (1994). The coding sequences of the heavy and light chain portions of the Fab molecules selected from the phage display library can be isolated or synthesized and cloned into any suitable vector or replicon for expression. Any suitable expression system can be used.

[0233] V. Obtaining Encoded Antibodies

[0234] In some respects, there are nucleic acid molecules encoding antibody polypeptides (e.g., heavy chain or light chain, only variable domains or total length). These can be produced by methods known in the art, for example, by separation, phage display, expression in any suitable recombinant expression system and allowing assembly to form antibody molecules from the B cells of immunized and isolated mice.

[0235] A. Expression

[0236] Nucleic acid molecules can be used to express large amounts of recombinant antibodies or to produce chimeric antibodies, single-chain antibodies, immunoadhesins, diabodies, mutant antibodies, and other antibody derivatives. If the nucleic acid molecule is derived from a non-human, non-transgenic animal, the nucleic acid molecule can be used for antibody humanization.

[0237] 1. Carrier

[0238] In some aspects, expression vectors comprising nucleic acid molecules encoding polypeptides or portions thereof (e.g., fragments comprising one or more CDRs or one or more variable region domains) of the desired sequences are contemplated. Expression vectors comprising nucleic acid molecules can encode heavy chains, light chains, or antigen binding portions thereof. In some aspects, expression vectors comprising nucleic acid molecules can encode fusion proteins, modified antibodies, antibody fragments, and probes thereof. In addition to control sequences for controlling transcription and translation, vectors and expression vectors can also contain nucleic acid sequences with other functions.

[0239] In order to express the antibody or its antigen-binding fragment, the DNA encoding part or full-length light and heavy chains is inserted into the expression vector so that the gene region is operably connected to the transcription and translation control sequence. In some aspects, the vector encoding the functionally complete human CH or CL immunoglobulin sequence is transformed with appropriate restriction sites so that any VH or VL sequence can be easily inserted and expressed. Generally, the expression vector used in any host cell comprises sequences for plasmid or virus maintenance and for cloning and expression of exogenous nucleotide sequences. Such sequences, collectively referred to as "flanking sequences", generally include one or more of the following operably connected nucleotide sequences: promoter, one or more than one enhancer sequence, replication origin, transcription termination sequence, complete intron sequence containing donor and acceptor splice sites, sequence encoding leader sequence for polypeptide secretion, ribosome binding site, polyadenylation sequence, multiple joint region and selectable marker element for inserting nucleic acid encoding polypeptide to be expressed. Such sequences and methods for using them are well known in the art.

[0240] 2. Expression system

[0241] There are multiple expression systems comprising at least part or all of the above-mentioned expression vectors. Systems based on prokaryotes and / or eukaryotes can be used for use with the embodiments to prepare nucleotide sequences or their associated polypeptides, proteins and peptides. Commercially and widely available systems include but are not limited to bacteria, mammals, yeast and insect cell systems. Different host cells have the characteristics and specific mechanisms of post-translational processing and protein modification. Suitable cell lines or host systems can be selected to ensure the correct modification and processing of the expressed foreign protein. Those skilled in the art can use suitable expression system expression vectors to prepare nucleotide sequences or their associated polypeptides, proteins or peptides.

[0242] 3. Gene transfer method

[0243] Suitable methods for nucleic acid delivery for achieving expression of the composition include any method that can actually introduce nucleic acid (e.g., DNA, including viral and non-viral vectors) into cells, tissues or organisms, as described herein or as known to those of ordinary skill in the art. Such methods include, but are not limited to, direct delivery of DNA, such as by injection (U.S. Patents 5994624, 5981274, 5945100, 5780448, 5736524, 5702932, 5656610, 5589466 and 5580859, all incorporated herein), including microinjection (Harland and Weintraub, 1985; U.S. Patent 5789215, incorporated herein by reference); by electroporation (U.S. Patent No. 5384253, incorporated herein by reference); by calcium phosphate precipitation (Graham and Van Der Eb, 1973; Chen and Okayama, 1987; Rippe et al., 1990); using DEAE dextran followed by polyethylene glycol (Gopal, 1985); by direct sonication (Fechheimer et al., 1987); by liposome-mediated transfection (Nicolau and Sene, 1982; Fraley et al., 1979; Nicolau et al., 1987; Wong et al., 1980; Kaneda et al., 1989; Kato et al., 1991); by microprojectile bombardment (PCT Application No. WO Nos. 94 / 09699 and 95 / 06128; U.S. Pat. Nos. 5,610,042; 5,322,783, 5,563,055, 5,550,318, 5,538,877 and 5,538,880, all of which are incorporated herein by reference); by agitation with silicon carbide fibers (Kaeppler et al., 1990; U.S. Pat. Nos. 5,302,523 and 5,464,765, all of which are incorporated herein by reference); by Agrobacterium-mediated transformation (U.S. Pat. Nos. 5,591,616 and 5,563,055, all of which are incorporated herein by reference); or by PEG-mediated transformation of protoplasts (Omirulleh et al., 1993; U.S. Pat. Nos. 4,684,611 and 4,952,500, all of which are incorporated herein by reference); by desiccation / inhibition-mediated DNA uptake (Potrykus et al., 1985). Other methods include viral transduction, such as gene transfer by lentiviral or retroviral transduction.

[0244] B. Host Cells

[0245] In another aspect, it is contemplated to use a host cell into which a recombinant expression vector has been introduced. Antibodies can be expressed in a variety of cell types. Expression constructs encoding antibodies can be transfected into cells according to a variety of methods known in the art. Vector DNA can be introduced into prokaryotic or eukaryotic cells by conventional transformation or transfection techniques. Some vectors can use control sequences that allow them to replicate and / or express in prokaryotic and eukaryotic cells. In certain aspects, the antibody expression construct can be placed under the control of a promoter associated with T cell activation, such as a promoter controlled by NFAT-1 or NF-?, both of which are transcription factors that can be activated when T cells are activated. The control of antibody expression allows T cells, such as tumor-targeting T cells, to sense their surroundings and to regulate cytokine signaling in real time in the T cells themselves and the surrounding endogenous immune cells. Those skilled in the art will understand the conditions for incubating host cells to maintain them and allow vector replication. It is also understood and known that the technology and conditions for allowing large-scale preparation of vectors and the preparation of nucleic acids encoded by vectors and their homologous polypeptides, proteins or peptides are also understood and known.

[0246] For stable transfection of mammalian cells, it is known that only a small portion of cells can integrate foreign DNA into their genomes, depending on the expression vector and transfection technique used. In order to identify and select these integrants, a selection marker (e.g., for antibiotic resistance) is usually introduced into the host cell together with the gene of interest. In methods known in the art, cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells incorporating the selection marker gene will survive, while other cells die).

[0247] C. Separation

[0248] Nucleic acid molecules encoding one or both of the entire heavy and light chains of an antibody or their variable regions can be obtained from any source that produces the antibody. Methods for isolating mRNA encoding an antibody are well known in the art. See, e.g., Sambrook et al., supra. The sequences of human heavy and light chain constant region genes are also known in the art. See, e.g., Kabat et al., 1991, supra. Nucleic acid molecules encoding full-length heavy and / or light chains can then be expressed in cells into which they have been introduced and the antibody isolated.

[0249] VI. Administration of Therapeutic Compositions

[0250] Therapies provided herein may include administering a combination of therapeutic agents, such as a first cancer treatment and a second cancer treatment. Treatment may be administered in any suitable manner known in the art. For example, a first cancer treatment and a second cancer treatment may be administered sequentially (at different times) or simultaneously (at the same time). In some embodiments, the first cancer treatment and the second cancer treatment are administered in a separate composition. In some embodiments, the first cancer treatment and the second cancer treatment are in the same composition.

[0251] Embodiments of the present disclosure relate to compositions and methods comprising therapeutic compositions. Different treatments can be administered in the form of one composition or more than one composition, such as 2 compositions, 3 compositions, or 4 compositions. Various combinations of agents can be used.

[0252] The therapeutic agents of the present disclosure can be administered by the same route of administration or by different routes of administration. In some embodiments, cancer treatment is administered intravenously, intramuscularly, subcutaneously, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally. In some embodiments, antibiotics are administered intravenously, intramuscularly, subcutaneously, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally. Appropriate dosage can be determined based on the type of disease to be treated, the severity and course of the disease, the individual's clinical condition, the individual's clinical history and response to treatment, and the judgment of the attending physician.

[0253] Treatment may include various "unit doses". A unit dose is defined as a therapeutic composition containing a predetermined amount. The amount to be administered, as well as the specific route and formulation, is within the skill of a person skilled in the clinical art to determine. A unit dose need not be administered as a single injection, but may include continuous infusion over a set period of time. In some embodiments, a unit dose includes a single administration dose.

[0254] The dosage is determined by the number of treatments and the unit dose. An effective dose is understood to be the amount necessary to achieve a specific effect. In the practice of certain embodiments, it is expected that a dosage of 10 mg / kg to 200 mg / kg may affect the protective ability of these agents. Thus, contemplated dosages include about 0.1, 0.5, 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, and 200, 300, 400, 500, 1000 μg / kg, mg / kg, μg / day, or mg / day, or any range derivable therein. In addition, such dosages may be administered multiple times a day, and / or administered over days, weeks, or months.

[0255] In certain embodiments, the effective dose of the pharmaceutical composition is a pharmaceutical composition that can provide a blood level of about 1 μM to 150 μM. In another embodiment, the effective dose provides a blood level of about 4 μM to 100 μM; or about 1 μM to 100 μM; or about 1 μM to 50 μM; or about 1 μM to 40 μM; or about 1 μM to 30 μM; or about 1 μM to 20 μM; or about 1 μM to 10 μM; or about 10 μM to 150 μM; or about 10 μM to 100 μM; or about 10 μM to 50 μM; or about 25 μM to 150 μM; or about 25 μM to 100 μM; or about 25 μM to 50 μM; or about 50 μM to 150 μM; or about 50 μM to 100 μM (or any derivable range therein). In other embodiments, the dose can provide a blood level of the therapeutic agent resulting from administration of the therapeutic agent to a subject of about, at least about, or at most about 1 μM, 2 μM, 3 μM, 4 μM, 5 μM, 6 μM, 7 μM, 8 μM, 9 μM, 10 μM, 11 μM, 12 μM, 13 μM, 14 μM, 15 μM, 16 μM, 17 μM, 18 μM, 19 μM, 20 μM, 21 μM, 22 μM, 23 μM, 24 μM, 25 μM, 26 μM, 27 μM, 28 μM, 29 μM, 30 μM, 31 μM, 32 μM, 33 μM, 34 μM, 35 μM, 36 μM, 37 μM, 38 μM, μM, 21μM, 22μM, 23μM, 24μM, 25μM, 26μM, 27μM, 28μM, 29μM, 30μM, 31μM, 32μM, 33μM, 3 4μM, 35μM, 36μM, 37μM, 38μM, 39μM, 40μM, 41μM, 42μM, 43μM, 44μM, 45μM, 46μM, 47μM, 4 8μM, 49μM, 50μM, 51μM, 52μM, 53μM, 54μM, 55μM, 56μM, 57μM, 58μM, 59μM, 60μM, 61μM, 62μM, 63μM, 64μM, 65μM, 66μM, 67μM, 68μM, 69μM, 70μM, 71μM, 72μM, 73μM, 74μM, 75μM , 76μM, 77μM, 78μM, 79μM, 80μM, 81μM, 82μM, 83μM, 84μM, 85μM, 86μM, 87μM, 88μM, 89μM, 90μM, 91μM, 92μM, 93μM, 94μM, 95μM, 96μM, 97μM, 98μM, 99μM, or 100μM or any derivable range therein. In certain embodiments, the therapeutic agent administered to the subject is metabolized in vivo to a metabolized therapeutic agent, in which case the blood level may refer to the amount of the metabolized therapeutic agent. Alternatively, to the extent that the therapeutic agent is not metabolized by the subject, the blood levels discussed herein may refer to the unmetabolized therapeutic agent.

[0256] The precise amount of the therapeutic composition also depends on the judgment of the practitioner and varies from person to person. Factors affecting dosage include the patient's physical and clinical state, route of administration, the intended goal of treatment (relief of symptoms versus cure), and the potency, stability, and toxicity of the specific therapeutic substance or other treatments the subject may be receiving.

[0257] Those skilled in the art will understand and appreciate that dosage units of μg / kg or mg / kg body weight can be converted and expressed as comparable concentration units of μg / ml or mM (blood levels), e.g., 4 μM to 100 μM. It will also be understood that absorption depends on the species and organ / tissue. Applicable conversion factors and physiological assumptions made regarding uptake and concentration measurements are well known and will allow those skilled in the art to convert one concentration measurement to another and make reasonable comparisons and conclusions regarding the dosages, efficacies, and results described herein.

[0258] VII. Examples

[0259] The purpose of giving the following examples is to illustrate various embodiments of the present invention and is not meant to limit the present invention in any way. It will be readily appreciated by those skilled in the art that the present invention is well suited for achieving these purposes and obtaining the objects and advantages mentioned, as well as those objects, endpoints and advantages inherent in this article. The present examples, together with the methods described herein, currently represent preferred embodiments, are exemplary, and are not intended to limit the scope of the present invention. It will be appreciated by those skilled in the art that variations and other uses therein within the spirit of the present invention as defined by the scope of the claims will be included.

[0260] Example 1: Antibody Treatment of MRSA Colonization and Infection

[0261] Methicillin-resistant Staphylococcus aureus (MRSA) colonizes the nasopharynx and gastrointestinal tract of healthy individuals and hospitalized patients (1). Colonization is a key risk factor for the 238,000 cases of community-acquired (2,3) and 101,000 cases of hospital-acquired MRSA invasive disease (4 to 8). MRSA infection is associated with treatment failure, increased morbidity, and increased mortality (9). Although MRSA-specific antibiotics have been developed, the bacteria rapidly evolve resistance to new drugs (10). Previous attempts to develop vaccines or immunotherapies that could prevent MRSA colonization or invasive disease or improve outcomes of MRSA infections have failed (11 to 13). Infected individuals fail to mount a protective antibody response (immunity), which allows MRSA to persist within host tissues and lead to disease recurrence (14, 15).

[0262] Here, the inventors describe a monoclonal antibody, MAb 3F6, that binds and neutralizes Staphylococcal protein A (SpA) and Staphylococcal immunoglobulin binder (Sbi). The inventors show that galactosylation of MAb 3F6 on Fcγ promotes C1q binding, opsonophagocytic killing (OPK) of MRSA, and protection of mice from MRSA bloodstream infection. In addition, the inventors isolated amino acid substitutions in Fcγ that abolished SpA and Sbi binding and enhanced OPK activity of the variant MAb 3F6 hIgG1Fcγ1-6. Intravenous injection of MAb 3F6 into mice neutralized circulating SpA and blocked its B cell superantigen activity (BCSA), thereby promoting antibody responses against bacterial surface antigens and clearance of S. aureus from the nasopharynx and gastrointestinal tract of mice. Here, the inventors will test the hypothesis that intravenous administration of saccharide and Fcγ engineered human 3F6-hIgG1 promotes S. aureus decolonization, prevents invasive MRSA disease, and improves the outcome of MRSA bloodstream infections in experimental animals. If so, the saccharide and Fcγ engineered 3F6 MAbs can be developed for clinical testing to prevent and / or treat MRSA infections in U.S. hospitals.

[0263] The approach includes the following innovations. a) Establishment of a mouse model of persistent S. aureus colonization (27). b) Discovery that SpA BCSA is essential for persistent S. aureus colonization (27). c) Treatment of mice with a neutralizing SpA MAb promoted decolonization of S. aureus (28). d) Isolation of IgG1 Fcγ-variants whose effector function could not be inactivated by SpA and Sbi. e) Demonstration that 3F6-IgG1 glycosylation provides enhanced disease protection. f) Identification of 3F6-IgG1 glycoforms with enhanced MRSA OPK activity. g) Use of tifilomab (anti-ClfA IgG1) (14) as a calibration standard to quantify the effects of Fcγ amino acid sequence and glycosylation on effector binding, plasma half-life, in vitro MRSA opsonization, MRSA OPK, S. aureus colonization, and the preventive and therapeutic effects of S. aureus against MRSA bloodstream infections. h) Use transgenic cells to produce on a large scale 3F6-IgG1 with a unique Fcγ sequence and glycoforms useful for clinical efficacy.

[0264] Neutrophils play a central role in protecting humans from infection with Staphylococcus aureus (63). Entry and replication of Staphylococci in host tissues results in the release of bacterial products (formyl peptides, lipoproteins, or peptidoglycans) and in damaged tissues with inflammatory signals, namely chemoattractants and cytokines (16). Immune cells sense Staphylococcal products via Toll-like and G protein-coupled receptors, and the released cytokines activate cognate immune receptors (16). Neutrophils respond to this call by extravasating from the blood vessels and migrating to the site of infection to phagocytose and kill bacteria or to immobilize and destroy pathogens via NETosis—the release of neutrophil extracellular traps (NETs) containing DNA and antimicrobial peptides (64, 65). The importance of neutrophils in controlling S. aureus infection has been demonstrated by studies of immune deficiencies. Mutations in the gene encoding NADPH oxidase, an enzyme that produces bactericidal superoxide in phagocytes, result in chronic granulomatous disease (CGD), which is associated with defective phagocytic killing of S. aureus and frequent infections (66, 67). Individuals with faulty STAT1 / STAT3 signaling on innate immune cells have perturbations in the IL-17 cytokine pathway, which reduces mucocutaneous immunity and promotes S. aureus infection (68). IL-17-dependent T cell signaling is a key activator of neutrophil and anti-staphylococcal defenses (69). Finally, cancer patients with reduced blood neutrophil counts are highly susceptible to S. aureus infection (70). However, the vast majority of MSSA / MRSA disease occurs in immunocompetent individuals without defects in phagocyte function following traumatic disruption of the skin barrier defenses or shedding into the bloodstream (71). To achieve this, S. aureus deploys a range of immune escape strategies to prevent immune cell extravasation, chemotaxis, complement activation, and phagocytosis (71). In addition, neutrophil-mediated killing of MRSA is counteracted by MRSA modification of the bacterial envelope and production of proteases, staphyloxanthin, superoxide dismutase, catalase, and alkyl hydroxide ester reductase, through the production of antimicrobial peptides, reactive nitrogen (NO), reactive oxygen species (ROS: hydrogen peroxide, superoxide, hydroxyl radicals), cell wall hydrolases, and proteolytic enzymes (16, 72). Thus, in the absence of opsonizing antibodies, neutrophils from immunocompetent mice or humans exhibit modest killing activity against MRSA (73 to 75) (Figures 5B and 5D). For all Gram-positive bacteria, antibodies that bind to the surface of staphylococci and activate complement do not exhibit bactericidal effects in the absence of immune cells (13). In contrast, antibody-mediated phagocytosis of S. aureus into neutrophils or macrophages promotes bacterial killing, termed opsonophagocytic killing (OPK) (13). However, MSSA / MRSA produce proteins that bind immunoglobulins to evade OPK.SpA and Sbi are displayed on the bacterial surface, bind to IgG Fcγ and block the effector function of the antibody by preventing the binding of complement (C1q) and Fc receptors on immune cells (16) (Figure 1). SpA contains five immunoglobulin binding domains (IgBDs), each of which binds to the Fcγ of human IgG1, IgG2, and IgG4 (but not IgG3) and mouse IgG (IgG1, IgG2a, IgG2b, IgG2c, and IgG3) (76, 77) (Figure 5A). Sbi contains two IgBDs with high sequence homology to the SpA IgBDs and binds human and mouse IgG Fcγ in the same manner (78, 79) (Figure 5A). Staphylococcal superantigen-like protein 10 (SSL10) is another secreted protein that binds to the Fcγ of human IgG1 but not mouse IgG (80). Notably, all MSSA / MRSA strains express spa and sbi, while ssl10 is only present in a few clinical isolates (16). Thus, even though specific IgG can bind to the staphylococcal surface, SpA and Sbi still provide protection against OPK for MSSA and MRSA (16) (Fig. 5B). Therefore, any therapeutic strategy involving MRSA-specific antibodies must address the staphylococcal SpA and Sbi defenses.

[0265] MRSA evades the adaptive immune response. A key feature of MSSA / MRSA disease is its recurrence, which occurs with a frequency of 8% to 33% for SSTIs and bloodstream infections (81, 82). Recovery from MSSA / MRSA disease does not confer protection against subsequent infections (83). The ability of the pathogen to cause recurrent disease implies the existence of mechanisms that effectively prevent the development of an adaptive immune response (84). Staphylococcus aureus manipulates adaptive B cell responses through SpA binding to BCSA of variant heavy chains of the VH3 idiotypes IgM, IgG, IgD, and IgE (85-87) (Figure 2). SpA is initially deposited in the staphylococcal envelope via its C-terminal sorting signal (LPXTG motif) and is subsequently released into the extracellular environment by cell wall hydrolases (88 to 90). The released SpA with a C-terminal peptidoglycan fragment crosslinks the variant heavy chains of the VH3 family B cell receptor (IgM) and triggers B cell proliferation and secretion of VH3 clonal antibodies (91). During infection in humans or mice, SpA released by MSSA / MRSA leads to massive expansion of VH3 clonal plasma cells that secrete VH3 clonal IgM and IgG antibodies that do not recognize staphylococcal antigens (92). Thus, the released SpA diverts B cell development to prevent the production of pathogen-specific IgG (91). The inhibitory effect of MRSA / MSSA on host adaptive B cell responses is alleviated during colonization or invasive disease with Δspa or spaKKAA strains, which triggers pathogen-specific IgG responses, leading to decolonization and preventing recurrent MSSA / MRSA disease (27, 76) (Figures 3A to 3E).

[0266] MAb 3F6 is a novel MRSA therapeutic. Humans, guinea pigs, and mice are unable to produce antibodies that bind to and neutralize IgBD of SpA and Sbi (76, 85, 92, 93). SpAKKAA is an engineered non-toxigenic recombinant variant that cannot bind to IgG Fcγ or VH3 clone variant heavy chains (85) (Figures 3A to 3B). When used as a vaccine antigen, SpAKKAA elicits SpA neutralizing antibodies in guinea pigs and mice (85, 93) (Figure 3F). Animals vaccinated with SpAKKAA neutralize Staphylococcus aureus BCSA during colonization and infection and produce a broad spectrum of antibody responses against secreted staphylococcal antigens (85, 93). Splenocytes from mice immunized with SpAKKAA were fused with myeloma cells, and hybridomas were screened for mAbs that bind to SpAKKAA (79). Mouse hybridoma mAb 3F6 (hy-3F6) has the highest affinity for SpAKKAA (Ka = 22.97×10 9 M -1hy-3F6 also binds to the IgBD of SpA and Sbi and blocks their binding to IgG Fcγ and VH3 clone variant heavy chains (SpA and Sbi neutralizing activity) (79). hy-3F6 is a VH1 idiotype mouse IgG2a antibody whose VH domain does not bind SpA (79, 94). When mice were injected intravenously (5 mg MAb kg -1When hy-3F6 (weight) was administered to 1-day-old mice but not to IgG2a controls, it protected animals from MRSA bloodstream challenge, reducing bacterial load and the number of abscess lesions (79) (Figure 3G). When administered to 1-day-old mouse pups, hy-3F6 prevented MRSA sepsis / meningitis after subcutaneous challenge (95). The inventors used the CDR1 to CDR3 amino acid sequences of the hy-3F6 heavy and light chains to generate plasmid-borne recombinant human VH1-idiotype 3F6 IgG1 (3F6-hIgG1) and recombinant mouse VH1-idiotype 3F6 IgG1 (3F6-mIgG1), IgG2a (3F6-mIgG2a), IgG2b (3F6-mIgG2b), and IgG3 (3F6-mIgG3). All antibodies were produced in HEK293 F cells. Similar to hybridoma 3F6, the recombinant antibody was bound to SpAKKAA, bound to and neutralized wild-type SpA and Sbi, protected adult mice from MRSA bloodstream infection, and protected newborn pups from MRSA sepsis (28, 79, 94, 95). The inventors attempted to explore the mechanism by which MAb 3F6 triggers OPK of MRSA in the blood and protects against invasive disease (Fig. 3H). Mice produce IgG antibodies of different subclasses - IgG1, IgG2a, IgG2b, (IgG2c) and IgG3 - each retaining the ability to bind C1q and activate complement (96). However, each IgG subclass involves a series of discrete FcγR receptors that are differentially expressed on immune effector cells (97). For each subclass, the affinity of specific IgG to different FcγRs differs by several orders of magnitude (98). Therefore, if MAb 3F6 requires specific FcγR receptors to activate immune effector cells and protect against S. aureus, one would expect protection to occur in an IgG subclass-specific manner (98, 99). On the other hand, if MAb 3F6 activates immune effectors through C1q binding, disease protection would occur in a complement-dependent but IgG subclass-independent manner. This was tested, and all four mouse subclass IgG antibodies (m3F6-IgG1, m3F6-IgG2a, m3F6-IgG2b, and m3F6IgG3) showed similar efficacy in protecting BALB / c mice from MRSA bloodstream infection. Treatment of mouse blood with a C3 complement inhibitor blocked m3F6-IgG2a OPK activity and mouse disease protection. Therefore, MAb 3F6-mediated protection against invasive MRSA disease requires complement activation (C1q binding and C3 convertase).

[0267] MAb-3F6 glycosylation is a determinant of MRSA OPK. Plasmid p3F6-hIgG1 was stably transfected into CHO cells, and a research cell bank for large-scale purification of 3F6-hIgG1CHO was developed. When compared with the same antibody (3F6-hIgG1HEK) expressed in HEK293 F cells, 3F6-hIgG1CHO was administered to BALB / c mice and could not prevent MRSA bloodstream infection (Fig. 4C to Fig. 4D). Therefore, the inventors performed liquid chromatography-electrospray ionization mass spectrometry analysis on 3F6-hIgG1HEK and 3F6-hIgG1CHO. The data in Fig. 4A to Fig. 4B prove that the two antibodies have the same protein sequence and their Fc glycan structures are different. The G1F and G2F glycoform content of 3F6-hIgG1HEK antibody is significantly higher than that of 3F6-hIgG1CHO. Interestingly, the antibody produced by HEK293 also shows an enhanced affinity for C1q (Fig. 4E). To determine whether Fc glycan structure is a key determinant of MRSA OPK and MRSA bloodstream infection protection, the inventors used a chemoenzymatic approach for glycan remodeling, first deglycosylation of 3F6-hIgG1CHO and 3F6-hIgG1HEK with Endo-S2, and secondly the presynthesized glycans were completely removed from the activated glycans in a transferase reaction catalyzed by EndoS2-D184M. In this way, four antibodies were synthesized: 3F6-hIgGHEK-G0F, 3F6-hIgGHEK-G1F, 3F6-hIgGHEK-G2F, and 3F6-hIgGCHO-G2F. Purified antibodies (5 mg × kg -1 A group of mice (n=10) were injected intraperitoneally with 3F6-hIgG1 (weight) and then challenged by intravenous inoculation of MRSA, while monitoring weight changes and survival rate over 14 days. After 14 days, the animals were euthanized and the bacterial load and abscess formation in the kidney tissue were examined. As a control, human IgG1 and 3F6-hIgG1CHO did not protect mice from MRSA bloodstream infection, while treatment with 3F6-hIgG1HEK reduced MRSA load as well as abscess formation (Figures 4F to 4G). Three antibodies with a unified glycan structure, 3F6-hIgGHEK-G1F, 3F6-hIgG1HEK-G2F and 3F6-hIgG1CHO-G2F, can prevent MRSA bloodstream infection, while 3F6-hIgGHEK-G0F cannot. The G2F glycoform of 3F6-hIgG1 provides the best protection against MRSA (Figures 4F to 4G).

[0268] MAb-3F6 promotes decolonization of S. aureus. Early work identified S. aureus colonization factors, bacterial surface proteins that bind to host ligands on nasal and pharyngeal epithelial cells or promote bacterial aggregation. Although the sum of these molecular interactions is essential for S. aureus colonization, each individual factor (i.e., surface proteins ClfA, ClfB, IsdA, IsdB, or SasG) is not. The inventors isolated S. aureus WU1 (ST88) as the causative agent of an SSTI outbreak in a mouse breeding facility. S. aureus WU1 persistently colonizes the nasopharynx and gastrointestinal tract of C57BL / 6 mice and causes SSTI disease in colonized animals with an incidence of 2% to 4% (27). SpA is dispensable for initial S. aureus WU1 colonization of the nasopharynx and gastrointestinal tract, but the Δspa strain fails to persist and begins to be cleared from mucosal surfaces 21 days after the initial colonization event (27). Decolonization with S. aureus Δspa is associated with increased serum IgG and mucosal IgA responses to bacterial surface molecules, including antibodies to ClfA, ClfB, IsdA, IsdB, and SasG. However, mice lacking immunoglobulins or adaptive immune responses (μMT mice) do not require SpA for sustained colonization. Immunization of mice with SpAKKAA elicits SpA neutralizing antibodies and enhances secondary antibody responses to bacterial surface determinants during S. aureus colonization (27). Together, these IgG and IgA antibodies promote decolonization of S. aureus from the nasopharynx and gastrointestinal tract of mice (27). Notably, treatment of colonized mice with a SpA neutralizing MAb (m3F6 IgG2a) had similar effects (28). Increased serum IgG and mucosal IgA responses to S. aureus surface molecules promote decolonization of S. aureus WU1 from the nasopharynx and gastrointestinal tract of mice (28) (Figure 6). Thus, SpA released from the bacterial capsule exerts local and systemic BCSA to divert host adaptive B cell responses, allowing S. aureus to persist in colonizing humans and mice. Treatment of S. aureus-colonized individuals with SpA-neutralizing monoclonal antibodies blocks BCSA of SpA and promotes the development of antibody responses that block colonization. The inventors hypothesize that treatment of MSSA- and MRSA-colonized individuals admitted to U.S. hospitals promotes decolonization and immunity, eliminating key risk factors for hospital-acquired infections.

[0269] The Fcγ domain of human 3F6-hIgG1 was engineered to enhance opsonophagocytic killing (OPK) of MRSA. The X-ray structure of the IgBD-B domain of SpA bound to human Fcγ revealed four hydrogen bonds that facilitate the interaction between the two molecules: Q 9 (IgGS 254 ), Q 10 (IgG Q 311 ), N11 (IgG N 434 ) and Y 14 (IgG L 432 )(103). The other four residues establish hydrophobic or ionic interactions: F 13 、N 28 ,I 31 , Q 32 and K 35 (50). All eight residues are conserved in the IgBD of SpA and Sbi (85). The inventors made amino acid substitutions in the Fcγ domain of 3F6-IgG1: S 254 A.Q 311 E.L 432 S and N 434 P, named 3F6-hIgG1 AESP The inventors generated amino acid substitutions in the Fcγ domain of 3F6-IgG1: H 435 R, named 3F6-hIgG1 R 3F6-hIgG1 AESP and 3F6-hIgG1 R Expression in HEK293 F cells, purification by protein L affinity chromatography, preparation of Fcγ domain and analysis of its binding to SpA AA (variant defective in binding to Fab but not Fcγ) and FcRn binding (76) (Figure 5D to Figure 5E). 3F6-hIgG1 AESP For SpA AA When MRSA OPK activity was measured in human blood and compared to 3F6-IgG1 and 2A12-IgG1 (antibodies developed by the inventors that bind to CLFA, another S. aureus protein, Figure 5A), 3F6-IgG1 AESP Thus, although 3F6-hIgG1 is able to neutralize SpA and Sbi via its 3F6 paratope, its Fcγ effector function can be inhibited by staphylococcal IBP. AESP 3F6-hIgG1 was insensitive to SpA- and Sbi-mediated interference with Fcγ effector function and exhibited increased MRSA OPK activity. AESPFcγ replacement in the inactivates FcRn binding, thereby shortening the in vivo half-life of the antibody and hindering further development. The inventors used a forward genetic approach to isolate IgG1 Fcγ variants that a) cannot be inactivated by SpA and Sbi and b) retain the ability to bind FcRn. Earlier work used phagemids to assemble Fcγ at the tip protein (pIII) of filamentous phage and isolated Fcγ variants (104 to 106) with enhanced FcRn binding and extended blood half-life. Pursuing a similar strategy, the inventors cloned Fcγ, codons 226 to 447 (Kabat Eu), into phage to produce pFCγ-PIII (AMP r ), PELB signal peptide, translational hybridization between FCγ and truncated PIII of bacteriophage M13 (107). pFCγ-PIII was transformed into Escherichia coli XL-1 Blue (F + -tet, recA - ) and ampicillin-resistant colonies were isolated. When infected with M13KO7 helper phage, E. coli XL-1Blue (pFcγ-PIII) produced filamentous particles that displayed Fcγ-PIII at the tip and also contained the single-stranded DNA genome of M13KO7 and pFcγ-PIII. Fcγ-PIII particles were precipitated from the culture supernatant with polyethylene glycol, suspended in buffer and analyzed by SDS-PAGE and immunoblotting, showing expression of Fcγ-PIII (107, 108) (Figure 5J). Notably, when Fcγ-PIII was expressed in E. coli, N-linked glycans were absent (103). However, the binding of Fcγ to FcRn (109 to 111), SpA or Sbi is independent of Asn 297 To isolate pFcγ-PIII variants, we performed error-prone PCR on the Fcγ coding sequence. The mutant population of Fcγ-PIII particles (10 10 PFU) to remove phages that retained the ability to bind SpA and Sbi. Fcγ-PIII particles that did not bind to S. aureus were amplified overnight and sequenced to characterize mutations that abolished SpA binding. The depletion procedure was repeated three times to select Fcγ-PIII particles that were unable to bind SpA and Sbi. The variant Fcγ-PIII particles were then analyzed for binding to purified SpA and FcRn using an ELISA assay. The inventors isolated Fcγ-PIII phage that failed to bind SpA and Sbi but retained the ability to bind FcRn. By quantifying the binding properties of 550 phagemid Fcγ-PIII variants, the inventors selected six candidates (hIgG1 Fcγ1-6) for future studies (Figure 5L to Figure 5M). DNA sequencing showed that the Fcγ domain contained 2 to 8 amino acid substitutions. The inventors replaced hIgG1 Fcγ1-6 Replacement of human MAb 2A12-hIgG1 and expression of 2A12-hIgG1 in HEK293 F cells Fcγ1-6 In an earlier study, the inventors immunized mice with purified recombinant ClfA and isolated mouse hybridoma MAb 2A12 (IgG1), which provided partial protection against MRSA in a mouse bacteremia model (Figure 5H to Figure 5I). The inventors used the CDR1 to CDR3 sequences of 2A12 to generate plasmid-borne human V H 1-Idiotype 2A12hIgG1. 2A12-hIgG1 binds to the A domain of coagulation factor A (ClfA) and blocks its ability to bind to human or mouse fibrinogen. Thus, similar to tifilomab, 2A12-hIgG1 interferes with the assembly of antiphagocytic fibrin / fibrinogen protectors (derived from the coagulase of MSSA / MRSA) to promote S. aureus OPK (73, 113) (Figure 5D).

[0270] 1.a. Analysis of 2A12-hIgG1 Fcγ1-6 Glycosylation, C1q and IBP binding of the variants and enhanced OPK of MRSA in blood. Fcγ1-6 For the variant MRSA OPK, the inventors selected antibodies whose paratopes did not recognize SpA or Sbi. In this way, the inventors could analyze hIgG1 Fcγ1-6 Effects of mutations on SpA and Sbi binding to the Fcγ effector domain and the effects of spa and sbi deletions on antibody-mediated OPK of wild-type and ΔspaΔsbi mutant MRSA. In order to calibrate the activity of the newly developed MAbs according to industry standards, the inventors selected tifezumab. Tifezumab is a humanized IgG1 antibody whose CDR1 to CDR3 sequences are derived from MAb 12-9, a mouse IgG1 hybridoma antibody that neutralizes ClfA (37, 114). The tifezumab coding sequence was cloned into expression plasmids for the heavy and light chains. The recombinant plasmid ptifezumab was then transfected into HEK293 F cells and the recombinant MAbs were purified. Tifezumab, 2A12-hIgG1 and 2A12-hIgG1 Fcγ1-6 Mass spectrometry will be performed to verify the amino acid sequence of each MAb. The inventors will perform mass spectrometry analysis on the enzymatically released Fc glycans of each of the eight MAbs to reveal whether amino acid substitutions in Fcγ affect the structure of the biantennary glycans. The inventors will determine whether tifilomab, 2A12-hIgG1, and 2A12-hIgG1 Fcγ1-6Affinity for human Clq, human FcRn, SpA, Sbi and SSL10. Finally, the inventors will measure the OPK activity of tifilomab and each 2A12-hIgG1 test article against MRSA USA300 LAC and its ΔspaΔsbi mutant in human blood. The inventors expect to measure baseline OPK activity against wild-type MRSA and increased OPK activity against ΔspaΔsbi mutants with tifilomab and 2A12-hIgG1. For 2A12-hIgG1 Fcγ1-6 , the inventors expected to observe increased OPK activity against wild-type MRSA (compared to tifizumab or 2A12-hIgG1) and similar levels of OPK activity against the ΔspaΔsbi mutant. Fcγ1-6 The two best performing antibodies from the collection were selected for further study.

[0271] 1.b. Analysis of 3F6-hIgG1 Fcγ The present inventors combined the best performing hIgG1 Fcγ1-6 Substitution of variants introduced into 3F6-hIgG1 to generate p3F6-hIgG1 Fcγa and p3F6-hIgG1 Fcγb The plasmid was transfected into HEK293 F cells and the MAb was purified. 3F6-hIgG1 was analyzed by mass spectrometry Fcγa and 3F6-hIgG1 Fcγb The inventors will also perform mass spectrometry analysis on the enzymatically released Fc-glycans to reveal whether the substitutions in Fcγ affect the structure of the biantennary glycans. The inventors will measure the HEK 、3F6-hIgG1 Fcγa and 3F6-hIgG1 Fcγb Binding to human Clq, FcRn, FcγRIII, SpA, Sbi and SSL10. If Fc glycosylation is not affected by the substitution, the inventors expect that 3F6-hIgG1 Fcγa and 3F6-hIgG1 Fcγb will show similarity to 3F6-hIgG1 HEK or 2A12-hIgG1 and 2A12-hIgG1 Fcγ Variants have similar human C1q and FcRn binding activity. Fcγ1-6 Different, 3F6-hIgG1 is expected Fcγa and 3F6-hIgG1 Fcγb Through their paratopes, they bind with high affinity (Ka = 22.97 × 10 9 M-1 ) binds to SpA and Sbi, but not to SSL10. Finally, the inventors measured the expression of teflonone and 3F6-hIgG1 in human blood. HEK 、3F6-hIgG1 Fcγa and 3F6-hIgG1 Fcγb OPK activity against wild-type MRSA and ΔspaΔsbi mutants. The inventors expected to measure baseline activity against wild-type and increased OPK against ΔspaΔsbi mutants with tifilomab. HEK , the inventors expected higher OPK activity against wild-type MRSA (compared to tifizumab) and a complete loss of OPK activity against the ΔspaΔsbi mutant (the antibody cannot bind to the mutant bacteria). Fcγa and 3F6-hIgG1 Fcγb The inventors expect that OPK activity against wild-type MRSA will be enhanced (compared with tifilomab or 3F6-hIgG1 HEK ) and a complete loss of OPK in the ΔspaΔsbi mutant.

[0272] Synthesis of 3F6-IgG1 Fcγ The inventors determined that 3F6-hIgG1 Fcγa and 3F6-hIgG1 Fcγb Whether the OPK activity of 3F6-hIgG1 can be further enhanced by synthesizing homologous glycans. Preliminary data demonstrate the feasibility of transferring three glycoforms (G0F, G1F and G2F) to 3F6-hIgG1 (Figure 4F to Figure 4G). The inventors have shown that enzymatic remodeling of Fc glycans into terminally galactosylated glycoforms (e.g., G1F and G2F) can enhance the inactive 3F6-hIgG1. CHO Here, the inventors extended the analysis to eight glycoforms: S2G2F, G2F, G1F, G0F, S2G2, G2, G1, and G0. The inventors developed a highly convergent chemoenzymatic method for glycan remodeling of intact mAbs, which consists of two enzymatic transformations: a single-step deglycosylation using wild-type endoglycosidases such as Endo-S and Endo-S2, and a subsequent deglycosylation step from activated glycans using glycosynthase mutants such as EndoS2-D184M. The oxazolines enzymatically transfer large glycans enzymatically to reconstitute homogeneous glycoforms of antibodies (100-102). In particular, Endo-S2 and its mutant (D184M) showed significant enzymatic activity and efficiency in deglycosylation and transglycosylation of IgG antibodies, respectively (115). The inventors used this strategy to construct eight homogeneous glycoforms, each derived from 3F6-hIgG1, 3F6-hIgG1 Fcγa and 3F6-hIgG1 Fcγb The MAb will be analyzed by mass spectrometry to verify its amino acid sequence and determine the structure of the released glycoforms. HEK 、3F6-hIgG1 Fcγa or 3F6-hIgG1 Fcγb Each glycoform attached to human C1q, FcRn, FcγRIII, SpA, Sbi, and SSL10 binding. The inventors expect that specific glycoforms will increase or decrease the affinity of the antibody for human C1q and FcγRIII. Since it is not known that the binding of SpA, Sbi, SSL10, or FcRn is affected by the glycoform structure, the inventors expect that the binding constants of the glycoformed MAb and the parent MAb will be similar. Finally, the inventors will measure the binding constants of teflonomab, 3F6-hIgG1 HEK 、3F6-hIgG1 Fcγa and 3F6-hIgG1 Fcγb OPK activity of the parental control and 24 test articles (glycoform variants) against MRSA. The inventors expect that certain glycoform variants will have enhanced OPK activity against MRSA (compared to tifilomab, 3F6-hIgG1 HEK 、3F6-hIgG1 Fcγa or 3F6-hIgG1 Fcγb compared to).

[0273] Analysis of binding of 3F6-IgG1 Fcγ-variants to murine Fc ligands and in vivo plasma half-life. Here, the inventors will measure the affinity of MAbs to murine FcRn and their plasma half-life in mice. The inventors will analyze ten different antibodies: tefezinomab, 2A12-hIgG1, 2A12-hIgG1 Fcγa , 2A12-hIgG1 Fcγb 、3F6-hIgG1 HEK 、3F6-hIgG1 Fcγa and 3F6-hIgG1 Fcγband their best three glycovariants. Each of these antibodies will be examined for pH-dependent binding to mouse FcRn. The in vivo pharmacodynamics of antibodies is critically dependent on the neonatal Fc receptor (FcRn), a heterodimer with MHC class I-like α-chain and β-2 microglobulin that captures IgG engulfed into endosomes or kidney filtrates under acidic conditions (pH 6.0) for subsequent release under neutral pH conditions (51). Earlier work by the inventors showed that at pH 6.0, the dissociation constant (K) of hybridoma 3F6-IgG2a and recombinant 3F6-mIgG2a was 2.3 fold higher than that of recombinant 3F6-mIgG2a. d ) is similar to mouse FcRn (28). Intraperitoneal injection of 3F6-mIgG2a into mice is associated with a biexponential plasma concentration-time curve, which includes a short distribution phase followed by a long elimination phase (28). The plasma concentration of 3F6-mIgG2a peaked at 6 hours after injection and was 58nM after 28 days, with a calculated half-life of 8.6 days. The inventors expect the engineered MAb to exhibit a similar in vivo half-life (8.6 days). Finally, the inventors will measure the binding of the 10 test articles to mouse C1q to determine whether the MAbs show similar affinity for human and mouse C1q.

[0274] Fcγ and glycoengineered 3F6 mAbs were prepared in cultured cells. Chinese hamster ovary (CHO) cells are the dominant industrial production platform for large-scale production of clinical-grade antibody therapeutics, with more than 90% of all antibodies currently commercialized. Protein glycosylation on these antibodies contributes to the plasma half-life and efficacy of the therapeutic. 297The N-glycans are composed of a heptasaccharide core (GlcNAc2Man3GlcNAc2) to which fucose (F), galactose (G), and sialic acid (S) are added. Glycoform analysis of recombinant antibodies showed that G0F and G1F are the most abundant IgG glycoforms produced in CHO cells, with >20 other glycoforms of lower abundance (1-4). However, IgG G0F and G1F have reduced binding to complement factor C1q and do not activate complement-mediated opsonophagocytic killing (OPK) of MRSA (116). Antibody glycoengineering strategies in CHO cells include a) overexpression of specific glycosyltransferases, b) CRISPR-Cas9 / sgRNA mutations in glycosyltransferases (fucosylation and sialylation), and c) medium supplementation to increase the abundance of G2F. Given the importance of galactose binding to C1q for 3F6-hIgG1 function, the inventors attempted to increase G2F levels in Fc-glycans by overexpression of β1,4-galactosyltransferase 1 (B4GALT1). This enzyme specifically transfers galactose from its UDP-galactose donor to the GlcNAc acceptor in the Golgi and can be overexpressed by cloning and generating stable B4GALT1 overproducing cell lines under the control of a constitutive promoter. A complementary strategy to improve overall galactosylation is to make more UDP-Gal substrate available in the Golgi. This was achieved by modifying the culture medium to include galactose alone or in combination with manganese chloride and uridine supplements to increase IgG galactosylation (117, 118). In addition, sialylation depends on the levels of the CMP-Neu5Ac nucleotide sugar substrate. Addition of N-acetylmannosamine (ManNAc) and other additives including butyrylated ManNAc can improve CMP-Neu5Ac and sialylation in CHO cells, exceeding the levels achieved by sialyltransferase expression (119, 120). If these studies show that improved sialylation is beneficial to MRSA OPK, the inventors will modify the culture medium by adding these supplements. Then, because more G2F and G2 polysaccharides are needed, the inventors will test different concentrations of galactose, uridine and manganese to improve galactosylation, while testing ManNAc and butyrylated ManNAc to improve sialylation and the production of S2G2F and G2F polysaccharides. If mass spectrometry shows that galactosylation and / or sialylation levels of 3F6-hIgG1 are improved, the inventors will also perform nucleotide sugar analysis to examine the extent of the effect of each nutritional supplement on intracellular UDP-Gal and CMP-Neu5Ac levels. The inventors will examine the effects of media modifications on product yield, C1q and Fc receptor binding and ultimately MRSA killing.From this analysis, the inventors will infer which combination of changes, from galactosyltransferase overexpression to knockout of Fut8 (preventing fucosylation) and 23STGal4 / 6 (preventing sialylation) to nutritional supplementation, will help produce the desired glycans. The feasibility of engineering CHO cells to large-scale production of 3F6-hIgG1 with the desired glycosylation pattern will then be analyzed.

[0275] Decolonization of the mouse nasopharynx and gastrointestinal tract with S. aureus using Fcγ and glycoengineered 3F6-IgG1. The inventors hypothesized that treatment of humans colonized with S. aureus with 3F6-hIgG1 or its engineered variants would induce antibody responses against bacterial surface determinants and clearance of staphylococci from the nasopharynx and gastrointestinal tract. As a preclinical test of this hypothesis, the inventors will analyze here the efficacy of humanized 3F6-hIgG1 or its variants in promoting decolonization of S. aureus in mice.

[0276] Serum and mucosal antibody responses of S. aureus-colonized mice treated with Fcγ and glycoengineered 3F6-IgG1 were analyzed. The inventors hypothesized that the decolonization activity of 3F6-mIgG2a is based on its ability to neutralize the IgBD of SpA (28). If so, the inventors expect humanized 3F6-IgG1 and its Fcγ and glycoengineered variants to functionally replace 3F6-mIgG2a, neutralize SpA BCSA, and elicit S. aureus-specific IgG and IgA, provided that the humanized antibodies exhibit plasma distribution and half-life similar to those of mouse monoclonal antibodies. These conjectures will be tested here. 1×10 8 Groups of C57BL / 6 mice (n=10) colonized with CFU of S. aureus WU1 for one week were injected intraperitoneally with 5 mg×kg -1 Human hIgG1 (negative control), 3F6-mIgG2a (positive control), 3F6-hIgG1 HEK 、3F6-hIgG1 Fcγa 、3F6-hIgG1 Fcγbor three candidate sugar variants. On day 63 (14 days after the final antibody administration), the inventors will collect fecal samples and bleed the mice to obtain serum samples from coagulated venous blood. Fecal samples collected from mice on day 0 (before S. aureus inoculation) and day 63 will be suspended in 100 mg per ml of PBS + protease inhibitor cocktail, centrifuged at 16,000 × g for 5 minutes, and the supernatant will be analyzed for IgA antibodies. The response of mouse IgG and IgA in serum and fecal samples to 46 purified staphylococcal antigen matrices will be analyzed (27). Briefly, 2 μg of each purified antigen will be spotted onto nitrocellulose, the membrane will be blocked and incubated with diluted mouse serum (and goat anti-mouse IgG conjugated with IRDye 680) or diluted mouse fecal samples (and goat anti-mouse IgA conjugated with Alexa Fluor 680). Signal intensity will be quantified using the Odyssey Infrared Imaging System (Li-cor) (85). With Two-way ANOVA with multiple comparison test will be used to analyze the differences in pathogen-specific IgG / IgA responses in the presence or absence of MAb treatment.

[0277] Mice treated with Fcγ and glycoengineered 3F6-IgG1 were analyzed for S. aureus colonization. On day 7, 1 × 10 8 Groups of C57BL / 6 mice (n=10) colonized with CFU of S. aureus WU1 for one week were injected intraperitoneally with 5 mg×kg -1 hIgG1 (negative control), 3F6-mIgG2a (positive control), 3F6-hIgG1 HEK 、3F6-hIgG1 Fcγa 、3F6-hIgG1 Fcγb or three candidate sugar variants. Antibody treatment will continue on days 21, 35, and 49. On day 7 post-inoculation and at weekly intervals thereafter (days 14, 21, 28, 35, 42, 49, 56, and 63), the nasopharynx of the mice will be swabbed, the swabs will be smeared on MSA, and the plates will be incubated at 37°C for 16 hours for CFU counts. In addition, fecal pellets from each mouse (100 mg in 1 ml PBS) will be suspended, aliquots will be plated on selective agar, and the plates will be incubated at 37°C for 16 hours for CFU counts. Two-way ANOVA with multiple comparison test was used to analyze the differences in mouse colonization data for statistical significance, comparing the groups receiving the different test article treatments to the negative (hlgG1) and positive control (3F6-mIgG2a) groups.

[0278] Mice decolonized with Fcγ and glycoengineered 3F6-IgG1 will be analyzed for recolonization with S. aureus. Mice that have cleared S. aureus from the nasopharynx and gastrointestinal tract after treatment with specific antibodies (2.b) will be transferred to clean cages without S. aureus colonized mice (these mice excrete staphylococci in feces). Decolonized animals and age-matched naive control animals (never exposed to S. aureus) will be studied for recolonization with S. aureus. The inventors hypothesize that the S. aureus-specific antibody response induced by treatment with SpA neutralizing MAbs confers immunity to recolonization. If so, the inventors predict that age-matched naive control mice, rather than C57BL / 6 animals that have cleared staphylococci after SpA-MAb treatment, could be treated with 1×10 8 CFU S. aureus WU1 post-colonization. Groups of C57BL / 6 mice (n=10)—decolonized or naive—will receive 1×10 8 Intranasal inoculation of CFU S. aureus WU1. On day 7 post-inoculation (and weekly intervals thereafter - 14, 21, 28, 35, 42, 49, 56, and 63), the nasopharynx of mice was swabbed, the swabs were spread on selective agar, and the plates were incubated at 37°C for 16 h for CFU enumeration. In addition, fecal pellets (100 mg in 1 ml PBS) from each mouse were suspended, aliquots were plated on mannitol salt agar (MSA), and the plates were incubated at 37°C for 16 h for CFU enumeration. Two-way ANOVA with multiple comparison test will be used to analyze the statistical significance of the differences in the data of mouse colonization response to MAb treatment and specific IgG responses. On day 0 and day 49 of the experiment, fecal samples will be collected and mice will be bled to extract serum samples from coagulated venous blood. Mouse serum samples will be analyzed for IgG responses and fecal samples will be studied for IgA responses to the above 46 purified Staphylococcus antigen matrices.

[0279] Mice treated with Fcγ and glycoengineered 3F6-IgG1 will be analyzed for protective immunity against MRSA bloodstream infection. Mice that have cleared S. aureus from the nasopharynx and gastrointestinal tract after treatment with the specific antibody will be isolated in clean cages. These animals and age-matched naive control animals (never exposed to S. aureus) will be analyzed for protective immunity against MRSA bloodstream infection. Specifically, the inventors will test the hypothesis that the S. aureus antibody response induced by treatment with a MAb that neutralizes SpA confers immunity to invasive MRSA disease in mice. If so, animals that have cleared Staphylococci from the nasopharynx and gastrointestinal tract after 3F6-MAb treatment, but not age-matched naive control mice, are expected to be more resistant to 1×10 7Resistance to intravenous challenge with CFUMRSA USA300 LAC was demonstrated (124). As described above, the inventors will analyze serum IgG and mucosal IgA in naive and decolonized animals using a Staphylococcus aureus antigen matrix to look for pathogen-specific antibodies. Groups of C57BL / 6 mice (n=10)—decolonized or naive—will receive 1×10 7 CFU MRSA USA300 LAC was inoculated intravenously. Infected animals will be monitored daily for weight change (weight loss > 25% indicates moribund mice) and survival over 14 days. Moribund animals will be necropsied and kidney tissue removed and analyzed for bacterial load (MRSA CFU × g -1 The renal tissue was removed for histopathology and bacterial load quantification by comparing the original animals with those treated with mouse 3F6-mIgG2a, human 3F6-hIgG1 HEK 、Human 3F6-hIgG1 Fcγa 、Human 3F6-hIgG1 Fcγb or three glycovariants human 3F6-hIgG1 Fcγ The data will be analyzed by comparing disease in a population of mice that have been cleared of S. aureus using antibody treatment. In addition, the inventors will seek to correlate specific serum IgG responses in decolonized mice with protection against invasive MRSA disease.

[0280] The results of MRSA bloodstream infection are improved with Fcγ and glycoengineered human 3F6-IgG1. In the U.S., 120,000 MRSA surgical site infection patients, 72,000 MRSA bacteremia patients, 2,000 MRSA ventilator-associated pneumonia patients and 600 VLBW newborns with MRSA sepsis will benefit from antibody treatment that improves MRSA infection results. Early work has demonstrated the preclinical efficacy of tifostatin and ASN100 as MRSA prevention (37,38,43,114). However, these antibodies do not show therapeutic efficacy in animals suffering from active MRSA disease. Here, the inventor will develop a mouse model for recurrent MRSA bacteremia to analyze the efficacy of antibodies combined with antibiotic therapy (standard of care).

[0281] Recurrence and survival of MRSA bloodstream infected mice under standard care antibiotic treatment. To determine pathogen-specific IgG and IgA responses using antigenic matrices, the inventors obtained blood and fecal samples from naive mice (day 0) and mice with MRSA bacteremia, i.e., survivors of the 74-day experiment or animals dying before euthanasia. BALB / c mice were assigned to experimental groups (n=10) and injected intravenously with 8×106 CFU MRSA USA300 LAC (day 0) infection. In order to monitor the disease, the weight of mice will be measured every day. If mice do not receive antibiotic treatment, MRSA bacteremia attack will lead to disseminated abscess lesions and cause 100% mortality in the first 14 days (37,38,43,114). On the 2nd day, 48 hours after MRSA bloodstream attack, mice will be treated with vancomycin for 10 days (15mg vancomycin / kg body weight injected intraperitoneally every 12 hours). [Vancomycin dosage reflects the clinical guidelines for the treatment of MRSA bacteremia (10)]. The inventors expect that 80% to 100% of the mice treated with vancomycin will survive in the first 14 days. Then the mice will be observed for another 60 days to observe the recurrence of MRSA bloodstream infection. Again, the animals with recurrent infection will be identified as losing 20% ​​or more than 20% of their weight, and blood culture is positive (venous blood samples will be extracted from the periorbital venous plexus, and LAC strains will be identified by MLST and spa typing). The inventors also expect that >50% of the mice will die from recurrent MRSA bloodstream infection within the 74-day observation period. The moribund animals will be euthanized, autopsied, and analyzed for histopathology of thin-sectioned tissues (kidney, liver, spleen, lung, femur, and brain) stained with HE. The inventors will also determine the MRSA load in various organ tissues as CFU×g -1 Tissues. At the end of the 74-day experiment, surviving animals will be euthanized and necropsied to determine whether vancomycin treatment has eliminated MRSA from all tissues or whether surviving animals have residual foci of infection. This experiment will be repeated twice to ensure reproducibility and generate mean survival curves, mean histopathology, and bacterial load data for mice with MRSA bloodstream infections.

[0282] Recurrence and survival of MRSA bloodstream infection mice under tifeizumab treatment. Here, the inventors will measure the effect of tifeizumab therapy on the overall survival rate and recurrent infection incidence of MRSA bloodstream infection mice. As mentioned above, the animal group will be attacked and analyzed. On the 2nd day (i.e. 48 hours after the initial inoculation), in addition to vancomycin treatment, mice will also receive intravenous infusion of 5mg / kg body weight of human hIgG1 control or tifeizumab. Assuming that the plasma half-life of human IgG1 in mice is 8 days, the inventors will repeat intravenous infusion of 5mg / kg body weight IgG1 control or tifeizumab on the 16th, 30th, 44th and 58th days. The recurrence of MRSA bloodstream infection in mice will be observed within 74 days. The dying animals will be euthanized, autopsied and the histopathology of thin-sectioned tissues stained with HE will be analyzed. The inventors will also determine the MRSA load in various organ tissues. At the end of the 74-day experiment, surviving animals will be euthanized and necropsied to determine whether vancomycin and antibody treatment has eliminated MRSA. The experiments will be repeated to ensure data reproducibility. One-way ANOVA with Bonferroni correction will be used to determine the statistical significance of observed differences in disease parameters (weight change, number of abscess lesions, and MRSA burden). Two-way ANOVA with multiple comparisons test analyzed the association of S. aureus-specific antibody responses with the antibody therapeutic (tifizumab) and hIgG1. Because tifizumab failed its clinical testing (lack of efficacy against MRSA bacteremia), the inventors expected that the antibody would also fail preclinical trials as a therapeutic for MRSA bacteremia (38). In addition, the inventors did not expect that tifizumab could enhance pathogen-specific IgG and IgA responses during MRSA bacteremia.

[0283] Relapse and survival of MRSA bloodstream infected mice treated with 3F6-hIgG1 or its Fcγ and glycoengineered variants. Here, the inventors will measure the therapeutic efficacy of 3F6-hIgG1 or its Fcγ and glycoengineered variants (6 test articles: 3F6-hIgG1 HEK 、3F6-hIgG1 Fcγa 、3F6-hIgG1 FcγbAnd three candidate sugar variants). The animal group will be attacked and analyzed as described in 3.ab. On the 2nd day (i.e. 48 hours after the initial inoculation), in addition to vancomycin treatment, mice will receive intravenous infusion of 5mg / kg body weight of human IgG1 control antibody or one of six 3F6-hIgG1 test products. Assuming that the plasma half-life of human IgG1 in mice is 8 days, the inventor will repeat intravenous infusion of 5mg / kg body weight IgG1 control or test product on the 16th, 30th, 44th and 58th days. The MRSA bloodstream infection recurrence of mice will be observed. The dying animals will be euthanized, autopsied and analyzed for the histopathology of the thin section tissue of HE staining. The inventor will also determine the MRSA load in various organ tissues. At the end of the 74-day experiment, the surviving animals will be euthanized and autopsied to determine whether vancomycin and antibody treatment have eliminated MRSA. The experiment will be repeated to ensure repeatability and generate the average survival curve, average histopathology and MRSA load data of MRSA USA300 LAC bloodstream infected mice. The statistical analysis of disease parameters (weight change, animal survival rate, histopathologically measured disease, MRSA load and Staphylococcus aureus specific antibody response) differences will be examined for association with antibody therapy. The inventors speculate that 3F6-hIgG1 and its engineering variants will promote MRSA OPK and eliminate bacteria from host tissues, thereby reducing MRSA recurrent infection rate and increasing the survival rate of blood-infected mice. The inventors also estimate that 3F6-hIgG1 and its Fcγ and glycoengineering variants will enhance the response of mouse IgG and IgA to MRSA.

[0284] Immunity to MRSA bloodstream infection in mice after 3F6-hIgG1 treatment. Earlier work showed that Staphylococcus aureus bloodstream infection in mice resulted in MRSA bloodstream infection. KKAA Animals challenged with mutant but not wild-type Staphylococci developed protective immunity (76) (Figure 3). Here, the inventors will ask whether mice infected with MRSA bacteremia and treated with antibodies that neutralize SpA will develop immunity against subsequent infection. Briefly, groups of mice will be infected with MRSA, treated with vancomycin and control hIgG1 or 3F6-hIgG1 or their engineered variants, and analyzed for disease parameters. At the end of the 74-day observation period, survivors of MRSA bloodstream infection or age-matched naive control mice will be re-inoculated intravenously with 8×10 6CFU MRSA challenge. For naive control mice, MRSA bloodstream challenge resulted in disseminated abscess lesions and 100% mortality within 14 days. However, the inventors expected that animals treated with 3F6-hIgG1 would have enhanced MRSA-specific IgG and IgA responses and confer immunity to subsequent bloodstream infections. If so, serum IgG responses and mucosal IgA responses to a matrix of 46 purified staphylococcal antigens were expected to identify differences between naive and immunized mice, which could be confirmed by two-way ANOVA and Multiple comparison tests were used to verify the statistical significance.

[0285] B. Reference Documents

[0286] The following references are specifically incorporated herein by reference, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein.

[0287] 1. Kuehnert MJ, Kruszon-Moran D, Hill HA, McQuillan G, McAllister SK, Fosheim G, McDougal LK, Chaitram J, Jensen B, Fridkin SK, Killgore G, Tenover FC. 2006. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis 193:172-179.

[0288] 2. Kluytmans J, van Belkum A, Verburgh H. 1997. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 10: 505-520.

[0289] 3. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, Nouwen JL. 2005. The role of nasal carriage in Staphylococcus aureusinfections. Lancet Infect Dis 5: 751-62.

[0290] 4.Kavanagh T,Abusalem S,Calderon LE.2017.The incidence of MRSAinfections in the United States:is a more comprehensive tracking systemneeded?Antimicrob Res Infect Control 6:34.

[0291] 5.Gerber JS,Coffin SE,Smathers SA,Zaoutis TE.2009.Trends in theIncidence of Methicillin-Resistant Staphylococcus aureus Infection inChildren′s Hospitals in the United States.Clin Infect Dis 49:65-71.

[0292] 6.Dukic VM,Lauderdale DS,Wilder J,Daum RS,David MZ.2013.Epidemics ofcommunity-associated methicillin-resistant Staphylococcus aureus in theUnited States:a meta-analysis.PLoS One 8:e52722

[0293] 7.Dantes R,Mu Y,.,Belflower R,Aragon D,Dumyati G,Harrison L,Lessa F,Lynfield R,Nadle J,Petit S,Ray S,Schaffner W,Townes J,Fridkin S,InvestigatorsEIPABCSMS.2013.National burden of invasive methicillin-resistantStaphylococcus aureus infections,United States,2011.JAMA Intern Med 173:1970-1978.

[0294] 8.Duffy J,Dumyati G,Bulens S,Namburi S,Gellert A,Fridkin S,K,Lessa F,C.2013.Community-onset invasive methicillin-resistant Staphylococcus aureusinfections following hospital discharge.Am J Infect Control 41:782-786.

[0295] 9.Lessa FC,Mu Y,Ray SM,Dumyati G,Bulens S,Gorwitz RJ,Fosheim G,DeVries AS,Schaffner W,Nadle J,Gershman K,Fridkin SK,Program.ABCsAMIotEI.2012.Impact of USA300 methicillin-resistantStaphylococcus aureus on clinical outcomes of patients with pneumonia orcentral line-associated bloodstream infections.Clin Infect Dis 55:232-241.

[0296] 10.Liu C,Bayer AS,Cosgrove SE,Daum RS,Fridkin SK,Gorwitz RJ,KaplanSL,Karchmer AW,Levine DP,Murray BE,Rybak MJ,Talan DA,ChambersHF.2011.Clinical practice guidelines by the Infectious Diseases Society ofAmerica for the treatment of methicillin-resistant Staphylococcus aureusinfections in adults and children:executive summary.Clin Infect Dis 52:285-292.

[0297] 11.Daum RS,Spellberg B.2012.Progress toward a Staphylococcus aureusvaccine.Clin Infect Dis 54:560-567.

[0298] 12.Otto M.2010.Novel targeted immunotherapy approaches forstaphylococcal infection.Expert Opin Biol Ther10:1049-1059.

[0299] 13.Missiakas D,Schneewind O.2016.Staphylococcus aureus vaccines:deviating from the carol.J Exp Med231:1645-1653.

[0300] 14.Patti JM.2004.A humanized monoclonal antibody targetingStaphylococcus aureus.Vaccine 22:S39-S43.

[0301] 15.Kim HK,Thammavongsa V,Schneewind O,Missiakas D.2012.Recurrentinfections and immune evasion strategies of Staphylococcus aureus.Curr OpinMicrobiol 15:92-99.

[0302] 16.Thammavongsa V,Kim HK,Missiakas DM,SchneewindO.2015.Staphylococcal manipulation of host immune responses.Nat Rev Microbiol13:529-543.

[0303] 17.van Belkum A,Melles DC,Nouwen J,van Leeuwen WB,van Wamel W,Vos MC,Wertheim HF,Verbrugh HA.2009.Co-evolutionary aspects of human colonisationand infection by Staphylococcus aureus.Infect Genet Evol 9:32-47.

[0304] 18.yon EiffC,Becker K,Machka K,Stammer H,Peters G.2001.Nasal carriageas a source of Staphylococcus aureus bacteremia.N Engl J Med 344:11-16.

[0305] 19.Daum RS,Miller LG,Immergluck L,Fritz S,Creech CB,Young D,Kumar N,Downing M,Pettibone S,Hoagland R,Eells SJ,Boyle MG,Parker TC,Chambers HF,TeamD-.2017.A placebo-controlled trial of antibiotics for smaller skinabscesses.N Engl J Med 376:2545-2555.

[0306] 20.Tong SY,Davis JS,Eichenberger E,Holland TL,FowlerVGJ.2015.Staphylococcus aureus infections:epidemiology,pathophysiology,clinical manifestations,and management.Clin Microbiol Rev 28:603-661.

[0307] 21.Klevens RM,Morrison MA,Nadle J,Petit S,Gershman K,Ray S,HarrisonLH,Lynfield R,Dumyati G,Townes JM,Craig AS,Zell ER,Fosheim GE,McDougal LK,Carey RB,Fridkin SK.2007.Invasive methicillin-resistant Staphylococcus aureusinfections in the United States.JAMA 298:1763-1771.

[0308] 22.Najjar PA,Smink DS.2015.Prophylactic antibiotics and prevention ofsurgical site infections.Surg Clin North Am 95:269-283.

[0309] 23.Neu HC.1992.The crisis in antibiotic resistance.Science 257:1064-1073.

[0310] 24.Holland TL,Arnold C,Fowler VGJ.2014.Clinical management ofStaphylococcus aureus bacteremia:a review.JAMA 312:1330-1341.

[0311] 25.Noskin GA,Rubin RJ,Schentag JJ,Kluytmans J,Hedblom EC,Smulders M,Lapetina E,Gemmen E.2005.The burden of Staphylococcus aureus infections onhospitals in the United States:an analysis of the 2000 and 2001 NationwideInpatient Sample Database.Arch Intern Med 165:1756-1761.

[0312] 26.Stone PW.2009.Economic burden of healthcare-associated infections:an American perspective.Expert Rev Pharmacoecon Outcomes Res 9:417-422.

[0313] 27.Sun Y,Emolo CE,Holtfreter S,Wiles S,Kreiswirth B,Missiakas D,Schneewind O.2018.Staphylococcal protein A is required for persistentcolonization of mice with Staphylococcus aureus.J Bacteriol 200:e00735-17.

[0314] 28.Chen X,Sun Y,Missiakas D,Schneewind O.2018.Staphylococcus aureusdecolonization of mice with monoclonal antibody neutralizing protein A.JInfect Dis in press.

[0315] 29.Fattom A,Matalon A,Buerkert J,Taylor K,Damaso S,BoutriauD.2015.Efficacy profile of a bivalent Staphylococcus aureus glycoconjugatedvaccine in adults on hemodialysis:Phase III randomized study.Hum VaccinImmunother 11:632-641.

[0316] 30.Fattom AI,Horwith G,Fuller S,Propst M,Naso R.2004.Development ofStaphVAX,a polysaccharide conjugate vaccine against S.aureus infection:fromthe lab bench to phase III clinical trials.Vaccine 22:880-887.

[0317] 31.Fattom AI,Sarwar J,Ortiz A,Naso R.1996.A Staphylococcus aureuscapsular polysaccharide(CP)vaccine and CP-specific antibodies protect miceagainst bacterial challenge.Infect Immun 64:1659-1665.

[0318] 32.Benjamin DK,Schelonka R,White R,Holley HP,Bifano E,Cummings J,Adcock K,Kaufman D,Puppala B,Riedel P,Hall B,White J,Cotton CM.2006.Ablinded,randomized,multicenter study of an intravenous Staphylococcus aureusimmune globulin.J Perinatol 26:290-295.

[0319] 33.Rupp ME,Holley HP,Lutz J,Dicpinigaitis PV,Woods CW,Levine DP,VeneyN,Fowler VG.2007.Phase II,randomized,multicenter,double-blind,placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsularpolysaccharide immune globulin in treatment of Staphylococcus aureusbacteremia.Antimicrob Agents Chemother 51:4249-4254.

[0320] 34.Shah PS,Kaufman DA.2009.Antistaphylococcal immunoglobulins toprevent staphylococcal infection in very low birth weight infants.CochraneDatabase Syst Rev 15:CD006449.

[0321] 35.Schaffer AC,Lee JC.2009.Staphylococcal vaccines andimmunotherapies.Infect Dis Clin North Am 23:153-171.

[0322] 36.DeJonge M,Burchfield D,Bloom B,Duenas M,Walker W,Polak M,Jung E,Millard D,Schelonka R,Eyal F,Morris A,Kapik B,Roberson D,Kesler K,Patti J,Hetherington S.2007.Clinical trial of safety and efficacy of INH-A21 for theprevention of nosocomial staphylococcal bloodstream infection in prematureinfants.J Pediatr 151:260-265.

[0323] 37.Domanski PJ,Patel PR,Bayer AS,Zhang L,Hall AE,Syribeys PJ,GorovitsEL,Bryant D,Vernachio JH,Hutchins JT,Patti JM.2005.Characterization of ahumanized monoclonal antibody recognizing clumping factor A expressed byStaphylococcus aureus.Infect Immun 73:5229-5232.

[0324] 38.Weems Jr.JJ,Steinberg JP,Filler S,Baddley JW,Corey GR,SampathkumarP,Winston L,John JF,Kubin CJ,Talwani R,Moore T,Patti JM,Hetherington S,TexterM,Wenzel E,Kelley VA,Fowler Jr VG.2006.Phase II,randomized,double-blind,multicenter study comparing the safety and pharmacokinetics of Tefibazumab toplacebo for treatment of Staphylococcus aureus bacteremia.Antimicrob AgentsChemother 50:2751-2755.

[0325] 39.Patel M,Kaufman DA.2015.Anti-lipoteichoic acid monoclonal antibody(pagibaximab)studies for the prevention of staphylococcal bloodstreaminfections in preterm infants.Expert Opin Biol Ther 15:595-600

[0326] 40.Weisman LE.2007.Antibody for the prevention of neonatal nosocomial staphylococcal infection:a review of the literature.Arch Ped 14:S31-S34.

[0327] 41.Weisman LE,Fischer GW,Thackray HM,Johnson KE,Schuman RF,Mandy GT,Stratton BE,Adams KM,Kramer WG,Mond JJ healthy adults,IntImmunopharmacol 9:639–644.

[0328] 42.Weisman LE, Thackray HM, Steinhorn RH, Walsh WF, Lassiter HA, Dhanireddy R, Brozanski BS, Palmer KG, Trautman MS, Escobedo M, Meissner HC, Sasidharan P, Fretz J, Kokai-Kun JF,Kramer WG,Fischer GW,Mond JJ.2011.Randomized study of monoclonal antibody(pagibaximab)to prevent staphylococcal sepsis.Pediatrics 128:271-279.

[0329] 43.Rouha H,Badarau A,Visram ZC,Battles MB,Prinz B,Magyaricsa Z,NagyG,Mirkina I,Stulik L,Zerbs M, M,Maierhofer B,Teubenbacher A,Dolezilkova I,Gross K,Banerjee S,Zauner G,Malafa S,Zmajkovic J,Maier S,MabryR,Krauland E,Wittrup KD,Gerngross TU,Nagy E.2015.Five birds,one stone:neutralization of alpha-hemolysin and four bi-component leukocidins ofStaphylococcus aureus with a single human monoclonai antibody.mAbs 7:243-254.

[0330] 44.Alonzo Fr,Torres VJ.2014.The bicomponent pore-forming leucocidinsof Staphylococcus aureus.Microbiol Mol Biol Rev 78:199-230.

[0331] 45.Kernodle DS.2011.Expectations regarding vaccines and immunetherapies directed against Staphylococcus aureus alpha-hemolysin.J Infect Dis203:1692-1693.

[0332] 46.Shinefield H,Black S,Fattom A,Horwith G,Rasgon S,Ordonez J,Yeoh H,Law D,Robbins JB,Schneerson R,Muenz L,Fuller S,Johnson J,Fireman B,Alcorn H,Naso R 2002.Use of a Staphylococcus aureus conjugate vaccine in patientsreceiving hemodialysis.N Engl J Med 346:491-496.

[0333] 47.Fowler VG,Allen KB,Moreira ED,Moustafa M,Isgro F,Boucher HW,CoreyGR,Carmeli Y,Betts R,Hartzel JS,Chan IS,McNeely TB,Kartsonis NA,Guris D,Onorato MT,Smugar SS,DiNubile MJ,Sobanjo-ter Meulen A.2013.Effect of aninvestigational vaccine for preventing Staphylococcus aureus infections aftercardiothoracic surgery:a randomized trial.JAMA 309:1368-1378.

[0334] 48.Anderson AS,Miller AA,Donald RG,Scully IL,Nanra JS,Cooper D,JansenKU.2012.Development of a multicomponent Staphylococcus aureus vaccinedesigned to counter multiple bacterial virulence factors.Hum VaccineImmunother 8:1585-94.

[0335] 49.Varshney AK,Kuzmicheva GA,Lin J,Sunley KM,Bowling RAJ,Kwan TY,Mays HR,Rambhadran A,Zhang Y,Martin RL,Cavalier MC,Simard J,ShivaswamyS.2017.A natural human monoclonal Antibody targeting Staphylococcus Protein Protects against Staphylococcus aureus bacteremia.PLoS ONE 13:e0190537.

[0336] 50.Graille M,Stura EA,Corper AL,Sutton BJ,Taussig MJ,Charbonnier JB,SilvermanGJ.2000.Crystal structure of a Staphylococcus aureus protein Adomain complexed with the Fab fragment of a human IgM antibody:structuralbasis for B-cell recognition receptors and superantigen activity.Proc NatAcad Sci USA 97:5399–5404.

[0337] 51.Raghavan M,Bjorkman PJ.1996.Fc receptors and their interactionwith immunoglobulins.Annu Rev Cell Dev Biol 12:181-220.

[0338] 52.Hazenbos WLW,Kajihara KK,Vandlen R,Morisaki JH,Lehar SM,KwakkenbosMJ,Beaumont T,Bakker AQ,Phung Q,Swem LR,Ramakrishnan S,Kim J,Xu M,Shah IM,Diep BA,Sai T,Sebrell A,Khalfin Y,Oh A,Koth C,Lin SJ,Lee BC,Strandh M,Koefoed K,Andersen PS,Spits H,Brown EJ,Tan MW,Mariathasan S.2013.Novelstaphylococcal glycosyltransferases SdgA and SdgB mediate immunogenicity andprotection of virulence-associated cell wall proteins PLoS Pathogens 9:e1003653.

[0339] 53.Lehar SM,TP,MX,LS,KKK,Vandlen R,DePalatis L,Raab H,HazenbosWL,Morisaki JH,Kim J,Park S,Darwish M,Lee B,Hernan-Loudet H,Luetus K. P, Fong R, Yan D, Chalouni C, Luis E, Khalfin Y, Plise E, Cheong J, Lyssikatos JP, Strandh M, Koefoed K, Andersen PS, Flygare JA, Wah Brown M EJ,MariathasanS.2015.Novel antibody-antibiotic conjugate eliminates intracellularS.aureus.Nature 527:323-328.

[0340] 54.Zhou C,Lehar S,Gutierrez J,Rosenberger CM,Ljumanovic N,Dinoso J,Koppada N,Hong K,Baruch A,Carrasco-Triguero M,Saad O,Mariathasan S,Kamaco and Pharmacopetics. pharmacodynamics of DSTA4637A:A novel THIOMAB TM antibody antibiotic conjugate against Staphylococcus aureus in mice.MAbs 8:1612-1619.

[0341] 55.Mariathasan S,Tan MW.2017.Antibody-Antibiotic Conjugates:a noveltherapeutic platform against bacterial infections.Trends Mol Med 23:135-149.

[0342] 56.Brown S,Xia G,Luhachack LG,Campbell J,Meredith TC,Chen C,WinstelV,Gekeler C,Irazoqui JE,Peschel A,Walker S.2012.Methicillin resistance inStaphylococcus aureus requires glycosylated wall teichoic acids.Proc NatlAcad Sci USA 109:18909-18914.

[0343] 57.Guérillot R, da Silva A,Monk I,Giulieri S,Tomita T,AlisonE,Porter J,Pidot S,Gao W,Peleg AY,Seemann T,Stinear TP,HowdenBP.2018.Convergent evolution driven by rifampin exacerbates the global burdenof drug-resistant Staphylococcus aureus.mSphere 3:e00550-17.

[0344] 58.Bubeck-Wardenburg J,Patel R,Schneewind O.2007.Surface proteins andexotoxins are required for the pathogenesis of Staphylococcus aureuspneumonia.Infect Immun 74:1040-1044.

[0345] 59.Bubeck Wardenburg J,Schneewind O.2008.Vaccine protection againstStaphylococcus aureus pneumonia.J Exp Med 205:287-294.

[0346] 60.Ragle BE,Bubeck-Wardenburg J.2009.Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia.InfectImmun 77:2712-2718.

[0347] 61.DeLeo FR,Kennedy AD,Chen L,Bubeck-Wardenburg J,Kobayashi SD,Mathema B,Braughton KR,Whitney AR,Villaruz AE,Martens CA,Porcella SF,McGavinMJ,Otto M,Musser JM,Kreiswirth BN.2011.Molecular differentiation of historicphage-type 80 / 81 and contemporary epidemic Staphylococcus aureus.Proc NatlAcad Sci USA 108:18091-18096.

[0348] 62.Sharma-Kuinkel BK,Wu Y,Tabor DE,Mok H,Sellman BR,Jenkins A,Yu L,Jafri HS,Rude TH,Ruffin F,Schell WA,Park LP,Yan Q,Thaden JT,Messina JA,FowlerVGJ,Esser MT.2015.Characterization of alpha-toxin hla gene variants,alpha-toxin expression levels,and antibody levels to alpha-toxin in hemodialysisand postsurgical patients with Staphylococcus aureus bacteremia.J ClinMicrobiol 53:227-236.

[0349] 63.Spaan AN,Surewaard BGJ,Nijland R,van Strijp JAG.2013.Neutrophilsversus Staphylococcus aureus:a biological tug of war.Annu Rev Microbiol 67:629-650.

[0350] 64.Thammavongsa V,Missiakas DM,Schneewind O.2013.Staphylococcusaureus conversion of neutrophil extracellular traps into deoxyadenosinepromotes immune cell death Science 342:863-866.

[0351] 65.Brinkmann V,Reichard U,Goosmann C,Fauler B,Uhlemann Y,Weiss DS,Weinrauch Y,Zychlinsky A.2004.Neutrophil extracellular traps killbacteria.Science 303:1532-1535.

[0352] 66.Baehner RL,Nathan DG.1967.Leukocyte oxidase defective activity inchronic granulomatous disease.Science 155:835.

[0353] 67.Baehner RL.1990.Chronic granulomatous disease of childhood:clinical,pathological,biochemical,molecular,and genetic aspects of thedisease.Pediatr Pathol 10:143-153.

[0354] 68.Puel A,Cypowyj S,Bustamante J,Wright JF,Liu L,Lim HK,Migaud M,Israel L,Chrabieh M,Audry M,Gumbleton M,Toulon A,Bodemer C,E1-Baghdadi J,Whiners M,Paradis T,Brooks J,Collins M,Wolfman NM,Al-Muhsen S,Galicchio M,Abel L,Picard C,Casanova JL 332:65-6

[0355] 69.Casanova JL,Holland SM,Notarangelo LD.2012.Inborn errors of humanJAKs and STATs.Immunity 36:515-528.

[0356] 70.Holland T,Fowler VGJ,Shelburne SAr.2014.Invasive gram-positivebacterial infection in cancer patients.Clin Infect Dis 59:S331-S334.

[0357] 71.Lowy FD.1998.Staphylococcus aureus infections.New Engl J Med 339:520-532.

[0358] 72.Thammavongsa V,Kern JW,Missiakas DM,SchneewindO.2009.Staphylococcus aureus synthesizes adenosine to escape host immune responses.J Exp Med 206:2417-2427.

[0359] 73.Thomer L,Emolo C,Thammavongsa V,Kim HK,McAdow ME,Yu W,Kieffer M,Schneewind O,Missiakas D.2016.Antibodies against a secreted product ofStaphylococcus aureus trigger phagocytic killing.J Exp Med 213:293-3

[0360] 74.Rogers DE,Tompsett R.1952.The survival of staphylococci withinhuman leukocytes.J Exp Med 95:209-230.

[0361] 75.Gresham HD,Lowrance JH,Caver TE,Wilson BS,Cheung AL,LindbergFP.2000.Survival of Staphylococcus aureus within neutrophils contributes to infection.J Immunol 164:3713-3722.

[0362] 76.Falugi F,Kim HK,Missiakas DM,Schneewind O.2013.The role of proteinA in the evasion of host adaptive immune responses by Staphylococcus aureusmBio 4:e00575-13.

[0363] 77.van Loghem E,Frangione B,Recht B,Franklin EC.1982.Staphylococcal protein A and human IgG subclasses and allotypes.Scand J Immunol 15:275-278.

[0364] 78.Zhang L,Jacobsson K,Strom K,Lindberg M,FrykbergL.1999.Staphylococcus aureus expresses a cell surface protein that binds bothIgG and beta2-glycoprotein I.Microbiology 145:177-183.

[0365] 79.Kim HK,Emolo C,DeDent AC,Falugi F,Missiakas DM,SchneewindO.2012.Protein A-specific monoclonal antibodies and the prevention ofStaphylococcus aureus disease in mice.Infect Immun 80:3460-3470.

[0366] 80.Patel D,Wines BD,Langley RJ,Fraser JD.2010.Specificity ofstaphylococcal superantigen-like protein 10 toward human IgG1 Fc domain.JImmunol 184:6283-6292.

[0367] 81.Creech CB,Al-Zubeidi DN,Fritz SA.2015.Prevention of recurrentstaphylococcal skin infections.Infect Dis Clin North Am 29:429-464.

[0368] 82.Fowler Jr.VG,Kong LK,Corey GR,Gottlieb GS,McClelland RS,Sexton DJ,Gesty-Palmer D,Harrell LJ.1999.Recurrent Staphylococcus aureus bacteremia:pulsed-field gel electrophoresis findings in 29 patients.J Infect Dis 179:1157-1161.

[0369] 83.Rogers DE,Melly MA.1965.Speculation on the immunology ofstaphylococcal infections.Ann NY Acad Sci 128:274-284.

[0370] 84.Kim HK,Kim HY,Schneewind O,Missiakas DM.2011.Identifyingprotective antigens of Staphylococcus aureus,a pathogen that suppresses hostimmune responses.FASEB J 25:3605-3612.

[0371] 85.Kim HK,Cheng AG,Kim H-Y,Missiakas DM,Schneewind O.2010.Non-toxigenic protein A vaccine for methicillin-resistant Staphylococcus aureusinfections.J Exp Med 207:1863-1870.

[0372] 86.Forsgren A, K.1974.Protein A from Staphylococcus aureus:the biological significance of its interaction with IgG.Ann N Y Acad Sci 236:252-266.

[0373] 87.Forsgren A,Svedjelund A,Wigzell H.1976.Lymphocyte stimulation byprotein A of Staphylococcus aureus.Eur J Immunol 6:207-213.

[0374] 88.Schneewind O,Fowler A,Faull KF.1995.Structure of the cell wallanchor of surface proteins in Staphylococcus aureus.Science 268:103-106.

[0375] 89.Mazmanian SK,Liu G,Ton-That H,Schneewind O.1999.Staphylococcusaureus sortase,an enzyme that anchors surface proteins to the cellwall.Science 285:760-763.

[0376] 90.Becker S,Frankel MB,Schneewind O,Missiakas DM.2014.Release ofprotein A from the cell wall envelope of Staphylococcus aureus.Proc Natl AcadSci USA 111:1574-1579.

[0377] 91.Kim HK,Falugi F,Missiakas D,Schneewind O.2016.Peptidoglycan-linkedprotein A promotes T-cell dependent antibody expansion during Staphylococcusaureus infection.Proc Natl Acad Sci USA 113:5718-5723.

[0378] 92.Pauli NT,Kim HK,Falugi F,Huang M,Dulac J,Dunand CH,Zheng NY,KaurK,Andrews S,Huang Y,Dedent A,Frank K,Charnot-Katsikas A,Schneewind O,WilsonPC.2014.Staphylococcus aureus infection induces protein A-mediated immuneevasion in humans.J Exp Med 211:2331-2339.

[0379] 93.Kim HK,Falugi F,Thomer L,Missiakas DM,Schneewind O.2015.ProteinAsuppresses immune responses during Staphylococcus aureus bloodstreaminfection in guinea pigs.mBio 6:e02369-14.

[0380] 94.Kim HK,Emolo C,Missiakas DM,Schneewind O.2014.A monoclonalantibody that recognizes the E domain of staphylococcal protein A.Vaccine 32:464-469.

[0381] 95.Thammavongsa V,Rauch S,Kim HK,Missiakas DM,SchneewindO.2015.Protein A-neutralizing monoclonal antibody protects neonatal miceagainst Staphylococcus aureus.Vaccine 33:523-526.

[0382] 96.Leatherbarrow RJ,Dwek RA.1984.Binding of complement subcomponentC1q to mouse IgG1,IgG2a and IgG2b:a novel Clq binding assay.Mol Immunol 21:321-327.

[0383] 97.Nimmerjahn F,Ravetch JV.2008.Fc-gamma receptors as regulators ofimmune responses.Nat Rev Immunol 8:34-47.

[0384] 98.Nimmerjahn F,Ravetch JV.2005.Divergent immunoglobulin g subclassactivity through selective Fc receptor binding.Science 310:1510-1512.

[0385] 99.Abboud N,Chow SK,Saylor C,Janda A,Ravetch JV,Scharff MD,CasadevallA.2010.A requirement for FcγR in antibody-mediated bacterial toxinneutralization.J Exp Med 207:2395-2405.

[0386] 100.Wang LX,L,omino JV.2012.Emerging technologies for making glycan-defined glycoproteins.ACS Chem Biol 7:110-22.

[0387] 101.Wang LX,Amin MN.2014.Chemical and chemoenzymatic synthesis ofglycoproteins for deciphering functions.Chem Biol 21:51-66.

[0388] 102.Huang W,Giddens J,Fan SQ,Toonstra C,Wang LX.2012.Chemoenzymaticglycoengineering of intact IgG antibodies for gain of functions.J Am Chem Soc134:12308-18.

[0389] 103.Deisenhofer J.1981.Crystallographic refinement and atomic modelsof a human Fc fragment and its complex with fragment B of protein A fromStaphylococcus aureus at 2.9-and 2.8-A resolution.Biochemistry 20:2361-2370.

[0390] 104.Monnet C,Jorieux S,Urbain R,Fournier N,Bouayadi K,De Romeuf C,Behrens CK,Fontayne A,Mondon P.2015.Selection of IgG variants with increasedFcRn binding using random and directed mutagenesis:impact on effectorfunctions.Front Immunol6:39.

[0391] 105.Monnet C,Jorieux S,Souyris N,Zaki O,Jacquet A,Fournier N,CrozetF,de Romeuf C,Bouayadi K,Urbain R,Behrens CK,Mondon P,FontayneA.2014.Combined glyco-and protein-Fc engineering simultaneously enhancecytotoxicity and half-life of a therapeutic antibody.MAbs 6:422-36.

[0392] 106.Renaut L,Monnet C,Dubreuil O,Zaki O,Crozet F,Bouayadi K,KharratH,Mondon P.2012.Affinity maturation of antibodies:optimized methods togenerate high-quality ScFv libraries and isolate IgG candidates by high-throughput screening.Methods Mol Biol 907:451-61.

[0393] 107.Winter G,Griffiths AD,Hawkins RE,Hoogenboom HR.1994.Makingantibodies by phage display technology.Annu Rev Immunol 12:433-455.

[0394] 108.McCafferty J,Griffiths AD,Winter G,Chiswell DJ.1990.Phageantibodies:filamentous phage displaying antibody variable domains.Nature 348:552-554.

[0395] 109.Burmeister WP,Gastinel LN,Simister NE,Blum ML,BjorkmanPJ.1994.Crystal structure at 2.2A resolution of the MHC-related neonatal Fcreceptor.Nature 372:336-343.

[0396] 110.Martin WL,Bjorkman PJ.1999.Characterization of the 2∶1 complexbetween the class I MHC-related Fc receptor and its Fc ligand insolution.Biochemistry 38:12639-12647.

[0397] 111.Burmeister WP,Huber AH,Bjorkman PJ.1994.Crystal structure of thecomplex of rat neonatal Fc receptor with Fc.Nature 372:379-383.

[0398] 112.Shah IS,Lovell S,Mehzabeen N,Battaile KP,TolbertTJ.2017.Structural characterization of the Man5 glycoform of human IgG3Fc.Mol Immunol 92:28-37.

[0399] 113McAdow M,Kim HK,DeDenta AC,Hendrickx APA,Schneewind O,MissiakasDM.2011.Preventing Staphylococcus aureus sepsis through the inhibition of itsagglutination in blood.PLoS Pathog 7:e1002307.

[0400] 114.Hall AE,Domanski PJ,Patel PR,Vemachio JH,Syribeys PJ,Gorovits EL,Johnson MA,Ross JM,Hutchins JT,Patti JM.2003.Characterization of a protectivemonoclonal antibody recognizing Staphylococcus aureus MSCRAMM proteinclumping factor A.Infect lmmun 71:6864-6870.

[0401] 115.Li T,Tong X,Yang Q,Giddens JP,Wang LX.2016.Glycosynthase mutantsof endoglycosidase S2 show potent transglycosylation activity and remarkablyrelaxed substrate specificity for antibody glycosylation remodeling.J BiolChem 291:in press.

[0402] 116.Jefferis R.2009.Glycosylation as a strategy to improve antibody-based therapeutics.Nat Rev Drug Discov 8:226-34.

[0403] 117.Gramer MJ,Eckblad JJ,Donahue R,Brown J,Shultz C,Vickerman K,PriemP,van den Bremer ET,Gerritsen J,van Berkel PH.2011.Modulation of antibodygalactosylation through feeding of uridine,manganese chloride,andgalactose.Biotechnol Bioeng 108:1591-602.

[0404] 118.Hills AE,Patel A,Boyd P,James DC.2001Metabolic controI ofrecombinant monoclonal antibody N-glycosylation in GS-NS0 cells.BiotechnolBioeng 75:239-51.

[0405] 119.Gu X,Wang DI.1998.Improvement of interferon-gamma sialylation inChinese hamster ovary cell culture by feeding of N-acetylmannosamine.Biotechnol Bioeng 58:642-8.

[0406] 120.Yin B,Wang Q,Chung C-Y,Ren X,Bhattacharya R,Yarema KJ,BetenbaughMJ.Butyrated ManNAc analog improves protein expression in Chinese hamsterovary cells.Biotechnology and Bioengineering doi:10.1002 / bit.26560:n / a-n / a.

[0407] 121.Wang LX,Lomino JV.2012.Emerging technologies for making glycan-defined glycoproteins.ACS Chem Biol 7:110-122.

[0408] 122.Wang LX,Amin MN.2014.Chemical and chemoenzymatic synthesis ofglycoproteins for deciphering functions.Chem Biol 21:51-66.

[0409] 123.Huang W,Giddens J,Fan SQ,Toonstra C,Wang LX.2012.Chemoenzymaticglycoengineering of intact IgG antibodies for gain of functiohs.J Am Chem Soc134:12308-12318.

[0410] 124, Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, Davidson MG, Lin F, Lin J, Carleton HA, Mongodin EF, Sensabaugh GF, Perdreau-Remington F. 2006. Completegenome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 367:731-739.

[0411] 125. Cheng AG, McAdow M, Kim HK, Bae T, Missiakas DM, Schneewind O. 2010. Contribution of coagulases towards Staphylococcus aureus disease and protective immunity. PLoS Pathog 6: e1001036.

[0412] 126. Cheng AG, Kim HK, Burts ML, Krausz T, Schneewind O, Missiakas DM. 2009. Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues. FASEB J 23: 3393-3404.

[0413] Example 2: Glycosylation-dependent opsonophagocytic activity of Staphylococcal protein A antibodies

[0414] Staphylococcus aureus escapes opsonophagocytic clearance by producing a surface protein, staphylococcal protein A (SpA), which binds to the Fc region of immunoglobulin G (IgG). SpA also impedes the development of protective immunity by cross-linking IgM B cell receptors. This interaction triggers polyclonal B cell proliferation and leads to the secretion of antibodies that cannot recognize S. aureus. 3F6 human IgG1 (3F6-hIgG1) is a monoclonal antibody that binds and neutralizes SpA. Here, the inventors show that galactosylation of 3F6-hIgG1 is essential for opsonophagocytosis of the bacteria and for protecting mice from S. aureus bloodstream infection. The inventors demonstrate that fucosylation of the antibody prevents binding to FcγRs, while galactosylation promotes Clq recruitment and explains the therapeutic activity of 3F6-hIgG1.

[0415] Staphylococcus aureus (MSSA, methicillin-resistant S. aureus) and its resistant isolates (MRSA, methicillin-resistant S. aureus) persistently colonize the nasopharynx of 31% (MSSA) and 2% (MRSA), respectively, of the U.S. population, whereas the remainder is intermittently colonized (1, 2). Colonization is a major risk factor for invasive disease, manifesting as skin and soft tissue infections, osteomyelitis, pneumonia, septic arthritis, bacteremia, and endocarditis (3). Community-acquired disease is associated with 3.2 million (MSSA) and 238,000 (MRSA) clinical visits per year in the United States (4). In addition, 359,000 cases of MSSA and 101,000 cases of MRSA hospital-acquired infections occurred among 37 million hospitalizations (5). MRSA infections are associated with treatment failure and increased mortality (6). Several attempts to develop vaccines or immunotherapies to prevent disease or improve outcomes of S. aureus infections have failed (7).

[0416] S. aureus is a Gram-positive bacterium with a thick envelope that, unlike most Gram-negative bacteria, cannot be lysed by complement and the membrane attack complex (7). Secreted Sbi and cell wall-bound SpA capture the crystallizable fragment region (Fcγ) of immunoglobulin G and prevent opsonization by S. aureus-specific antibodies. Sbi and SpA contain two and five immunoglobulin binding domains (IgBDs), respectively. Each IgBD binds to the Fcγ of human IgG1, IgG2, and IgG4 (but not IgG3) and mouse IgG (IgG1, IgG2a, IgG2b, IgG2c, and IgG3) (8 to 11). SpA, but not Sbi, also binds to V H 3 Idiotypes of IgM, IgG, IgD and IgE 12-14During infection, S. aureus releases SpA, which cross-links variant heavy chains of the VH3 family B cell receptor (IgM) and triggers B cell proliferation and secretion of VH3 clone antibodies (15, 16). The released SpA alters B cell development and prevents the production of pathogen-specific IgG (15, 16). Humans, guinea pigs, and mice are unable to produce antibodies that neutralize SpA (12, 16, 17). Therefore, any therapeutic strategy involving S. aureus-specific antibodies must address the staphylococcal SpA and Sbi defenses.

[0417] Earlier, the inventors developed a non-toxigenic SpA that no longer binds to immunoglobulins. KKAA (12), and isolated the mouse hybridoma monoclonal antibody 3F6 (3F6-mhIgG2a). The antibody binds to the folded triple helical structure of IgBD and blocks the binding of ligands to SpA and Sbi. When administered to mice, 3F6-mhIgG2a protects animals from Staphylococcus aureus bloodstream infection (11, 12, 18). In the effort to develop therapeutic antibodies, the complementary determining regions (CDRs) of 3F6-mhIgG2a were sutured to the VH and VL gene elements of human IgG1 (hIgG1) antibodies (18, 19) (Fig. 7A). The new humanized 3F6 IgG1 antibody (3F6-hIgG1) improves the results of MRSA bloodstream infection in experimental animals (18, 19). Here, the inventors use a combination of glycoengineering and site-directed mutagenesis to identify the effector functions of the 3F6 therapeutic antibody.

[0418] A. Results

[0419] 1. 3F6-hIgG1 HEK Instead of 3F6-hIgG1 CHO Protects mice from Staphylococcus aureus bloodstream infection

[0420] Two cell lines, CHO-DG44 and HEK-293F, were used to produce humanized anti-SpA antibodies. Named 3F6-hIgG1 CHO and 3F6-hIgG1 HEK The corresponding antibodies of (Fig. 7A) were affinity purified and their integrity and homogeneity were documented by Coomassie-stained sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing and non-reducing conditions (Fig. 7B). Both antibodies were specific for SpA. KKAA 7C), and the interaction between hIgG and SpA was more effective than that between hIgG1 and SpA (Fig. 7D). CHO and 3F6-hIgG1 HEKInjected into BALB / c mice, and then challenged intravenously with methicillin-resistant Staphylococcus aureus isolate MW2, referred to herein as MRSA (Figure 7E, Figure 7F). Animals treated with PBS and hIgG1 or 3F6-mhIgG2a were used as negative and positive controls, respectively. Animals were killed 15 days after the attack. Disease was assessed by visual inspection of intact kidneys in areas with pus (Figure 11A), by counting colony forming units (CFU) after renal tissue plating (Figure 7E) and counting abscess lesions in renal tissue sections stained with H & E (Figure 7F). Compared with animals receiving PBS or hIgG1, those receiving 3F6-mhIgG2a or 3F6-hIgG1 showed a significant increase in pus. HEK Animals with 3F6-mhIgG2a and 3F6-hIgG1 had fewer abscess lesions (Fig. 11A, Fig. 7F) and reduced bacterial load in kidney tissue (Fig. 7E). HEK Surprisingly, 3F6-hIgG1 CHO Administration did not provide protection and performed similarly to PBS and hIgG1 controls (Figure 11A, Figure 7E, Figure 7F). Earlier reports have shown that successful neutralization of SpA blocks its B cell superantigen activity, resulting in the production of polyclonal antibodies against staphylococcal antigens (12, 18). Serum collected from animals after challenge was used to measure IgG titers against a staphylococcal antigen matrix containing 17 purified antigens (Figure 7G). HEK Or the reference control 3F6-mhIgG2a immunization induced the production of antibodies against the virulence determinants ClfA, IsdB, Coa and vWbp and the surface antigens ClfB, SasI and FnBPA; this was not the case with 3F6-hIgG1 CHO No observation was observed in animals treated with PBS or hIgG1 (Fig. 7G; Fig. 11B). CHO and 3F6-hIgG1 HEK The results were consistent with the typical biexponential plasma concentration-time curves, showing similar half-lives (Figure 1h). CHO and 3F6-hIgG1 HEK In vitro, it showed similar binding affinity to human neonatal Fc receptor (FcRn) (Figure 11C). Together, these data suggest that 3F6-hIgG1 HEK Instead of 3F6-hIgG1 CHO Protected mice from MRSA infection, and the difference in protection was not due to 3F6-hIgG1 CHO caused by a shortened half-life.

[0421] 2. The protective activity of 3F6 antibody requires Fc-galactosylation

[0422] Antibody-mediated effector functions are regulated by N-glycosylation of Fc (20). 297 Modified with a heptasaccharide core (GlcNAc2Man3GlcNAc2) and variable additions of fucose (F), galactose (G), and sialic acid (S). Binding to immobilized Erythrina chinensis lectin (ECL) and Sambucus nigra lectin (SNA) showed that 3F6-hIgG1H EK Compared with 3F6-hIgG1 CHO Higher galactose and sialic acid content (Figure 12A to Figure 12B). For a more thorough analysis, glycans were released from the antibody preparation and subjected to matrix-assisted laser desorption / ionization time-of-flight (MALDI-TOF) mass spectrometry to reveal a complex sugar composition distribution with peaks corresponding to fucosylated non-galactosylated (G0F), monogalactosylated (G1F), and di-galactosylated N-glycans (G2F) (Figure 8A). CHO Compared with the preparation, 3F6-hIgG1 HEK G1F and G2F glycoforms were more abundant in the formulation (Figure 8A to Figure 8B). Quantification of glycoforms showed that 3F6-hIgG1 HEK The galactosyl and sialic acid residues contained in 3F6-hIgG1 are CHO To determine whether the Fc glycan structure is a key determinant for protection against S. aureus bloodstream infection, we used enzymes to transfer or remove galactose to generate 3F6-hIgG1 CHO -Gal or 3F6-hIgG1 HEK -deGal. Neuraminidase is used to generate sialic acid-deficient 3F6-hIgG1 CHO -deSia and 3F6-hIgG1 HEK -deSia. None of these treatments altered the integrity of the antibody (Figures 12C, 12F). The new glycoforms bind SpA with similar affinity KKAA (Table 1; Figure 12D, Figure 12G). Lectin binding assay confirmed galactosylation, degalactosylation or desialylation modification of the antibodies (Figure 12E, Figure 12H). CHO -Gal, 3F6-hIgG1 HEK 、3F6-hIgG1 HEK -deGal or 3F6-hIgG1 HEK-deSia were injected intraperitoneally and then challenged by intravenous inoculation of MRSA, and body weight changes were monitored over 14 days (Figure 8C). On day 15, animals were euthanized and kidney tissues were examined for bacterial load and abscess formation (Figure 8D, Figure 8E). HEK Instead of human IgG1 and 3F6-hIgG1 CHO Treatment reduced MRSA burden and abscess formation (Figure 8D, Figure 8E). This protective activity does not require sialic acid modification (3F6-hIgG1 HEK -deSia), while galactosylation is essential, as shown with 3F6-hIgG1 HEK -deGal-treated animals lose protection and are treated with 3F6-hIgG1 CHO To specifically identify the Fc glycan structures responsible for protection from MRSA bloodstream infection, we used a chemoenzymatic approach to glycan remodeling. We first remodeled 3F6-hIgG1 with Endo-S2. CHO and 3F6-hIgG1 HEK Deglycosylation followed by removal of activated glycans in an EndoS2-D184M-dependent manner The presynthesized glycans (21 to 24) were transferred by oxazoline. Four antibodies 3F6-hIgG were synthesized HEK -G0F, 3F6-hIgG HEK -G1F, 3F6-hIgG HEK -G2F and 3F6-hIgG CHO -G2F, which have highly homogeneous and well-defined glycan profiles and were tested for integrity and association with SpA KKAA When injected into animals, the two digalactosylated antibodies 3F6-hIgG HEK -G2F and 3F6-hIgG CHO -G2F protected animals from MRSA challenge (Figure 12F, Figure 12H). HEK -G1F was equally well protected. However, no protection was observed for the G0F glycoform 3F6-hIgG1 HEK -G0F protective effect (Figure 8F, Figure 8H). 3F6 antibody-mediated protection is associated with the development of a broader immune response against multiple bacterial molecules, as monitored with MRSA antigen matrix (Figure 8I, Figure 8J). In summary, galactosylation is key to the protective properties of 3F6-hIgG1 in vivo.

[0423] 3. 3F6-hIgG1 HEKComplement is required for protection in mice

[0424] 3F6-hIgG1 HEK It showed better performance than 3F6-hIgG1 for both human and mouse C1q CHO Higher affinity (Fig. 13A, Fig. 13B; Table 2). Differential glycosylation of CHO and HEK produced antibodies did not affect their binding affinity to mouse FcγR (Fig. 13C; Table 2). When human FcγR and its allotypes were used for examination, the binding affinity of 3F6-hIgG1 HEK In comparison, 3F6-hIgG1 CHO FcγRIIA R131 , FcγRIIA H131 , FcγRIIIA V158 , FcγRIIIA F158 The CHO-produced antibody showed higher affinity to the inhibitory receptor FcγRIIB (Figure 13D; Table 2). Both antibodies bound similarly to FcγRIA (Figure 13D; Table 2). Addition of galactose to the CHO-produced antibody enhanced C1q binding, whereas removal of galactose from the HEK-produced antibody reduced C1q binding (Figure 13E; Table 2). 3F6-hIgG1 CHO -G2F has the highest affinity for C1q, comparable to 3F6-hIgG1 HEK -G2F showed comparable affinities (Figure 13F; Table 2). Glycoforms 3F6-hIgG1HEK-G1F and 3F6-hIgG1HEK-G2F showed high affinities for C1q (Figure 13F; Table 2). HEK Removal of sialic acid from the cytosol slightly improved C1q binding but had no significant effect on 3F6-hIgG1 CHO There was no effect on activity (Figure 13F; Table 2). This is not surprising, as sialic acid is only added to galactose residues; thus, only 0.45% of CHO-produced antibodies were modified with sialic acid, whereas approximately 4% of all HEK-produced antibodies were modified with sialic acid (Figure 8B).

[0425] Amino acids K322 and L233 / L234 are involved in the interaction of antibodies with C1q (27, 28). HEK To investigate the therapeutic activity of antibodies, the inventors produced variant 3F6-hIgG1 with substitutions K322A and L233A / L234A, respectively. HEK -KA and 3F6-hIgG1 HEK-LALA (Figure 14A). The new substitutions did not affect antigen binding, sialylation, fucosylation or galactosylation (Figure 14B, Figure 14C; Table 2). Both variants showed significantly reduced binding to C1q, consistent with previous reports (27, 28) (Figure 14D; Table 2). 3F6-hIgG1 HEK The KA and LALA variants interacted similarly with recombinant human FcγRs, but the LALA variant interacted only with human FcγRIA and FcγRIIIA. V158 14E; Table 2). The KA variant had a slightly higher affinity for all mouse FcγRs compared to 3F6-hIgG1HEK; the LALA variant interacted much worse with mouse FcγRI and FcγRIV (Figure 14F; Table 2). When administered to animals, the KA and LALA variants failed to restore body weight, reduce bacterial loads in tissues, and abscesses 15 days after infection with MRSA, indicating an inability to clear bacteria (Figures 9A to 9C). The KA and LALA variants also failed to neutralize the B cell superantigen activity of SpA, as reflected by the lack of a broad neutralizing antibody response (Figure 14G). Binding of C1q to antibodies triggers the classical complement pathway, thereby activating C3 and C5 (29). Cobra venom factor (CVF) depletes C3 and C5 in mice (30, 31). When administered to animals, CVF abolished the ability of 3F6-hIgG1HEK to protect against MRSA attack (Figures 9D, 9E; Figures 14H, 14I). Notably, CVF treatment of hIgG1-control animals also exacerbated MRSA disease, suggesting an intrinsic (antibody-independent) role for complement (Fig. 9D, Fig. 9E). Collectively, these findings suggest that C1q recruitment may be critical for the therapeutic activity of anti-MRSA antibodies.

[0426] 4. FcγR contributes to 3F6-hIgG1 HEK The therapeutic activity

[0427] The interaction of antibodies with FcγRs can be modulated by fucosylation. Loss of fucosylation results in weaker and higher binding to inhibitory and activating FcγRs, respectively (32). HEK 8B), a modification that may not be optimal for FcγR-mediated activity. To test this possibility, non-fucosylated 3F6-hIgG1 was produced by adding kifunine to the culture medium. HEK (3F6-hIgG1 HEK -afu) in an effort to enrich for the low-fucose glycoform. 3F6-hIgG1 HEK -afu maintains its integrity and SpA KKAA Binding (Figure 15A, Figure 15B). HEKIn contrast, the lectin-based assay confirmed that 3F6-hIgG1 HEK -afu was low-level fucosylation and galactosylation (Figure 15C). Binding to C1q and the inhibitory receptor human FcγRIIB was reduced; binding to the activating receptors, human FcγRIIIA (both alleles) and mouse FcγRIII and FcγRIV was enhanced (Figures 15D to 15F, Table 2), effectively shifting the activation-inhibition (A / I) ratio of FcγR (33). When transferred to animals, 3F6-hIgG1 HEK -afu controlled MRSA infection, as reflected in weight loss, bacterial burden, abscesses, and extensive antibody responses against secreted antigens ( Figures 9F to 9H , Figure 15G ). These results suggest that 3F6-hIgG1 HEK The therapeutic activity of TNF-α can be achieved in vivo in a complement- and FcγR-dependent manner.

[0428] 5. Complement and FcγR both contribute to 3F6-hIgG1 in human blood HEK OPK activity

[0429] In addition to capturing immunoglobulins in an SpA- and Sbi-dependent manner, S. aureus also utilizes the host factors prothrombin and fibrinogen to induce the formation of fibrin aggregates, thereby protecting the bacteria from phagocytic invasion. Secreted coagulase, Coa, and vWbp, as well as surface-displayed ClfA, are key factors involved in this process (34). The relevance of vaccine protection is typically measured as the concentration of antibody that is able to induce opsonophagocytosis of a given pathogen by HL60 cells (i.e., human promyelocytic leukemia cells) (35). Because this assay lacks hemostatic factors (prothrombin and fibrinogen), it is not adequate to assess the opsonophagocytic activity of antibodies against S. aureus. Early work developed a whole blood assay that enumerated S. aureus after one hour of incubation in freshly drawn anticoagulated blood by releasing bacteria from aggregates after treatment with the plasminogen activator streptokinase (34). Using this assay, 3F6-hIgG1 HEK Pretreatment of blood with cytochalasin D, an inhibitor of actin polymerization, and thus phagocytosis, or with CVF eliminated 3F6-hIgG1 HEK mediated killing of MRSA in human blood (Figure 10A, Figure 10B). HEK Neither the KA nor the LALA variants of 3F6 promoted opsonophagocytic killing. However, non-fucosylated 3F6-hIgG1 with reduced C1q binding and enhanced FcγR binding activity HEK Promoted the killing of MRSA in human blood (Figure 10C).

[0430] B. Discussion

[0431] In the early 20th century, the discovery that sera from infected animals contained antimicrobial activity was readily exploited, primarily against diphtheria toxin (36). Broad-spectrum drugs and antibiotics soon eclipsed serum therapy. To date, only a few therapeutic antibodies have been approved for the prevention of infectious diseases (37). This is in contrast to the growing number of mAbs used for immune-mediated diseases and cancer (38). While target selection through Fab recognition is critical for success, disease amelioration is governed by the deployment of effector mechanisms mediated by the antibody Fc region. The effector functions of anticancer antibodies have been best characterized, with specific destruction of tumor cells or enhancement of tumor-specific T cell immunity being readily measured (39, 40). Interaction with FcγRs triggers antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP) of tumor cells (39, 40). Interaction with C1q activates the classical complement pathway, promoting direct lysis of tumor cells following insertion of the membrane attack complex (i.e., complement-dependent cytotoxicity, CDC) or covalent deposition of opsonins such as C3b onto the cell surface. Complement receptors on effector cells bind to opsonized targets, promoting complement-dependent cell-mediated cytotoxicity (CDCC) and complement-dependent cell-mediated phagocytosis (CDCP) (41, 42). The mode of action required for antibody-mediated elimination of bacterial pathogens is unclear.

[0432] The inventors have previously shown that protection against S. aureus disease by the candidate 3F6-hIgG1 correlates with the ability of this antibody to bind to multiple IgBDs of SpA and block further interactions with the Fcγ and Fab VH3 domains of Ig (11). CHO No therapeutic activity was shown in a mouse model of MRSA infection. This is different from 3F6-hIgG1 produced in HEK293F cells. CHO cells are non-human mammalian cell lines that are often selected for commercial production of therapeutic proteins due to high productivity and low operating costs (43). The lack of antibody activity cannot be attributed to a shortened half-life in vivo or an inability to form immune complexes with SpA. Instead, the defect was associated with a lower abundance of galactosylated antibodies in CHO cells compared to HEK 293 cells (approximately 30% versus approximately 58% G0F, approximately 48% versus approximately 28% G1F, and approximately 11% versus approximately 4% G2F) (44 to 46), suggesting that Fc-mediated effector activity is altered (25, 26, 47). Enzymatic addition of galactosyl residues enhances the activity of 3F6-hIgG1. CHO The therapeutic activity of 3F6-hIgG1 was reduced by enzymatic degalactosylation. HEKChemoenzymatic glycoengineering also demonstrated the therapeutic activity of G1F and G2F glycoforms on 3F6-hIgG1, but G0F had no therapeutic activity.

[0433] The length and substitution of the N-glycan at Asn297 have been shown to affect the stability of the polypeptide loop containing Asn297 and to affect binding to FcγR and C1q (25, 26, 47). Increased galactosylation and removal of sialic acid residues in ...

Claims

1. An engineered anti-SpA antibody comprising a light chain variable region and a heavy chain variable region, comprising: LCDR1, LCDR2 and LCDR3 of the antibody light chain variable region and HCDR1, HCDR2 and HCDR3 of the antibody heavy chain variable region, and wherein the antibody comprises an amino acid at Asn 297 wherein the antibody is further defined as having a modified structure of G2S2F, G2F, G1F, G2 or G1, wherein HCDR1, HCDR2 and HCDR3 are the amino acid sequences of SEQ ID NOs: 2, 3 and 4, respectively, and wherein LCDR1, LCDR2 and LCDR3 are the amino acid sequences of SEQ ID NOs: 5, 6 and 7, respectively, and Wherein the modified structure of G2S2F, G2F, G1F, G2 or G1 is:

2. The antibody of claim 1, wherein the antibody is humanized.

3. A humanized anti-SpA antibody comprising an amino acid residue between Asn 297 an Fc region modified by glycosylation at one end and a crystallizable fragment gamma (Fcγ), wherein the antibody is further defined as having a modified structure of G2S2F, G2F, G1F, G2 or G1, wherein the antibody comprises LCDR1, LCDR2 and LCDR3 of the antibody light chain variable region and HCDR1, HCDR2 and HCDR3 of the antibody heavy chain variable region, and wherein HCDR1, HCDR2 and HCDR3 are the amino acid sequences of SEQ ID NOs: 2, 3 and 4, respectively, wherein LCDR1, LCDR2 and LCDR3 are the amino acid sequences of SEQ ID NOs: 5, 6 and 7, respectively, and Wherein the modified structure of G2S2F, G2F, G1F, G2 or G1 is:

4. The antibody of claim 1, wherein the antibody comprises a crystallizable fragment region gamma (Fcγ).

5. The antibody according to any one of claims 1 to 3, wherein the replacement of the Fc region of the antibody is S 254 A.Q 311 E.L 432 S, N 434 P and / or H 435 R.

6. The antibody according to claim 5, wherein the replacement of the Fc region of the antibody is S 254 A.Q 311 E.L 432 S and / or N 434 P substitution.

7. The antibody according to any one of claims 1 to 3, wherein the substitution in the Fc region of the antibody is T256D, N286D, T307R, T307Q, Q311V, A378V or a combination thereof.

8. The antibody of any one of claims 1 to 3, wherein the antibody is capable of increasing OPK activity in a subject compared to tifizumab.

9. A nucleic acid encoding the heavy chain and light chain of the antibody according to any one of claims 1 to 8.

10. A host cell comprising the nucleic acid according to claim 9.

11. A method for preparing an antibody, comprising expressing the nucleic acid according to claim 9 in a cell and isolating the expressed protein.

12. The method of claim 11, wherein the cells comprise expression of a heterologous glycosyltransferase.

13. The method of claim 12, wherein the glycosyltransferase is modified.

14. The method according to any one of claims 11 to 13, wherein the cells are modified to reduce or eliminate the expression of one or more than one fucosylation and / or sialylation enzymes.

15. The method of claim 14, wherein the cells are modified to reduce or eliminate the expression of Fut8 and / or 23STGal4 / 6.

16. The method of claim 11 or 12, wherein the cells comprise mammalian cells.

17. The method of claim 11 or 12, wherein the cells comprise human cells.

18. The method of any one of claims 11 to 13, wherein the cell comprises endogenous glycosyltransferase activity.

19. The method of any one of claims 11 to 13, wherein the cells comprise CHO cells.

20. The method according to any one of claims 11 to 13, wherein the method comprises culturing the cells in a medium supplemented with galactose alone or in a medium supplemented with galactose in combination with manganese chloride and / or uridine.

21. The method according to any one of claims 11 to 13, wherein the method comprises culturing the cells in afucosylation-enriched medium.

22. The method of claim 21, wherein the afucosylation-free enrichment medium comprises kifunine.

23. The method according to any one of claims 11 to 13, wherein the method comprises culturing the cells in a desialylated enriched medium.

24. The method of claim 23, wherein the desialylated enriched medium comprises neuraminidase.

25. The method according to any one of claims 11 to 13, wherein the method comprises culturing the cells in a medium supplemented with N-acetylmannosamine (ManNAc) and / or butylated ManNAc.

26. Use of an antibody according to any one of claims 1 to 8 in the preparation of a medicament for preventing or treating staphylococcal infection or colonization, wherein the antibody according to any one of claims 1 to 8 is administered to a subject in need thereof.

27. The use of claim 26, wherein the treatment or prevention comprises one or more of promoting decolonization of S. aureus, preventing invasive MRSA disease, and improving the outcome of MRSA bloodstream infection in a subject.

28. The use according to any one of claims 26 to 27, wherein the Staphylococcal infection or colonization comprises an infection or colonization with Staphylococcus aureus.

29. Use according to claim 28, wherein the Staphylococcus aureus is resistant to one or more than one treatment.

30. The use according to claim 29, wherein the bacteria is methicillin-resistant.

31. The use according to any one of claims 26 to 27, wherein the subject does not show any signs of toxicity from the isolated polypeptide or composition.

32. The use according to claim 31, wherein the subject does not show any signs of anaphylactic shock from the isolated polypeptide or composition.

33. The use according to any one of claims 26 to 27, wherein the subject is a human.

34. The use according to any one of claims 26 to 27, wherein the antibody is administered intravenously.

Citation Information

Patent Citations

  • Safety hook

    EP0000367A1

  • Transgenic non-human animals capable of producing heterologous antibodies

    EP0546073A1

  • Production and use of transgenic non-human animals capable of producing heterologous antibodies

    EP0546073B1

  • Staphylococcus aureus polynucleotides and sequences

    EP0786519A2

  • Muteins of apolipoprotein d

    US20050106660A1